

CKiD Study Forms by Visit

Order in PDF	Form Code	Form Name	<u>V1a</u>	<u>V1b</u>	<u>V2</u>	<u>V3</u>	<u>V4</u>
1	F01	SYMPTOMS LIST	X		Х	Х	Х
2	F02	SMOKING, ALCOHOL AND DRUG USE	X				
3	F12	SMOKING, ALCOHOL AND DRUG USE			X	X	Х
4	GH	GENERAL HISTORY	X				
5	F13	FOLLOW-UP GENERAL HISTORY			X		Х
6	F13a	ABBREVIATED FOLLOW-UP GENERAL HISTORY				Х	
7	MH	MEDICAL HISTORY	X				
8	F14	FOLLOW-UP MEDICAL HISTORY			X	Х	Х
9	PE	PHYSICAL EXAMINATION	X	Х	X	Х	Х
10	F15	NUTRITIONAL ASSESSMENT	X		X	Х	Х
11	F17	OVERALL PHYSICAL ACTIVITY	X		X	Х	Х
12	F19	HAND GRIP TEST				Х	
13	MEDS	MEDICATION AND SUPPLEMENT INVENTORY	X		Х	X	Х
14		MEDS LIST ALPHABETICAL	X		Х	X	Х
15		MEDS LIST BY CLASSIFICATION	X		X	Х	Х
16	L01	SPECIMEN COLLECTION FORM	X				
17	L02	SPECIMEN COLLECTION FORM		Х			
18	L21	SPECIMEN COLLECTION FORM			X		
19	L31	SPECIMEN COLLECTION FORM				X	
20	L41	SPECIMEN COLLECTION FORM					Х
21	L03	LOCAL LABORATORY – RENAL PANEL RESULTS FORM	X		X	Х	Х
22	L04	LOCAL LABORATORY – CBC RESULTS FORM	X		X	Х	Х
23	L06	LOCAL LABORATORY – URINE ASSAY RESULTS FORM	Х		X	Х	Х
24	L05	CENTRAL LABORATORY – RENAL PANEL TESTS	X		X	Х	Х
25	L07	CENTRAL LABORATORY – IOHEXOL CONCENTRATIONS RESULTS	X		X		Х
26	L08	CENTRAL LABORATORY iPTH and hsCRP		X		Х	
27	L09	CENTRAL LABORATORY – LIPID PROFILE			X		Х
28	L11	CENTRAL LABORATORY — CYSTATIN C RESULTS	Χ		X	Х	Х
29	L12	CENTRAL LABORATORY – IRON TESTS					
30	L13	CENTRAL LABORATORY – VITAMIN D		X		X	

SYMPTOMS LIST (F01)

Chronic Kidney Disease in Children (CKiD) SECTION A: GENERAL INFORMATION

A1.	PARTICIPANT ID: AFFIX ID LABEL OR ENTER NUMBER IF ID LABEL IS NOT AVAILABLE					
		_ - -				
A2.	CKID STUDY VISIT #:					
A3.	FORM VERSION:	<u>0</u> <u>1</u> / <u>0</u> <u>1</u> / <u>0</u> <u>6b</u>				
A4.	DATE OF VISIT:	$\frac{1}{M} \frac{1}{M} \frac{1}{D} \frac{1}{D} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y}$				
A5.	INDICATE PERSON COMPLETING THE FORM	Child/young adult				
A6.	Is this study visit an irregular (accelerated) visit?	Both (Parent and Child/young adult) 3 Yes				

Instructions: Thinking back on the *last month*, indicate the number of days in which your child (or you, if child/young adult participant is completing the form) has felt each of the symptoms listed below. If you/your child has never felt the symptom, then enter a "0" (zero) in the space. *Do not leave the space blank*. If you/your child enter a "1" or number greater than 1, then *circle the number* under the column that best describes the severity of each of the symptom that was felt. Leave "severity" blank if the symptom was not felt.

	10		Severity	
Symptoms	Number of DAYS in past month (Enter 0 if none.)	Mild Symptoms did not interfere with usual activities	Moderate Symptoms interfered somewhat with usual activities	Severe Symptoms were so bothersome that usual activities could not be performed
1. Nausea or upset stomach?		1	2	3
2. Vomiting?		1	2	3
3. Diarrhea?		1	2	3
4. Constipation?		1	2	3
5. Itching?		1	2	3
6. Numbness and tingling in hands and/or feet?		1	2	3
7. Feeling faint when standing up?		1	2	3
8. Blurred vision?		1	2	3
9. Problems urinating (urgency, frequency, burning)?		1	2	3
10. Headaches?		1	2	3
11. A bad taste in mouth?		1	2	3

SYMPTOMS LIST (F01)

		Severity				
Symptoms	Number of DAYS in past month (Enter 0 if none.)	Mild Symptoms did not interfere with usual activities	Moderate Symptoms interfered somewhat with usual activities	Severe Symptoms were so bothersome that usual activities could not be performed		
12. Loss of appetite?		1	2	3		
13. Increased appetite?		1	2	3		
14. Weight increase?		1	2	3		
15. Heartburn?		1	2	3		
16. Abdominal bloating or gas?		10	2	3		
17. Abdominal pain?		1	2	3		
18. Swelling (excess fluid)?		Q 1	2	3		
19. Hiccoughs?		1	2	3		
20. Hives or another type of rash?		1	2	3		
21. Easy bruising or bleeding?		1	2	3		
22. Tiring easily, weakness?		1	2	3		
23. Muscle cramps? (Exclude menstrual cramps)		1	2	3		
24. Waking up too early in the morning?		1	2	3		
25. Falling asleep during the day?		1	2	3		
26. Feeling irritable?		1	2	3		
27. Decreased alertness?		1	2	3		
28. Leg pain?		1	2	3		
29. Flank pain (kidney pain)?		1	2	3		
30. Other unexpected symptoms?		1	2	3		
Specify:						

TO BE COMPLETED BY CLINICAL SITE:								
DATE: ///////	<u> </u>	INITIALS:						
ADMINISTRATION: (Circle "1", "2" or "3")	1 = Interviewer Assisted 2 = Self-Administered 3 = Both							

Chronic Kidney Disease in Children (CKiD)

SECTION A: GENERAL INFORMATION

Δ1	PARTICIPANT ID:	AFFIX ID I ARFI	OR ENTER NUMBER	IF ID I ARFI	IS NOT AVAILABLE
ΛΙ.	FANTIGIFANT ID.	ALLIV ID FADEL		IF ID LADEL	IO NOT AVAILABLE

		_ - -
A2.	CKID STUDY VISIT #:	<u>0 1 a</u>
A3.	FORM VERSION:	1 0 / 0 1 / 1 4
A4.	DATE OF VISIT:	$\frac{1}{M} \frac{1}{M} \frac{1}{D} \frac{1}{D} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y}$

This form is to be completed by children, 12 years old or older, who are enrolled in CKiD.

INTRODUCTION TO PARTICIPANT:

Thank you for participating in this study.

This questionnaire should take about 5 to 10 minutes. Please read each question carefully. Take as much time as you need to answer each question and be as accurate as possible. As with all study information, your answers will be kept private. No one will know who filled out the questionnaire, because there is only a code number at the top, not your name. Even your parents and your doctor will not see your answers. Please answer all questions honestly. Your answers are for research purposes only and may help doctors find better ways to treat children with kidney problems. If you have trouble reading or understanding a question, please ask the nurse/coordinator for assistance and she/he will be happy to help.

Questions begin on the next page. For each question, **FILL IN THE ANSWER or CIRCLE THE NUMBER** that best matches the answer. When you have completed the form, please return it to the nurse/coordinator.

SECTION B: SMOKING

The following are some personal questions about your tobacco use. Please <u>circle</u> the number that best matches your answer.

B1.	Have	e you ever smoked tobacco (e.g. a whole cigarette	, ci	gar, cigarillo or, little cigar)?
		Yes	1	
		No	2	(Skip to B4)
	a.	How old were you when you smoked tobacco for	the	e first time?
		years of age		



	_	
B2.	Do y	ou currently smoke tobacco?
		Yes
	a.	How old were you when you stopped smoking?
		years of age
	b.	While smoking, what was the average number of cigarettes, cigars, cigarillos or little cigars you smoked per week?
		number of cigarettes, cigars, cigarillos or little cigars
		(Skip to B4)
B3.	Wha	it is the average number of cigarettes, cigars, cigarillos or little cigars you
		ke per week?
		number of cigarettes, cigars, cigarillos or little cigars
B4.		ng your life, have you ever smoked tobacco or non-tobacco (e.g., shisha, an herbal erial) using a hookah?
		Yes 1
		No
B5.		ng the past 30 days , how many times have you smoked tobacco or non-cco using a hookah?
		number of times smoked tobacco or non-tobacco using a hookah
Stark	uzz.	questions ask about electronic vapor products, such as blu, NJOY, or Electronic vapor products include e-cigarettes, e-cigars, e-pipes, vape pipes, 1s, e-hookahs, and hookah pens.
•	٠.	
B6.	Have	e you ever used an electronic vapor product?
		Yes 1
		No 2 (Skip to C1)
B7.	Duri	ng the past 30 days , on how many days did you use an electronic vapor product?
-		days

SECTION C: ALCOHOL USE

Please answer some more personal questions; these are about drinking alcohol. Remember your answers are confidential. In these questions drinking alcohol does not include a few sips of wine for religious purposes. Drinking alcohol includes drinking beer, wine, wine coolers, and liquor such as rum, gin, vodka, or whiskey. For example, drinking alcohol includes drinking one bottle/can of beer, a glass of wine or a shot of rum.

C1.	Have you ever had a drink of alcohol?
	Yes
C2.	During your life, on how many occasions have you had at least one drink of alcohol?
	times
C3.	During the last 12 months, on how many occasions did you have at least one drink of alcohol?
	times
C4.	On a typical occasion during the past 12 months, how many alcoholic drinks did you have?
	drinks
C5.	During the past 30 days , on how many days did you have at least one drink of alcohol?
	days
	SECTION D: DRUG USE
drugs preso the q exam	following are personal questions about your use of "street drugs" or non-prescribed is to get high. These include marijuana, synthetic marijuana, inhalants, ecstasy, and cription drugs not prescribed to you. Remember your answers will be kept private. In juestions below, examples of opioids are OxyContin, Percocet, Vicodin, Codeine; inples of stimulants are Adderall, Ritalin, or Dexedrine; and examples of sedatives are ix, Valium, or Ambien.
D1.	During your life, have you ever used "street drugs"?
	Yes
D2.	During your life, how many times have you used marijuana? Marijuana is also called grass, pot, weed, or chronic.
	times
D3.	During the past 30 days, how many times have you used marijuana?
	times

D4.		ing the past 30 days , how many times have you used synthetic marijuana? Synthetic ijuana is also called K2, Spice, or fake weed.
		times
D5.		ing your life, how many times have you sniffed glue, breathed the contents of aerosol ay cans, or inhaled any paints or sprays to get high?
		times
D6.	Dur Mol	ing your life, how many times have you used ecstasy (also called MDMA, X, rolls, or ly)?
		times
D7.		ing your life, have you taken a prescription drug (such as opioids, stimulants, or atives) without a doctor's prescription (i.e., a drug that was not prescribed to you)?
		Yes 1
		No
	a.	How many times have you taken a prescription opioid that was not prescribed to you?
		times
	b.	How many times have you taken a prescription stimulant or amphetamine that was not prescribed to you?
		times
	C.	How many times have you taken a prescription sedative or benzodiazepine that was not prescribed to you? times
		THANK YOU FOR YOUR TIME AND EFFORT.

Chronic Kidney Disease in Children (CKiD)

SECTION A: GENERAL INFORMATION

A1.	PARTICIPANT ID: AFFIX ID LABEL OR ENTER NUMBER IF ID LABEL IS NOT AVAILABLE				
		- _ - _			
A2.	CKID VISIT #:				
A3.	FORM VERSION:	1 0 / 0 1 / 1 4			
A4.	DATE OF VISIT:				
A5.	INTERVIEWER'S INITIALS:	M M D D Y Y Y Y			

This form is to be completed by children, 12 years old or older, who are enrolled in CKiD.

INTRODUCTION TO PARTICIPANT:

Thank you for participating in this study.

This questionnaire should take about 5 to 10 minutes. Please read each question carefully. Take as much time as you need to answer each question and be as accurate as possible. As with all study information, your answers will be kept private. No one will know who filled out the questionnaire, because there is only a code number at the top, not your name. Even your parents and your doctor will not see your answers. Please answer all questions honestly. Your answers are for research purposes only and may help doctors find better ways to treat children with kidney problems. If you have trouble reading or understanding a question, please ask the nurse/coordinator for assistance and she/he will be happy to help.

Questions begin on the next page. For each question, **FILL IN THE ANSWER or CIRCLE THE NUMBER** that best matches the answer. When you have completed the form, please return it to the nurse/coordinator.

SECTION B: SMOKING

The following are some personal questions about your tobacco use. Please <u>circle</u> the <u>number</u> that best matches your answer.

B1.	In the past year, have you smoked tobacco (e.g., a whicigar)?	ole	cigarette, cigar, cigarillo or little
	Yes	1	
	No	2	(Skip to B4)



B2.	Do y	ou currently smoke tobacco?
		Yes
	a.	How old were you when you stopped smoking?
		years of age
	b.	While smoking, what was the average number of cigarettes, cigars, cigarillos or little cigars you smoked per week?
		number of cigarettes, cigars, cigarillos or little cigars (Skip to B4)
B3.		e past year, what is the average number of cigarettes, cigars, cigarillos or cigars you smoke per week?
		number of cigarettes, cigars, cigarillos or little cigars
B4.		e past year, have you smoked tobacco or non-tobacco (e.g., shisha, an herbal erial) using a hookah?
		Yes 1
		No
B5.		ng the past 30 days , how many times have you smoked tobacco or non-cco using a hookah?
		number of times smoked tobacco or non-tobacco using a hookah
Stark	uzz. l	questions ask about electronic vapor products, such as blu, NJOY, or Electronic vapor products include e-cigarettes, e-cigars, e-pipes, vape pipes, as, e-hookahs, and hookah pens.
B6.	In th	e past year, have you used an electronic vapor product?
		Yes
B7.	Duri	ng the past 30 days , on how many days did you use an electronic vapor product?
	-	days

SECTION C: ALCOHOL USE

Please answer some more personal questions; these are about drinking alcohol. Remember your answers are confidential. In these questions drinking alcohol does not include a few sips of wine for religious purposes. Drinking alcohol includes drinking beer, wine, wine coolers, and liquor such as rum, gin, vodka, or whiskey. For example, drinking alcohol includes drinking one bottle/can of beer, a glass of wine or a shot of rum.

C1.

C1.	In the past year, have you had a drink of alcohol? Yes
C2.	In the past year, on how many occasions have you had at least one drink of alcohol?
C3.	In the past year, on a typical occasion, how many alcoholic drinks did you have?
	drinks
C4.	During the past 30 days , on how many days did you have at least one drink of alcohol?
	days
	SECTION D: DRUG USE
presonant the q	is to get high. These include marijuana, synthetic marijuana, inhalants, ecstasy and cription drugs not prescribed to you. Remember your answers will be kept private. In questions below, examples of opioids are OxyContin, Percocet, Vicodin, Codeine; inples of stimulants are Adderall, Ritalin, or Dexedrine; and examples of sedatives are ax, Valium, or Ambien.
D1.	In the past year, have you used "street drugs"?
	Yes
D2.	In the past year, how many times have you used marijuana? Marijuana is also called grass, pot, weed, or chronic.
	times
D3.	During the past 30 days , how many times have you used marijuana?
	times

D4.		ing the past 30 days , how many times have you used synthetic marijuana? Synthetic ijuana is also called K2, Spice, or fake weed.
		times
D5.		ne past year, how many times have you sniffed glue, breathed the contents of aerosol ay cans, or inhaled any paints or sprays to get high?
		times
D6.		the past year, how many times have you used ecstasy (also called MDMA, X, rolls or olly)?
		times
D7.		ne past year, have you taken a prescription drug (such as opioids, stimulants, or atives) without a doctor's prescription (i.e., a drug that was not prescribed to you)?
		Yes 1
		No
	a.	How many times have you taken a prescription opioid that was not prescribed to you?
		times
	b.	How many times have you taken a prescription stimulant or amphetamine that was not prescribed to you?
		times
	C.	How many times have you taken a prescription sedative or benzodiazepine that was not prescribed to you?
		times

THANK YOU FOR YOUR TIME AND EFFORT.

Chronic Kidney Disease in Children (CKiD)

SECTION A: GENERAL INFORMATION

A1.	PARTICIPANT ID: AFFIX ID LABEL OR	ENTER NUMBER IF ID LABEL IS NOT AVAILABL	_E
		- _ - _	
A2.	CKID VISIT #:	<u>0</u> <u>1</u> <u>a</u>	
A3.	FORM VERSION:	0 3 / 0 1 / 1 8	
A4.	DATE OF VISIT:	$\frac{1}{M} \frac{1}{M} \frac{1}{D} \frac{1}{D} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y}$	
A5.	SITE COORDINATOR'S INITIALS:		
A6.	INDICATE PERSON COMPLETING THE	Parent or other adult 2	_
		Both (Parent and Child/young adult) 3	3

For each question, fill in the answer or circle the number that best matches the respondent's answer. Circle -8 for "Don't Know" responses. If a participant declines to answer a question, document -7 to the right of the response choice(s). For missing data, document -9 to the right of the response choice(s). Please document the reason for missing data (i.e., the question was accidentally skipped.)

Read each question and follow skip patterns as they appear on the form. Review the QxQ for detailed descriptions of questions.

INTRODUCTION TO PARTICIPANT:

Thank you for participating in this study.

The following pages contain questions about the participant's family background, birth history, developmental history and family medical history. Some of the questions may be difficult for you to answer and exact dates may be hard to remember. Please take as much time as you need, so I can gather information that is as accurate as possible.

As with all study information, your responses will be kept strictly confidential, and the responses you provide will in no way affect the participant's clinical care. The first set of questions asks about you and the participant's background. If you have trouble understanding anything, please feel free to ask for further clarification.



SECTION B: INFORMATION ABOUT YOU

The following questions are about your relationship to the participant who is participating in the study.

What is your relationship to (name of participant)?

B1.

	Mother
	a. If OTHER, specify your relationship: (Such as: grandmother, stepfather, uncle, etc.)
	SECTION C: PARTICIPANT'S BACKGROUND
Т	he next questions are about the participant's background.
C1.	What is (name of participant) date of birth?
	$\frac{1}{M}$ $\frac{1}{M}$ $\frac{1}{D}$ $\frac{1}{D}$ $\frac{1}{Y}$ $\frac{1}{Y}$ $\frac{1}{Y}$ $\frac{1}{Y}$
C2.	What is (<i>name of participant</i>) gender? Male
C3.	Was (name of participant) born in the United States of America (USA)? Yes
	a. Was (name of participant) born in Canada? Yes
	b. In what country was he or she born?
	c. When did (name of participant) move to the U.S. or Canada? (Year)
	Don't Know8



C4.	a.	Is (name of participant) of Hispanic or Latino/a Origin?
		Yes, Mexican-American, Chicano
		Yes, Puerto Rican 2 Yes, Cuban 3
		Yes, other Hispanic/Latino/a 4
		No, not of Hispanic or Latino/a origin
	b.	Which language does the participant speak most frequently?
		English
		Both (participant is bilingual) 3
C5.		ich of the following describe the race of (name of participant)? (Circle "Yes"," No", or on't Know" for EACH of the following. You may select "Yes" for more than one race.)
	a.	<u>Yes</u> <u>No</u> <u>Don't Know</u> White 1 2 -8
	b.	Black / African American 1 2 -8
	C.	American Indian / Alaskan Native 1 2 -8
	d. e.	
	f.	Other
		j. If Yes to Other , specify race:
		SECTION D: PARTICIPANT'S BIRTH
		xt questions are about the birth of the participant who is participating in the study. Iowing questions also ask about the participant's biological parents. Biological
p	arents	s are defined as the participant's birth or blood-related father or mother.
D1.	Was	s (<i>name of participant</i>)'s birth weight in pound (lbs) or kilograms (kg)?
		lbs
		Don't Know8 (Skip to D2)
	a.	What was (name of the participant)'s birth weight in lbs and ounces?
		lbs oz (Skip to D2)
	b.	What was (name of participant)'s birth weight in kilograms?
		kg
D2.		at was (name of participant) length at birth? (Round off to the nearest inch or centimeter. If ½ reater round up.) (Please circle "1" for inches or "2" for centimeters.)
		1= inches
		2= cm
		Don't Know8



D3.	Was (name of participant) born in a hospital? Yes
	No
	Don't Know8
D4.	How was (name of participant) delivered?
	Vaginal birth (natural) 1
	Cesarean section (c-section)2
	Don't Know8
D5.	Was (name of participant) born BEFORE due date?
	Yes 1
	No 2 (Skip to D6)
	Don't Know8 (Skip to D6)
	a. How many weeks BEFORE due date was (name of participant) born?
	weeks [this number should never exceed 20 weeks]
	Don't Know8
	b. Was (name of participant) considered "pre-mature" at the time of his/her birth?
	Yes 1
	No 2
	Don't Know8
D6.	Was (name of participant) a part of a multiple birth (e.g. a twin, triplet, etc.)?
	Yes 1
	No 2
D7.	Immediately after birth, did (name of participant) spend time in the intensive care unit (ICU or NICU) before being allowed to go home?
	Yes 1
	No 2
	Don't Know8
D8.	Immediately after birth, did (name of participant) have any kidney problems?
	Yes 1
	No 2
	Don't Know8
D9.	How long was (name of participant) birth mother in the hospital after the delivery?
	1 = $month(s)$ 3 = $day(s)$
	$2 = \text{week(s)}' \qquad -8 = \text{don't know}$



D10.	How long was (name of participant) in the hospital after the delivery?
	1 = month(s) 3 = day(s) 2 = week(s) -8 = don't know
D11.	What was the age of (name of participant) biological mother when the participant was born?
	years
	Don't Know8
D12.	Is (name of participant) biological mother of Hispanic or Latina Origin? Yes, Mexican-American, Chicano
	Yes, Cuban
D13.	Which of the following describe the race of (name of participant) biological mother? (Circle "Yes", "No" or "Don't Know" for EACH of the following. You may select "Yes" for more than one race.)
	Yes No Don't Know a. White
	f. Other
D14.	What was the age of (name of participant) biological father when the participant was born? years
	Don't Know8
D15.	Is (name of participant) biological father of Hispanic or Latino Origin? Yes, Mexican-American, Chicano



D16.	Which of the following describe the race of (r. "No" or "Don't Know" for EACH of the follow race.)				
		<u>Yes</u>	No	Dor	ı't Know
	a. White	. 1	2	-8	
	b. Black / African American	=	2	-8	
	c. American Indian / Alaskan Native	-	2	-8	
	d. Asian		2	-8	
	e. Native Hawaiian / Pacific Islander		2	-8	
	f. Other	. 1	2	-8	(If No or Don't Know to "Other", skip to E1)
	1. If Yes to Other , specify race:				
	SECTION E: PARTIC	IPANT	'S EC	UCA	ATION
 	The following questions are about the partici question asks about the highest grade or lev For example, if the participant is currently in participant is currently in the 6th grade, then the 1st grade, kindergarten or pre-school/presophomore in college, then enter "13".	el of so the 12 ^t enter "	chool ^h grac 5". In	the p le, th addi	articipant has completed. en enter "11", or if the tion, if the participant is in
E1.	What is the highest grade or level of schoo	that (n	ame d	of par	ticipant) has COMPLETED?
	Grade				
	Don't Know		-8		
	Not Applicable/child less than 5 years and does not attend pre-school/pre-k.		-1		
E2.	Does (<i>name of participant</i>) attend school (in home? Yes		1	chool →	and pre-K) outside of the (Skip to F1)
E3.	During the past school year, approximately from school because of not feeling well? Days	how ma	any da	ıys ha	as (name of participant) missed
	Don't Know		8		



The next two questions refer to service(s) the participant is currently receiving. If this form is completed during the summer months, please refer to the service(s) the participant received during the past school year.

E4.	Does (<i>name of participant</i>) have an individualized educational plan (IEP)? (An individualized educational plan includes special education and related services designed to address specific educational needs of children with disabilities. REFER TO QxQ FOR DETAILED DESCRIPTION.)
	Yes 1
	No 2
	Don't Know8
	Not Applicable/child less than 5 years old1 → (Skip to F1)
E5.	Does (name of participant) have a 504 plan (or equivalent for Canadian sites) at school? (A 504 plan is a program designed to assist students with physical or emotional disabilities or other special needs in a regular school environment. REFER TO QXQ FOR DETAILED DESCRIPTION.)
	Yes 1
	No 2
	Don't Know8
	×2
	SECTION F: PARTICIPANT'S FAMILY AND PRIMARY HOUSEHOLD

The following questions are to learn more about the participant's home and with whom he or she lives.

F1.	What is the curren	t relationship be	etween (<i>name</i> d	of participant)	biological	parents?
-----	--------------------	-------------------	------------------------	-----------------	------------	----------

Not married, living together	1
Married, living together	2
Married, separated	3
Widowed	
Divorced	5
Never married, not living together	6
Refuse to answer	-7
Don't Know	-8



The following questions ask about the participant's primary household. The primary household is the parent/guardian's home in which the participant lives at least half of the time. If the participant does not live with a parent/guardian (living independently, attending college or boarding school, emancipated, etc.), then the primary household is the parent/guardian's home where the participant used to live at least half the time prior to living independently.

F2.	How many days per week does (name of participal household? (For participants who do not live with a days the participant lived in parent/guardian's hom	a paren	t/guardian, indicat	e the number of
	Indicate a number between 4 and 7.			
	days			O'
	Don't Know	8	CC	
F3.	How many people live in the primary household at	least h	alf the time?	
	people		~0,	
	Don't Know	8	G	
F4.	How many adults live in the primary household at least 18 years of age. Include all persons at least non-relatives. Include participant if 18 years of age	18 yea		
	adults			
	Don't Know	8		
F5.	Which of the following adults (18 years of age or of half the time? (Circle "Yes", "No" or "Don't Know")			
		<u>Yes</u>	<u>No</u>	Don't Know
	a. Birth Mother	. 1	2	-8
	b. Birth Father	1	2	-8
	c. Step Mother/ Adoptive Mother	. 1	2	-8
	d. Step Father/ Adoptive Father	. 1	2	-8
	e. Participant	. 1	2	-8
	f. Otheri. Specify:	. 1	2 (Skip to F6)	-8 (Skip to F6)
F6.	Do any of the people, adults or children, living in the routinely smoke cigarettes, cigars, cigarillos or little			east half the time
	Yes	. 1		
	No	. 2		
	Dan't Know	0		



The following questions are about the education level of the participant's parent(s)/guardian(s) in the primary household. Remember, primary household is defined as the home in which the participant lives at least half of the time or lived prior to living independently.

F7.	What is the highest grade or level of school that (name of participant) MOTHER (including birth, adoptive or stepmother) in the primary household has COMPLETED? For example, if completed high school enter "12 years", if completed 4-year college degree enter "16 years", and if completed doctoral degree enter "20 years."
	Years
	Don't Know8 No Such Person
F8.	What is the highest grade or level of school that (<i>name of participant</i>) FATHER (including birth, adoptive or stepfather) in the primary household has COMPLETED? For example, if completed high school enter "12 years", if completed 4-year college degree enter "16 years", and if completed doctoral degree enter "20 years."
	Years
	Don't Know8 No Such Person1

For F9: ALLOW PARENT TO CIRCLE THE NUMBER IN THE FAR RIGHT COLUMN THAT CORRESPONDS TO THEIR TOTAL INCOME.

F9. Please estimate the total income (before taxes) of all members of the primary household. Include total income from wages, business, or investments for all members of (name of participant) primary household, by year, month, or week. Do NOT include social security, disability insurance, or other governmental assistance. Circle the number in the FAR RIGHT COLUMN that corresponds to the total income.

<u>YEAR</u>	<u>MONTH</u>	WEEK	_
\$6,000 OR LESS	\$500 OR LESS	\$115 OR LESS	1
\$6,001 TO \$12,000	\$501 TO \$1,000	\$116 TO \$231	2
\$12,001 TO \$18,000	\$1,001 TO \$1,500	\$232 TO \$346	3
\$18,001 TO \$24,000	\$1,501 TO \$2,000	\$347 TO \$461	4
\$24,001 TO \$30,000	\$2,001 TO \$2,500	\$462 TO \$577	5
\$30,001 TO \$36,000	\$2,501 TO \$3,000	\$578 TO \$692	6
\$36,001 TO \$75,000	\$3,001 TO \$6,250	\$693 TO \$1442	7
MORE THAN \$75,000	MORE THAN \$6,250	MORE THAN \$1442	8
Don't know			-8



F9a.	What is the current employment status of (name of participal adoptive or stepmother) in the primary household? Working full-time (35 hours or more per week) Working part-time (less than 35 hours per week) Unemployed but seeking work Unemployed not seeking work Student Retired Disability	1 2 3 4 5 6 7	 → SI → SI → SI → SI 	kip to F9b kip to F9b kip to F9b kip to F9b kip to F9b	ing birth,
	No such person in household/Not Applicable Don't Know			kip to F9b kip to F9b	
	i. Is (<i>name of participant</i>)'s MOTHER in the primary				ed?
	Yes			on ompley	.
	No				
	Don't Know				
F9b.	What is the current employment status of (name of participation)	nant)	's FAT	HFR (includir	na hirth
. 00.	adoptive or stepfather) in the primary household ?	Jarrej	01711	TILIT (IIIoiddii	ig ziitii,
	Working full-time (35 hours or more per week)	1			
	Working part-time (less than 35 hours per week)				
	Unemployed but seeking work		\rightarrow SI	kip to F9c	
	Unemployed not seeking work		\rightarrow SI	kip to F9c	
	Student	5	\rightarrow SI	kip to F9c	
	Retired		\rightarrow SI	kip to F9c	
	Disability	7	\rightarrow SI	kip to F9c	
	No such person in household/Not Applicable	-1	\rightarrow SI	kip to F9c	
	Don't Know	-8	\rightarrow SI	kip to F9c	
	i. Is (name of participant)'s FATHER in the primary I	hous	eholo	self-employe	ed?
	Yes				
	No				
	Don't Know	-8			
- 9c.	What is the current employment status of (name of participation)				
	(Circle "Yes", "No", "Not applicable (N/A)" or "Don't Know	w" fo			
	Yes		<u>No</u>	<u>N/A</u>	Don't Know
	Working full-time (35 hours or more per week) 1		2	-1	-8
	Working part-time (less than 35 hours per week) 1		2	-1	-8
	Disability Income		2	-1	-8
	Student		2	-1	-8
	Unemployed but seeking work 1 (skip to F		2	-1 (skip to F10)	-8 (skip to F10)
	Unemployed not seeking work 1 (skip to F	10)	2	-1 (skip to F10)	-8 (skip to F10)



	i. Is (name of participant) self-employed?
	Yes 1
	No 2
	Don't Know8
F10.	What is the zip code of the where the participant currently lives at least half of the time)?
F11.	Has the participant lived at the current zip code for more than 1 year?
	Yes
	Don't Know
	a. Approximately how many months has the participant lived at the current zip code?
	months Don't Know8
	b. What was the zip code where the participant previously lived?
	c. Approximately, how many years did the participant live at the previous zip code?
	years (Skip to Section G)
	Don't Know8 (Skip to Section G)
- 12.	Approximately, how many years has the participant lived at the current zip code?
	years Don't Know8
-40	
- 13.	Is the participant's zip code and their parents/guardians' zip code the same? Yes 1 (Skip to Section G)
	Tooman To
	Don't Know8 (Skip to Section G)
- 14.	What is the current zip code of the parent(s)/guardian(s) (i.e., the parent(s)/guardian(s) home where the participant used to live at least half the time prior to living independently)?
- 15.	Approximately, how long have the parent(s)/guardian(s) lived at the current zip code? year(s) month(s)



SECTION G: PARTICIPANT'S FAMILY HISTORY

The health conditions and illnesses experienced by close family members can provide important information about the participant's health. The following questions ask about the medical history of the participant's biological family. The participant's biological family includes his or her birth mother, birth father, grandparents, aunts, uncles, full brothers, full sisters and first cousins. (This does not include great aunts, great uncles and great grandparents.) Full brothers and full sisters are defined as siblings who have the same birth mother and birth father as the participant.

Some people who lost their parents at an early age, or who were adopted, may not have information on their birth family. If you are familiar with the health history of any of the members of the participant's biological or birth family, please answer the following questions about these relatives' health to the extent that you are able. If you are uncertain of the answer to any question, please select "Don't Know." If you have trouble understanding anything, please feel free to ask for further clarification.

G1.		you have knowledge of the health history of any members of (name of participant) birth nily (i.e. parents, grandparents, aunts, uncles, siblings and cousins)?
		Yes 1
		No 2 → (Skip to H1)
G2.	a.	How many living half siblings does (<i>name of participant</i>) have (Half siblings are defined as brothers and sisters, who have only one parent, either mother or birth father in common. Do not include deceased siblings.)?
		living half siblings \rightarrow (If "0", skip to G3)
		Don't Know8 \rightarrow (Skip to G3)
	b.	Does (name of participant) have any living half siblings in the study?
		Yes
		i. How many living half siblings does (name of participant) have participating in the study?
		living half siblings
G3.	a.	How many full siblings does (<i>name of participant</i>) have? (Full siblings are defined as brothers and sisters, who have the same birth mother and birth father as the participant. Include deceased siblings.)
		full (living and deceased) siblings → (If "0", skip to G5)
		Don't Know8 \rightarrow (Skip to G5)
	b.	How many living full siblings does (name of participant) have?
		full (living) siblings → (If "0", skip to G4)
		Don't Know8 \rightarrow (Skip to G4)
	c.	Does (name of participant) have any living full siblings in the study?
		Yes 1
		No
		i. How many living full siblings does (name of participant) have participating in the study?
		living full siblings



G4. Please provide the date of birth for EACH of (name of participant) full siblings (brothers & sisters).

	·				•				START GHs1
		Date o	f Birth	h			Date of	Birth	_
	a. Sibling 1			/		e. Sibling 5			
				YYYY				D D Y Y	
		Don't K	now		8		Don't Kn	ow	8
	b. Sibling 2	/		/		f. Sibling 6			
		M M		YYYY				DD YY	
		Don't K	now		8		Don't Kn	ow	8
	c. Sibling 3	/		<i>/</i>		g. Sibling 7			
	o. Olbillig o			Y Y Y Y		g. Olbillig 7		D D Y Y	 Y Y
								ow	
	1 0'1 1'								
	d. Sibling 4			/		h. Sibling 8		/	
				T T T				יי ע ט א 0W	
		DOILLY	IIOW				Dontkii	0w	o
									END GHs1
	Yes No Don't kn			1 2 →	(Skip to	•			
b	. Which family mem				pe of kidn	ey disease?			
	,			Alport's	Polycystic	Focal	Reflux	Other	Don't Know
	,	<u>Yes</u> N	0.	Hereditary Nephritis	Kidney Disease	Segmental Glomerulosclerosis	Nephropath (Kidney/bladde	-	
	_		- (ma)	_			Reflux)	_	
1	Mother 1	1 2	(#2)	1	2	3	4	5 (specif	y) -8
	l.						3	Specify:	
2	Father 1	1 2	(#3)	1	2	3	4	5 (specif	y) -8
							Ş	Specify:	
3	Sibling (full brother		(11.4)	_				.	. 0
	or sister)1	1 2	(#4)	1	2	3	4	5 (specif	
							5	Specify:	
4	Grandparent(s) 1	1 2	(#5)	1	2	3	4	5 (specif	y) -8
								Propiet :	
							•	Specify:	
5	Aunt(s)/Uncle(s) 1	1 2	(#6)	1	2	3	4	5 (specif	

G5.

6 Cousin(s)..... 1

(G6)

1



-8

Specify:

Specify:

5 (specify)

4

2

3

Next, the following questions ask about (name of participant) biological family members.

G6.	a.				participant) biological family members the SAME kidney disease as (name of
		Yes	1		
		No	2	\rightarrow	(Skip to G7)
		Don't know	-8	\rightarrow	(Skip to G7)
	b.	Which biological family members?	<u>Yes</u>	<u>No</u>	
		(Circle "Yes" or "No" for EACH of	f the f	ollowii	ng.)
		1. Mother	1	2	
		2. Father	1	2	. 01
		3. Sibling (full brother or sister)	1	2	
		4. Grandparent(s)	1	2	-0'
		5. Aunt(s)/Uncle(s)	1	2	G
		6. Cousin(s)	1	2	
G7.	a.	Including living and deceased, have ar had a kidney biopsy?	ny of (<i>n</i>	ame of	<i>participant</i>) biological family members
		Yes	1		
		No	2	\rightarrow	(Skip to G8)
		Don't know	-8	\rightarrow	(Skip to G8)
	b.	Which biological family members?	<u>Yes</u>	<u>No</u>	
		(Circle "Yes" or "No" for EACH of	f the f	ollowii	ng.)
		1. Mother	1	2	
		2. Father	1	2	
		3. Sibling (full brother or sister)	1	2	
		4. Grandparent(s)	1	2	
		5. Aunt(s)/Uncle(s)	1	2	
		6. Cousin(s)		2	



- G8. a. Including living and deceased, have any of (name of participant) biological family members been told by a health care professional (any doctor, nurse, physician assistant or nurse practitioner) that they had.
- b. Which biological family members? (Circle "Yes", "No", or "Don't Know" for EACH of the following.)

	stant or nurse practitioner) that they had	ionowing.)			
1.	High Blood Pressure or Hypertension		<u>Yes</u>		<u>Don't</u> Know
	Yes 1 Mo	other	1	2	-8
	No 2 → (Skip to 2) Fa	ther	1	2	-8
	Don't know8 \rightarrow (Skip to 2) Sit	bling (full brother			
	or	sister)	1	2	-8
	Gr	andparent(s)	1	2	-8
	Au	ınt(s)/Uncle(s)	1	2	-8
	Co	ousin(s)	1	2	-8
2.	High Cholesterol	G	<u>Yes</u>	<u>No</u>	Don't
					Know
	Yes 1 Mc	other	1	2	-8
		ther	1	2	-8
		bling (full brother			
		sister)			-8
		andparent(s)			-8
		ınt(s)/Uncle(s)			-8
	Co	ousin(s)	1	2	-8
3.	Diabetes (high blood sugar or sugar diabetes)		<u>Yes</u>		<u>Don't</u> Know
	Yes 1 Mc	other	1	2	-8
	No 2 → (Skip to 4) Fa	ther	1	2	-8
		bling (full brother			
		sister)			-8
		andparent(s)			-8
	Au	ınt(s)/Uncle(s)	1	2	-8

Cousin(s)..... 1



2

-8

(Circle "Yes", "No" or "Don't Know" for EACH of the following.)

•					-		
4.	Stroke before the ag	e of 50			<u>Yes</u>	<u>No</u>	Don't Know
	Yes	1		Mother	1	2	-8
	No	2 →	(Skip to 5)	Father	1	2	-8
	Don't know	-8 →	(Skip to 5)	Sibling (full brother		_	
				or sister)		2	-8
				Grandparent(s)			-8
				Aunt(s)/Uncle(s)		2	-8 -8
				Cousin(s)		2	-0
				70			
5.	Heart Attack before	the age o	of 50	.10	<u>Yes</u>	<u>No</u>	<u>Don't</u>
	V	_			4	2	Know
	Yes		(Claim to CO)	Mother	1	2	-8
	No		(Skip to G9)	Father	1	2	-8
	Don't know	-8 →	(Skip to G9)	Sibling (full brother or sister)	1	2	-8
			× C	Grandparent(s)	1	2	-8
			. 0	Aunt(s)/Uncle(s)		2	-8
			7.0.	Cousin(s)	1	2	-8
				G G G G G G G G G G G G G G G G G G G			
		10					
	A.*						
	X						
	5						
	(0)						

If more than one grandparent, aunt, uncle or first cousin has had dialysis, ask your site coordinator for further instructions.

G9.	a.	Including living and deceased, have any of (name of participant) biological family members had dialysis as treatment for kidney disease?	b. Which biological family members? (Circle "Yes", "No", or "Don't Know" for EACH of the following.)	c. At what age was treatment started?
		Yes 1	1. Mother	yrs
		No 2 \rightarrow (Skip to G10)	Yes 1	Don't Know8
		Don't Know8 \rightarrow (Skip to G10)	No	2)
			Don't Know8	
			2. Father	yrs
			Yes 1	Don't Know8
			No	3)
			Don't Know8	
			3. Sibling (full brother or sister)	yrs
			Yes 1	Don't Know8
			No 2 \rightarrow (skip to	4)
		.0.	Don't Know8	
		W/V	4.Grandparent(s)	yrs
		5	Yes 1	Don't Know8
			No 2 \rightarrow (skip to	5)
		¿O`	Don't Know8	
		×	5. Aunt(s)/Uncle(s)	yrs
		10	Yes 1	Don't Know8
		4	No 2 \rightarrow (skip to	6)
			Don't Know8	
			6. Cousin(s)	yrs
			Yes 1	Don't Know8
			No 2 \rightarrow (skip to	G10)



Don't Know..... -8

If more than one grandparent, aunt, uncle or cousin has had a kidney transplant, ask your site coordinator for further instructions.

G10.	a.	Including living and deceased, have any of (name of participant) biological family members had a kidney transplant as treatment for kidney disease?	b. Which biological family members? (Circle "Yes", "No" or "Don't Know" for EACH of the following.)	C.	At what age was transplant performed?
		Yes 1	1. Mother		yrs
		No 2 \rightarrow (Skip to G11)	Yes 1		Don't Know8
		Don't Know8 \rightarrow (Skip to G11)	No 2	\rightarrow (s	skip to 2)
			Don't Know8		
			2. Father		yrs
			Yes 1		Don't Know8
			No 2	ightarrow (s	skip to 3)
			Don't Know8		
			3. Sibling (full brother or sister)		yrs
			Yes 1		Don't Know8
		>	No 2	ightarrow (s	skip to 4)
			Don't Know8		
			4.Grandparent(s)		yrs
		4	Yes 1		Don't Know8
			No 2	ightarrow (s	skip to 5)
		X.V	Don't Know8		
			5. Aunt(s)/Uncle(s)		yrs
			Yes 1		Don't Know8
			No 2	ightarrow (s	skip to 6)
		·	Don't Know8		
			6. Cousin(s)		yrs
			Yes 1		Don't Know8
			No 2	\rightarrow (s	skip to G11)



Don't Know..... -8

G11.	Have any of the birth mother's pregnancies re (Circle "Yes", "No" or "Don't Know" for EAC	•
	Stillbirth (fetus died at birth) Miscarriage	
G12.	What is the current height of (name of participant) birth mother?	feet inches
		Don't Know8
G13.	What is the current weight of (name of participant) birth mother?	lbs
		Don't Know8
G14.	Has (name of participant) birth mother had r	ecurrent Urinary Tract Infections (UTI)?
	Yes No Don't Know	
G15.	What is the current height of (name of participant) birth father?	feet inches
		Don't Know8
G16.	What is the current weight of (name of participant) birth father?	lbs
G17.	Has (<i>name of participant</i>) birth father had re Yes No Don't Know.	1 2
G18.	Have any of (<i>name of participant</i>) siblings have a sibling si	
	N/A, participant does not have any sibl	lings1



SECTION H: PARTICIPANT'S DEVELOPMENTAL HISTORY

The following questions are to learn more about the participant's development. It may be difficult to recall the exact age so please take as much time as you need, allowing us to gather the most accurate information.

H1. At what age did (name of participant) first perform the following activities?

		- <u>- N</u>	<u>ge</u>	Don't Know	Not yet achieved
	a.	Turn over	months	-8	99
	b.	Sit alone	months	-8	99
	C.	Crawl	months	-8	99
	d.	Stand alone	months	-8	99
	e.	Walk alone	months	-8	99
	f.	Walk upstairs	months	-8	99
	g.	Walk downstairs	months	-8	99
	h.	Show interest in or attraction to sound (i.e., showed interest in shaking keys)	1=months 2=week(s)		99
			Don't know	-8	99
	i.	Understand first words	months	-8	99
	j.	Speak first words	months	-8	99
	k.	Speak in sentences			
		(3 or more words)	months	-8	99
H2.	a.	Is (name of participant) older than 5 age? Yes	1 → (Ski	p to H2c)	
	b.	Is (name of participant) currently bre fed?			
4		Yes	-	ip to H3)	
		No Don't Know		ip to H3)	
	C.	Was (name of participant) breast-fed Yes	1		
		No Don't Know	•	• '	



d.	How old was (name of participant) when he/she was weaned from breast feeding? (Please circle "1" for years, "2" for months, "3" for weeks or "4" for days.)
	Age 1 = year(s) 3 = week(s)
	2 = months 4 = days Don't Know8
H3. Is (name of participant) currently bottle-fed?
	Yes 1 \rightarrow (Skip to H4)
	No
a.	
	Yes 1
	No
	Don't Know8 → (Skip to H4)
b.	How old was (name of participant) when he/she was weaned from bottle feeding? (Please circle "1" for years, "2" for months, "3" for weeks or "4" for days.)
	Age 1 = year(s) 2 = months 3 = week(s) 4 = days
	Don't Know8
	UESTION H4 – H5, PLEASE PAY CLOSE ATTENTION TO THE SKIP PATTERNS. ACH SKIP PATTERN CAREFULLY. IT IS IMPORTANT TO ANSWER EACH QUESTION ACCORDING TO THE SKIP PATTERN.
	es (name of participant) have any wetness or leakage of urine (accidents) during the day
OI I	night? Yes 1
	No $2 \rightarrow \text{(Skip to c)}$
	Don't Know8 → (Skip to c)
a.	
	Yes 1
	No 2
b.	
ο.	Yes 1
	No



Don't Know.....-8

	C.	Does (name of participant) catheterize the bladder (i.e., put a tube in the bladder)?
		Yes 1
		No
		Don't Know8 \rightarrow (Skip to H5)
		i. Does (name of participant) catheterize through the urethra?
		Yes 1
		No
		Don't Know8
		ii. Does (name of participant) catheterize through a stoma?
		Yes 1
		No 2
		Don't Know8
⊣ 5.	ls (n	pame of participant) currently toilet trained?
		Yes
		No
	a.	When was (name of participant) toilet trained?
	a.	Wildli Wae (Name or participant) tellet trailled.
		years
	b.	After toilet training, did bed-wetting occur?
		Yes
		Don't Know
		i. Does bed-wetting still occur?
		Yes 1 → (Skip to iii)
		No 2
		Don't Know8 \rightarrow (Skip to C)
		ii. At what age did bed-wetting stop?
	4	(Please circle "1" for years or "2" for months.)
		Age 1 = years
		2 = months Don't Know8
		iii. Were medical reasons the cause of bed-wetting?
		Yes 1
		No 2
		Don't Know8



	c. Af	ter toilet training, did bed-soiling occur?		
		s		
)		
	Do	on't Know	8 →	(Skip to H6)
		. Does bed-soiling still occur?		
		Yes	1 →	(Skip to iii)
		No	2	
		Don't Know	8 →	(Skip to H6)
	i	At what age did bed-soiling stop?(Please circle "1" for years or "2" for	months.)	
		Age 1 = years		
		2 = months		
		Don't Know8		
	ii	 Were medical reasons the cause of be Yes 		
		No	2	
		Don't Know	-8	
H6.	Is (nam	e of participant) 4 years of age or older?		
	Yes	1		
	No	2 (Skip to	H9)	
H7.	During (name of participant) first 4 years, were a	ov problome	e noted in the graze listed helow?
117.		'Yes", "No" or "Don't Know" for EACH o		
		<u>Yes</u>	<u>No</u>	Don't Know
	a. Ea	ting 1	2	-8
	b. Ex	cessive crying 1	2	-8
	c. Fa	ilure to thrive 1	2	-8
	d. Mo	otor skills 1	2	-8
	e. Se	parating from parents 1	2	-8



2

2

2

-8

-8

-8

Sleeping too little...... 1

Sleeping too much.....

h. Temper tantrums..... 1

g.

H8.	Wh	ich hand does (name of participant) primarily use	to write	?	
	Prir	marily right		1	
	Prir	marily left		2	
	Am	bidextrous (writes equally with both left and right	hands)	3	
a docto	or or	cipant is under 4 years old, please answer the health care professional has told you that the problems.			
H9.		s (<i>name of participant</i>) experienced any of the fol rcle "Yes", "No" or "Don't Know" for EACH of th			ms?
	(Cii		Yes	No No	Don't Know
	a.	Feeding problem	1	2	-8
	b.	Eating disorder	1	2	-8
	C.	Underweight problem	1	2	-8
	d.	Overweight problem	1)	2	-8
	e.	Walking difficulty (per healthcare professional)	1	2	-8
	f.	Unclear speech (per healthcare professional)	1	2	-8
	g.	Sleep problem	1	2	-8
	h.	Colic	1	2	-8
DATE: ADMINI	M STR	MPLETED BY CLINICAL SITE: M / D D / Y Y Y Y ATION: 1 = Interviewer Assisted 2 = Self-Administered	INITI	ALS:	



FOLLOW-UP GENERAL HISTORY (F13)

Chronic Kidney Disease in Children (CKiD)

SECTION A: GENERAL INFORMATION

A1.	PARTICIPANT ID: AFFIX ID LABEL OR	ENTER NUMBER IF ID LABEL IS NOT AVAILABLE
		- _ - _
A2.	CKID VISIT #:	
A3.	FORM VERSION:	0 3 / 0 1 / 1 8
A4.	DATE OF VISIT:	$\overline{M} \overline{M} \overline{D} \overline{D} \overline{V} \overline{Y} \overline{Y} \overline{Y} \overline{Y}$
A5.	SITE COORDINATOR'S INITIALS:	
A6.	Is this study visit an irregular (acceler	rated) visit? Yes
A7.	INDICATE PERSON COMPLETING TH	Parent or other adult 2
		Both (Parent and Child/young adult)

For each question, fill in the answer or circle the number that best matches the respondent's answer. Circle -8 for "Don't Know" responses. If a participant declines to answer a question, document -7 to the right of the response choice(s). For missing data, document -9 to the right of the response choice(s). Please document the reason for missing data (i.e., the question was accidentally skipped.)

Read each question and follow skip patterns as they appear on the form. Review the QxQ for detailed descriptions of questions.

INTRODUCTION TO PARTICIPANT:

Thank you for participating in this study.

The following pages contain questions about the participant's family background and family medical history since their last study visit. Some of the questions may be difficult for you to answer and exact dates may be hard to remember. Please take as much time as you need, so I can gather information that is as accurate as possible.

As with all study information, your responses will be kept strictly confidential, and the responses you provide will in no way affect the participant's clinical care. The first set of questions asks about you and the participant's background. If you have trouble understanding anything please feel free to ask for further clarification.



SECTION B: INFORMATION ABOUT YOU

The following questions are about your relationship to the participant who is participating in the study.

B1.	Wha	t is your relationship to (name of participant)?
		Mother
		Father
		Self
		Other
	a.	If OTHER, specify your relationship:
	u.	
		(Such as: grandmother, stepfather, uncle, etc.)
		SECTION C: PARTICIPANT'S EDUCATION
	The follo	owing questions are about the participant's education. Specifically, the next
	question	asks about the highest grade or level of school the participant has completed.
	For exam	mple, if the participant is currently in the 12 th grade, then enter "11", or if the
		ant is currently in the 6 th grade, then enter "5". In addition, if the participant is in rade, kindergarten or pre-school/pre-K, then enter "0" or if participant is a
		ore in college, then enter "13".
C1.	Wha	it is the highest grade or level of school that (name of participant) has COMPLETED?
		Grade
		Don't Know8
		Not Applicable/child less than 5 years old and does not attend pre-school/pre-k1
C2	. Doe hon	es (name of participant) attend school (including pre-school and pre-K) outside of the ne?
		Yes 1
		No
C		ring the past school year, approximately how many days has (name of participant) seed from school because of not feeling well?
		Days
		Don't Know8
		DUIT (NIIOW8



The next two questions refer to service(s) the participant is currently receiving. If this form is completed during the summer months, please refer to the service(s) the participant received during the past school year.

C4.	Does (name of participant) have an individualized educational plan (IEP)? (An individualized educational plan includes special education and related services designed to address specific educational needs of children with disabilities. REFER TO QXQ FOR DETAILED DESCRIPTION.)
	Yes 1
	No 2
	Don't Know8
	Not Applicable/child less than 5 years old1 → (Skip to D1)
C5.	Does (name of participant) have a 504 plan at school (or equivalent for Canadian sites)? (A 504 plan is a program designed to assist students with physical or emotional disabilities or other special needs in a regular school environment. REFER TO QXQ FOR DETAILED DESCRIPTION.)
	Yes 1
	No 2
	Don't Know8
	SECTION D: PARTICIPANT'S FAMILY AND PRIMARY HOUSEHOLD
	ollowing questions are to learn more about the participant's home and with whom she lives.
D1.	What is the current relationship between (name of participant) biological parents?
	Not married, living together 1
	Married, living together 2
	Married, separated 3
	Widowed 4
	Divorced 5



The following questions ask about the participant's primary household. The primary household is the parent/guardian's home in which the participant lives at least half of the time. If the participant does not live with a parent/guardian (living independently, attending college or boarding school, emancipated, etc.), then the primary household is the parent/guardian's home where the participant used to live at least half the time prior to living independently.

D2.	How many days per week does (name of participant) live ir	n the primary hous	ehold?
	Indicate a number between 4 and 7. (For participants indicate the number of days the participant lived in p independently.)			
	days		X	
	Don't Know	-8	۷0,	
D3.	How many people live in the primary household at le	ast ha	If the time?	
	people		-0	
	Don't Know	-8		
		?>		
D4.	How many adults live in the primary household at least 18 years of age. Include all persons at least non-relatives. Include participant if 18 years of age.			
	adults			
	Don't Know	.8		
		J		
D5.	Which of the following adults (18 years of age and chalf the time? Include the participant, if applicable. (EACH of the following.)			
		<u>Yes</u>	<u>No</u>	Don't Know
	a. Birth Mother	1	2	-8
	b. Birth Father	1	2	-8
	c. Step Mother/ Adoptive Mother	1	2	-8
	d. Step Father/ Adoptive Father		2	-8
	e. Participant	1	2	-8
	f. Otheri. Specify:	1	2 (Skip to D6)	-8 (Skip to D6)
D6.	Do any of the people, adults or children, living in the routinely smoke cigarettes, cigars, cigarillos or little Yes No Don't Know.	cigars 1 2		east half the time



The following questions are about the education level of the participant's parent(s)/guardian(s) in the <u>primary household</u>. Remember, primary household is defined as the home in which the participant lives at least half of the time or lived prior to living independently.

<i>υ</i> 7.	birth, adoptive or stepmother) in the prin completed high school enter "12 years", and if completed doctoral degree enter "2	nary hoùsehold has Co if completed 4-year coll	OMPLETED? For example, if
	Years		
	Don't Know No Such Person		x'(0)
D8.	What is the highest grade or level of sch- birth, adoptive or stepfather) in the prima completed high school enter "12 years", and if completed doctoral degree enter "2	ary household has CO if completed 4-year coll	MPLETED? For example, if
	Years Don't Know	° Cl) `
	No Such Person		
	NO SUCH FEISOH	XO	
	For D9: ALLOW RESPONDENT TO CIR COLUMN THAT CORRESPONDS TO T		
D9.	Please estimate the total income (before Include total income from wages, busing participant) primary bounded by years	ness, or investments f	or all members of (<i>name of</i>

D9. Please estimate the total income (before taxes) of all members of the **primary household**. Include **total income from wages, business, or investments** for all members of (*name of participant*) primary household, by year, month, or week. Do **NOT** include social security, disability insurance, or other governmental assistance. **Circle** the number in the FAR RIGHT COLUMN that corresponds to the total income.

^	WEEK	<u>H</u>	MONT	YEAR	
1	\$115 OR LESS	R LESS	. \$500 C	\$6,000 OR LESS	\$
2	\$116 TO \$231	O \$1,000	\$501 T	\$6,001 TO \$12,000	\$
3	\$232 TO \$346	TO \$1,500	\$1,001	\$12,001 TO \$18,000	\$
4	\$347 TO \$461	TO \$2,000	\$1,501	\$18,001 TO \$24,000	\$
5	\$462 TO \$577	TO \$2,500	\$2,001	\$24,001 TO \$30,000	\$2
6	\$578 TO \$692	TO \$3,000	\$2,501	\$30,001 TO \$36,000	\$
7	\$693 TO \$1442	TO \$6,250	\$3,001	\$36,001 TO \$75,000	\$
8	MORE THAN \$1442	THAN \$6,250	. MORE	MORE THAN \$75,000	M
- 8				Don't know	D



D9a.	What is the current employment status of (<i>name of participan</i> adoptive or stepmother) in the primary household ?	t) MOTH	HER (including	ı birth,
	Working full-time (35 hours or more per week) 1			
	Working part-time (less than 35 hours per week) 2			
	Unemployed but seeking work 3	ightarrow Sk	ip to D9b	
	Unemployed not seeking work 4		ip to D9b	
	Student5		ip to D9b	
	Retired6		ip to D9b	
	Disability 7		ip to D9b	
	No such person in household/Not Applicable1		ip to D9b	
	Don't Know8		ip to D9b	
	i. Is (<i>name of participant</i>) MOTHER in the primary hous			?
	Yes 1	\ C		
	No	111		
	Don't Know8			
D9b.	What is the current employment status of (name of participant	, FATHE	R (including l	nirth
D00.	adoptive or stepfather) in the primary household ?	, , , , , , , , , ,	including i	Jii ti 1,
	Working full-time (35 hours or more per week) 1			
	Working part-time (less than 35 hours per week) 2			
	Unemployed but seeking work	ightarrow Ski	i p to D9c	
	Unemployed not seeking work4	ightarrow Ski	i p to D9c	
	Student5	ightarrow Ski	i p to D9c	
	Retired 6	ightarrow Ski	i p to D9c	
	Disability 7	ightarrow Ski	i p to D9c	
	No such person in household/Not Applicable1	ightarrow Ski	i p to D9c	
	Don't Know8	ightarrow Ski	i p to D9c	
	i. Is (name of participant)'s FATHER in the primary hous	ehold s	elf-employed	?
	Yes 1			
	No 2			
	Don't Know8			
D9c.	What is the current employment status of (name of participant)	?		
	Yes	<u>No</u>	N/A	Don't Know
	Working full-time (35 hours or more per week) 1	2	-1	-8
	Working part-time (less than 35 hours per week) 1	2	-1	-8
	Disability income	2	-1	-8
	Student 1	2	-1	-8
	Unemployed but seeking work	2	-1 (skip to D10)	
	Unemployed not seeking work	2		-8 (skip to D10)
	Champioyod not decking work	_	ו (פאוף נט טוט)	(פעום מו איים)



		Is (<i>name of participant</i>) self-employed? Yes1
		No
D10.		is the zip code where the participant currently lives at least half of the time?
D11.		he participant lived at the current zip code for more than 1 year? Yes
	a.	Approximately how many months has the participant lived at the current zip code?
		months Don't Know8
	b.	What was the zip code where the participant previously lived? ————————————————————————————————————
		Don't Know8
	C.	Approximately, how many years did the participant live at the previous zip code?
	,	years (Skip to Section E)
		Don't Know
D12.	Appro	eximately, how many years has the participant lived at the current zip code?
	,	
D13.		participant's zip code and their parents/guardians' zip code the same?
	· ·	Yes
		Don't Know8 (Skip to Section E)
D14.		is the current zip code of the parent(s)/guardian(s) (i.e., the parent(s)/guardian(s) home the participant used to live at least half the time prior to living independently)?
D15.		eximately, how long have the parent(s)/guardian(s) lived at the current zip code? year(s) month(s)
		DOILUMINOW



SECTION E: PARTICIPANT'S FAMILY HISTORY

The health conditions and illnesses experienced by close family members can provide important information about the participant's health. The following questions ask about the medical history of the participant's biological family. The participant's biological family includes his or her birth mother, birth father, grandparents, aunts, uncles, full brothers, full sisters and first cousins. (This does not include great aunts, great uncles and great grandparents.) Full brothers and full sisters are defined as siblings who have the same birth mother and birth father as the participant.

Some people who lost their parents at an early age, or who were adopted, may not have information on their birth family. If you are familiar with the health history of any of the members of the participant's biological or birth family, please answer the following questions about these relatives' health to the extent that you are able. If you are uncertain of the answer to any question, please select "Don't Know." If you have trouble understanding anything, please feel free to ask for further clarification.

E1.		you have knowledge of the health history of any members of (name of participant) birth ly (i.e. parents, grandparents, aunts, uncles, siblings and cousins)?
		Yes
E2.	a.	How many living half siblings does (<i>name of participant</i>) have (Half siblings are defined as brothers and sisters, who have only one parent, either mother or birth father in common. Do not include deceased siblings.)?
		living half siblings → (If "0", skip to E3)
		Don't Know8 \rightarrow (Skip to E3)
	b.	Does (name of participant) have any living half siblings in the study?
		Yes
		i. How many living half siblings does (<i>name of participant</i>) have participating in the study?
		living half siblings
E3.	a.	How many full siblings does (<i>name of participant</i>) have? (Full siblings are defined as brothers and sisters, who have the same birth mother and birth father as the participant. Include deceased siblings.)
		$-$ full (living and deceased) siblings \rightarrow (If "0", skip to E5) Don't Know8 \rightarrow (Skip to E5)
	b.	How many living full siblings does (name of participant) have?
		full (living) siblings \rightarrow (If "0", skip to E4) Don't Know8 \rightarrow (Skip to E4)
	C.	Does (name of participant) have any living full siblings in the study?
		Yes
		i. How many living full siblings does (<i>name of participant</i>) have participating in the study?
		living full siblings



									ST	ART F07s
		Date	of Birt	:h			Date o	f Birth		
	a. Sibling 1		/	/		e. Sibling 5	/	/		
	a. G.Sig	M		Y Y Y	- ,	or Gibining o	M	D D	YYYY	-
		Don't	Know		 -8		Don't K	now		8
	h Cibling 2		,	1		f Cibling 6	,	,		
	b. Sibling 2		_/	-/ - 	_ ,	f. Sibling 6	/ M M	/ .	YYYY	
		Bont	T (TIOWIII				Bontik			
	c. Sibling 3		<i></i>	_/	_	g. Sibling 7				_
				YYYY					YYYY	
		Don't	Know		8	4	Don't K	now		8
	d. Sibling 4		1	/		h. Sibling 8		/		
	J	M M	 I D D	Y Y Y			M M		Y Y Y	
		Don't	Know		 -8		Don't K	now		8
										END F07s
	The next que	estions	ask ab	out the fami	lv member	s who were tole	d thev ha	d kidn		
E5.	a. In the p	oast yea ers bee	ır, have n told l	oy a health ca	e of partic	ipant) living or on all that they ha			_	
E5.	a. In the period with the peri	oast yea	r, have	e any of (nam by a health ca 1 2	e of partic	onal that they ha			_	
	a. In the period with the peri	ers bee	n told b	e any of (nam by a health ca 1 2 8	e of partic are profession (Skip to (Skip to	onal that they ha			_	
	a. In the period with the peri	ers bee	n told b	e any of (<i>nam</i> by a health ca 1 2 8 C. What the	(Skip to (Skip to ype of kidne Polycystic	ponal that they have been been been been been been been be	d kidney Reflux	disease	_	
	a. In the period with the peri	ers bee	n told b	e any of (<i>nam</i> by a health ca 1 2 8 C. What t Alport's Hereditary	(Skip to (Skip to ype of kidner (Skip to	ponal that they have been been been been been been been be	d kidney Reflux Nephropa	disease	e in the pas	t year?
	a. In the period with the peri	ers bee	n told b	e any of (<i>nam</i> by a health ca 1 2 8 C. What the	(Skip to (Skip to ype of kidne Polycystic	ponal that they have been been been been been been been be	d kidney Reflux	disease	e in the pas	t year?
b.	a. In the period with the peri	ers bee	n told b	e any of (name oy a health can be also as a health can	(Skip to (Skip to ype of kidner (Skip to	ponal that they have been been been been been been been be	Reflux Nephropa (Kidney/blad	disease	e in the pas	t year?
b.	a. In the position in the posi	ers bee	n told b	e any of (name oy a health can be also as a health can	(Skip to (Skip to (Skip to ype of kidner Polycystic Kidney Disease	ey disease? Focal Segmental Glomerulosclerosis	Reflux Nephropa (Kidney/blad Reflux)	disease thy	e in the pas	t year? Don't Kno
b.	a. In the position in the posi	ers bee	n told l	e any of (name by a health can be also a health can	(Skip to (Skip to (Skip to ype of kidner Polycystic Kidney Disease	ponal that they have been been been been been been been be	Reflux Nephropa (Kidney/blad Reflux)	disease thy	Other 5 (specify)	t year? Don't Kno
b.	a. In the position in the posi	ers bee	n told b	e any of (name by a health can be also a health can	(Skip to (Skip to (Skip to ype of kidner Polycystic Kidney Disease	ey disease? Focal Segmental Glomerulosclerosis	Reflux Nephropa (Kidney/blad Reflux)	thy der Specify:	Other 5 (specify) 5 (specify)	t year? Don't Kno
b. 1	a. In the posterior membors and the posterior membors are seen as a seen as	ers bee	n told l	e any of (name by a health can be also a health can	(Skip to (Skip to (Skip to ype of kidner Polycystic Kidney Disease	ponal that they have been been been been been been been be	Reflux Nephropa (Kidney/blad Reflux)	thy der Specify:	Other 5 (specify)	t year? Don't Kno
b. 1 2 3	a. In the position in the posi	ers bee comments been been been been been been been bee	n told l	e any of (name by a health can be also a health can	(Skip to (Skip to (Skip to ype of kidner Polycystic Kidney Disease	ponal that they have been been been been been been been be	Reflux Nephropa (Kidney/blad Reflux)	thy der Specify:	Other 5 (specify) 5 (specify)	t year? Don't Kno
b. 1 2 3	a. In the posterior membors and the posterior membors are seen as a seen as	ers bee comments been been been been been been been bee	No 2 (#2	e any of (name by a health can be also a health can	(Skip to (Skip to (Skip to ype of kidner Polycystic Kidney Disease	ey disease? Focal Segmental Glomerulosclerosis 3	Reflux Nephropa (Kidney/blad Reflux) 4	thy der Specify:	Other 5 (specify) 5 (specify)	Don't Kno
b. 1 2	a. In the period membor yes No Don't keep with the period with the	ers bee comments been been been been been been been bee	No (#4	e any of (name by a health can be also as a health can	(Skip to (Skip to (Skip to ype of kidner Polycystic Kidney Disease 2 2	ponal that they have been been been been been been been be	Reflux Nephropa (Kidney/blad Reflux) 4 4	thy der Specify:	Other 5 (specify) 5 (specify) 5 (specify)	Don't Kno
b. 1 2	a. In the posterior membors and the posterior membors are seen as a seen as	ers bee comments been been been been been been been bee	No 2 (#2	e any of (name by a health can be also as a health can	(Skip to (Skip to (Skip to ype of kidner Polycystic Kidney Disease	ey disease? Focal Segmental Glomerulosclerosis 3	Reflux Nephropa (Kidney/blad Reflux) 4	thy der Specify: Specify:	Other 5 (specify) 5 (specify) 5 (specify) 5 (specify)	Don't Kno
b. 1 2 3 4	a. In the posterior membors and parent (s)	ers bee commenced by the commence of the comme	No 2 (#2 2 (#4 2 (#5	e any of (name by a health can be also a health can	(Skip to (Skip to (Skip to ype of kidner Polycystic Kidney Disease 2 2 2	ey disease? Focal Segmental Glomerulosclerosis 3 3	Reflux Nephropa (Kidney/blad Reflux) 4 4 4	thy der Specify: Specify:	Other 5 (specify) 5 (specify) 5 (specify) 5 (specify)	Don't Kno
b. 1 2 3 4	a. In the period membor yes No Don't keep with the period with the	ers bee commenced by the commence of the comme	No (#4	e any of (name by a health can be also a health can	(Skip to (Skip to (Skip to ype of kidner Polycystic Kidney Disease 2 2	ponal that they have been been been been been been been be	Reflux Nephropa (Kidney/blad Reflux) 4 4	thy der Specify: Specify: Specify:	Other 5 (specify) 5 (specify) 5 (specify) 5 (specify) 5 (specify)	Don't Kno
b. 1 2 3 4	a. In the posterior membors and parent (s)	ers bee commenced by the commence of the comme	No 2 (#4 2 (#5	e any of (name by a health can be also a health can	(Skip to (Skip to (Skip to ype of kidner Polycystic Kidney Disease 2 2 2	ey disease? Focal Segmental Glomerulosclerosis 3 3	Reflux Nephropa (Kidney/blad Reflux) 4 4 4	thy der Specify: Specify: Specify:	Other 5 (specify) 5 (specify) 5 (specify) 5 (specify)	Don't Kno



Specify:

Next, the following questions ask about (name of participant) biological family members.

E6.	a.	In the past year, have any of (name of members been told by a health care property (name of participant)?			iving or deceased biological family at they had the SAME kidney disease as
		Yes	1		
		No	2	\rightarrow	(Skip to E7)
		Don't know	-8	\rightarrow	(Skip to E7)
	b.	Which biological family members?	<u>Yes</u>	<u>No</u>	
		(Circle "Yes" or "No" for EACH of	the f	ollowi	ng.)
		1. Mother	1	2	
		2. Father	1	2	
		3. Sibling (full brother or sister)	1	2	
		4. Grandparent(s)	1	2	\sim
		5. Aunt(s)/Uncle(s)	1	2	
		6. Cousin(s)	1	2	
			\7)	
E7.	a.	In the past year, have any of (name of members had a kidney biopsy?	partic	cipant) l	iving or deceased biological family
		Yes	1		
		No	2	\rightarrow	(Skip to E8)
		Don't know	-8	\rightarrow	(Skip to E8)
	b.	Which biological family members?	<u>Yes</u>	<u>No</u>	
		(Circle "Yes" or "No" for EACH of	the f	iollowi	ng.)
		1. Mother	1	2	
		2. Father	1	2	
		3. Sibling (full brother or sister)	1	2	
		4. Grandparent(s)	1	2	
		5. Aunt(s)/Uncle(s)	1	2	
		6. Cousin(s)	1	2	



- E8. a. In the past year, have any of (name of participant) living or deceased biological family members been told by a health care professional (any doctor, nurse, physician assistant or nurse practitioner) that they had.
- b. Which biological family members? (Circle "Yes", "No", or "Don't Know" for EACH of the following)

assis	stant or nurse practitioner) that they had				
1.	High Blood Pressure or Hypertension		<u>Yes</u>	<u>No</u>	<u>Don't</u> Know
	Yes 1	Mother	1	2	-8
	No 2 \rightarrow (Skip to 2)	Father	1	2	-8
		Sibling (full brother			
	C	or sister)	1	2	-8
	(Grandparent(s)	1	2	-8
	A	Aunt(s)/Uncle(s)	1	2	-8
	(Cousin(s)	1	2	-8
2.	High Cholesterol	C	<u>Yes</u>	<u>No</u>	Don't Know
	Yes 1	Mother	1	2	-8
		Father		2	-8
		Sibling (full brother	•	_	
		or sister)	1	2	-8
		Grandparent(s)	1	2	-8
		Aunt(s)/Uncle(s)		2	-8
		Cousin(s)	1	2	-8
3.	Diabetes (high blood sugar or sugar diabetes	5)	<u>Yes</u>	<u>No</u>	Don't Know
		Mother	1	2	-8
	No 2 \rightarrow (Skip to 4)	Father	1	2	-8
		Sibling (full brother			
		or sister)		2	-8
		Grandparent(s)		2	-8
	A	Aunt(s)/Uncle(s)	1	2	-8

Cousin(s)..... 1



2

-8

(Circle "Yes", "No" or "Don't Know" for EACH of the following)

	•	· ·				•		
	4.	Stroke before the age of	of 50			<u>Yes</u>	<u>No</u>	Don't
		_						Know
		Yes 1			Mother	1	2	-8
		No 2	\rightarrow	(Skip to 5)	Father	1	2	-8
		Don't know8	\rightarrow	(Skip to 5)	Sibling (full brother			
				,	or sister)	1	2	-8
					Grandparent(s)		2	-8
					Aunt(s)/Uncle(s)	1	2	-8
					Cousin(s)	1	2	-8
					O00311(3)		_	Ü
	5.	Heart Attack before the	age c	of 50		<u>Yes</u>	<u>No</u>	Don't
					110			Know
		Yes 1			Mother	1	2	-8
		No 2	\rightarrow	(Skip to E9)	Father	1	2	-8
		Don't know8	\rightarrow	(Skip to E9)	Sibling (full brother			
					or sister)	1	2	-8
					Grandparent(s)	1	2	-8
					Aunt(s)/Uncle(s)	1	2	-8
				7.0	Cousin(s)		2	-8
					()			
			,					
			1	1				
		6						
		5						
		&O.						
-								



If more than one grandparent, aunt, uncle or cousin has had dialysis, ask your site coordinator for further instructions.

E9.	a.	In the past year, have any of (name of participant) living or deceased biological family members had dialysis as treatment for kidney disease?		c. At what age was treatment started?
		Yes 1	1. Mother	yrs old
		No 2 \rightarrow (Skip to E10)	Yes 1	Don't Know8
		Don't Know8 \rightarrow (Skip to E10)	No 2	ightarrow (skip to 2)
			Don't Know8	20
			2. Father	yrs old
			Yes 1	Don't Know8
			No 2	ightarrow (skip to 3)
			Don't Know8	
			3. Sibling (full	
			brother or sister)	yrs old
			Yes 1	Don't Know8
			No 2	ightarrow (skip to 4)
			Don't Know8	
			4.Grandparents	yrs old
		5	Yes 1	Don't Know8
			No 2	ightarrow (skip to 5)
		XO.	Don't Know8	
			5. Aunts/Uncles	yrs old
			Yes 1	Don't Know8
			No 2	ightarrow (skip to 6)
		¥	Don't Know8	
			6. Cousins	yrs old
			Yes 1	Don't Know8
			No 2	ightarrow (skip to E10)
			Don't Know8	



If more than one grandparent, aunt, uncle or cousin has had a kidney transplant, ask your site coordinator for further instructions.

E10.	a.	In the past year, have any of (name of participant) living or deceased biological family members had a kidney transplant as treatment for kidney disease?	b. Which biological family members? (Circle "Yes", "No", or "Don't Know" for EACH of the following)	c. At what age was transplant performed?
		Yes 1	1. Mother	yrs old
		No 2 \rightarrow (Skip to E11)	Yes 1	Don't Know8
		Don't Know8 \rightarrow (Skip to E11)	No 2	ightarrow (skip to 2)
			Don't Know8	
			2. Father	yrs old
			Yes 1	Don't Know8
			No2	ightarrow (skip to 3)
			Don't Know8	
			3. Sibling (full brother or sister)	vro old
			Yes 1	yrs old Don't Know8
			No 2	ightarrow (skip to 4)
		.0.	Don't Know8	
		*U	4.Grandparents	yrs old
		S	Yes 1	Don't Know8
		4	No 2	ightarrow (skip to 5)
		(0)	Don't Know8	
			5. Aunts/Uncles	yrs old
			Yes 1	Don't Know8
			No 2	ightarrow (skip to 6)
			Don't Know8	
			6. Cousins	yrs old
			Yes 1	Don't Know8
			No 2	ightarrow (skip to E11)
			Don't Know8	



≣11.	In the past year, has the birth mother been pregnant? Yes	(skip to E13)
Ξ12.	In the past year, have any of the birth mother's pregnancies r (Circle "Yes", "No" or "Don't Know" for EACH	•
	Stillbirth (fetus died at birth) Yes No Miscarriage 1 2 1 2	Don't Know -8 -8
Ξ13.	In the past year, has (name of participant) birth mother had re (UTI)? Yes	ecurrent Urinary Tract Infections
≣14.	In the past year, has (name of participant) birth father had rec (UTI)? Yes	current Urinary Tract Infections
Ξ15 .	In the past year, have any of (name of participant) siblings had (UTI)? Yes	ad recurrent Urinary Tract Infections



SECTION F: PARTICIPANT'S DEVELOPMENTAL HISTORY

The following questions are to learn more about the participant's development.

F1.	At th	ne last CKiD study visit, was (<i>name of participant</i>) older than 5 years of age? Yes
F2.	a.	Is (<i>name of participant</i>) currently older than 5 years of age? Yes
	b.	Is (name of participant) currently breast-fed? Yes
	C.	Was (name of participant) breast-fed? Yes
	d.	How old was (name of participant) when he/she was weaned from breast feeding? (Please circle "1" for years, "2" for months, "3" for weeks or "4" for days.) Age 1 = year(s)
F3.	Is (r	vame of participant) currently bottle-fed? Yes
	a.	Was (name of participant) bottle-fed? Yes
	b.	How old was (name of participant) when he/she was weaned from bottle feeding? (Please circle "1" for years, "2" for months, "3" for weeks or "4" for days) Age 1 = year(s)



FOR QUESTION F4 – F5, PLEASE PAY CLOSE ATTENTION TO THE SKIP PATTERNS. FOLLOW EACH SKIP PATTERN CAREFULLY. IT IS IMPORTANT TO ANSWER EACH QUESTION ACCORDING TO THE SKIP PATTERN.

F4.		ne past year, has <i>(name of participant)</i> had any wetness or leakage of urine (accidents) ng the day or night?
		Yes 1
		No
		Don't Know8 \rightarrow (Skip to c)
	a.	In the past year, is (name of participant) wet during the day?
		Yes 1
		No
		Don't Know8
	b.	In the past year, is (name of participant) wet during the night?
		Yes 1
		No
		Don't Know8
	C.	In the past year, has (name of participant) catheterized the bladder (i.e., put a tube in the bladder)? Yes
		No
		Don't Know8 → (Skip to F5)
		i. In the past year, has (name of participant) catheterized through the urethra?
		Yes 1
		No 2
		Don't Know8
		ii. In the past year, has (name of participant) catheterized through a stoma?
		Yes 1
		No 2
		Don't Know



F5.	At th	e last CKiD study visit, was (name of participant) toilet trained?
		Yes
		No
		Complete in
	a.	Is (name of participant) currently toilet trained?
		Yes
		Don't Know
	b.	When was (name of participant) toilet trained?
		Age years
	C.	After toilet training, did bed-wetting occur?
	0.	Yes 1
		No
		Don't Know8 \rightarrow (Skip to d)
		i Deschad wetting still secur?
		i. Does bed-wetting still occur?
		Yes
		Don't Know8 \rightarrow (Skip to c)
		ii. At what age did bed-wetting stop?
		(Please circle "1" for years and "2" for months)
		Age 1 = years 2 = months
		Don't Know8
		iii. Were medical reasons the cause of bed-wetting?
		Yes 1
		No 2
		Den't Knew



		After toilet training, did bed-soiling occur?
		Yes 1
		No
		Don't Know8 \rightarrow (Skip to F6)
		i Dana had adilian atill accur?
		i. Does bed-soiling still occur?
		Yes 1 → (Skip to iii)
		No 2
		Don't Know8 → (Skip to F6)
		ii Aturkat are did had asiling stan?
		ii. At what age did bed-soiling stop? (Please circle "1" for years and "2" for months)
		Age 1 = years
		2 = months
		Don't Know8
		iii. Were medical reasons the cause of bed-soiling?
		Yes 1
		No 2
		Don't Know8
F6.	At th	e last CKiD study visit, was (<i>name of participant</i>) 4 years of age or older?
		Yes 1 \rightarrow (Skip to F8)
		No 2
		Don't Know8
	a.	Is (name of participant) currently 4 years of age or older?
		Yes 1
		No
		Don't Know8 \rightarrow (Skip to F9)

F7.		ring (name of participant) first 4 years, were any		ns note	d in the areas listed below?
	mu	icate yes, no or don't know for each of the follow <u>Yes</u> <u>N</u>	virig. <u>√o</u>	<u>Don't</u>	Know
	a.	Eating 1 2	2	_	8
	b.	Excessive crying 1 2	2	_	8
	C.	• •	2	_	-8
	d.	Motor skills 1 2	2	_	8
	e.	Separating from parents 1 2	2	_	8
	f.	Sleeping too little 1 2	2	_	.8
	g.	Sleeping too much 1 2	2		8
	h.	Temper tantrums 1	2	(0)	8
F8.	Wh	ich hand does (name of participant) primarily us	e to writ	te?	
	Prir	narily right		1	
	Prir	marily left		2	
	Am	bidextrous (writes equally with both left and righ	t hands) 3	
a docto	r or l ig pr Has	pant is under 4 years old, please answer the health care professional has told you that the oblems. (name of participant) experienced any of the fo cle "Yes", "No" or "Don't Know" for EACH of the	e partic	ipant h	as had any of the
	a.	Feeding problem	1	2	-8
	b.	Eating disorder		2	-8
	C.	Underweight problem		2	-8
	d.	Overweight problem		2	-8
	e.	Walking difficulty (per healthcare professional)	1	2	-8
	f.	Unclear speech (per healthcare professional)	1	2	-8
	g.	Sleep problem	1	2	-8
	h.	Colic	1	2	-8
TO BE C	ОМР	PLETED BY CLINICAL SITE:			
DATE:	M	M / D D / Y Y Y	INITI	ALS:	
ADMINIS (Circle "		TION: 1 = Interviewer Assisted 2" or "3") 2 = Self-Administered			



3 = Both

Chronic Kidney Disease in Children (CKiD)

SECTION A: GENERAL INFORMATION

A1.	PARTICIPANT ID: AFFIX ID LABEL OF	RENTER NUMBER IF ID LABEL IS NOT AVAILABLE
		- _ - _
A2.	CKID VISIT #:	
A3.	FORM VERSION:	0 3 / 0 1 / 1 8
A4.	DATE OF VISIT:	$\frac{1}{M} \frac{1}{M} \frac{1}{D} \frac{1}{D} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y}$
A5.	SITE COORDINATOR'S INITIALS:	
A6.	Is this study visit an irregular (accele	rated) visit? Yes
A7.	INDICATE PERSON COMPLETING TH	
		Parent or other adult
		Both (Parent and Child/young adult)

For each question, fill in the answer or circle the number that best matches the respondent's answer. Circle -8 for "Don't Know" responses. If a participant declines to answer a question, document -7 to the right of the response choice(s). For missing data, document -9 to the right of the response choice(s). Please document the reason for missing data (i.e., the question was accidentally skipped.)

Read each question and follow skip patterns as they appear on the form. Review the QxQ for detailed descriptions of questions.

INTRODUCTION TO PARTICIPANT:

Thank you for participating in this study.

The following pages contain questions about your participant's family background and family medical history since their last study visit. Some of the questions may be difficult for you to answer and exact dates may be hard to remember. Please take as much time as you need, so I can gather information that is as accurate as possible.

As with all study information, your responses will be kept strictly confidential, and the responses you provide will in no way affect the participant's clinical care. The first set of questions asks about you and the participant's background. If you have trouble understanding anything, please feel free to ask for further clarification.



SECTION B: INFORMATION ABOUT YOU

The following questions are about your relationship to the participant who is participating in the study.

What is your relationship to (name of participant)?

B1.

		Mother
	a.	If OTHER, specify your relationship:
		(Such as: grandmother, stepfather, uncle, etc.)
		SECTION C: PARTICIPANT'S EDUCATION
quest For expartic the 1 st	ion as xample ipant i i grade	Ing questions are about the participant's education. Specifically, the next ks about the highest grade or level of school the participant has completed. It is, if the participant is currently in the 12 th grade, then enter "11", or if the is currently in the 6 th grade, then enter "5". In addition, if the participant is in e, kindergarten or pre-school/pre-K, then enter "0" or if participant is a in college, then enter "13".
C1.	Wha	at is the highest grade or level of school that (name of participant) has COMPLETED?
		Grade
		Don't Know8
		Not Applicable/child less than 5 years old and does not attend pre-school/pre-k1
C2.	Doe:	
		Yes
C3.		ng the past school year, approximately how many days has (<i>name of participant</i>) missed school because of not feeling well? Days
		Don't Know8



The next two questions refer to service(s) the participant is currently receiving unless this form is completed during the summertime when school is not in session. If this form is completed during the summer months, please refer to the service(s) the participant received during the past school year.

C4.	Does (name of participant) have an individualized educational plan (IEP)? (An individualized educational plan includes special education and related services designed to address specific educational needs of children with disabilities. REFER TO QXQ FOR DETAILED
	DESCRIPTION.) Yes 1
	No 2
	Don't Know8
	Not Applicable/child less than 5 years old1 \rightarrow (Skip to D1)
C5.	Does (name of participant) have a 504 plan at school (or equivalent for Canadian sites)? (A 504 plan is a program designed to assist students with physical or emotional disabilities or other special needs in a regular school environment. REFER TO QXQ FOR DETAILED DESCRIPTION.) Yes
	SECTION D: PARTICIPANT'S FAMILY AND PRIMARY HOUSEHOLD
The fe	
	llowing questions are to learn more about the participant's home and with whom she lives.

D1. What is the current relationship between (*name of participant*) **biological parents**?

Not married, living together	1
Married, living together	2
Married, separated	3
Widowed	4
Divorced	5
Never married, not living together	6
Refuse to answer	-7
Don't Know	-8



The following questions ask about the participant's primary household. The primary household is the parent/guardian's home in which the participant lives at least half of the time. If the participant does not live with a parent/guardian (living independently, attending college or boarding school, emancipated, etc.), then the primary household is the parent/guardian's home where the participant used to live at least half the time prior to living independently.

D2.	How many days per week does (name of participar	t) live	in the primary hou	sehold?
	Indicate a number between 4 and 7. (For participan indicate the number of days the participant lived in independently.)			
	days			
	Don't Know	-8		
D3.	How many people live in the primary household at I	east h	alf the time?	
	people			
	Don't Know	-8		
D4.	How many adults live in the primary household at least 18 years of age. Include all persons at least non-relatives. Include participant if 18 years of age.	st 18		
	adults			
	Don't Know	-8		
D5.	Which of the following adults (18 years of age or old half the time? Include the participant, if applicable. EACH of the following.)			
		Yes	<u>No</u>	Don't Know
	a. Birth Mother		2	-8
	b. Birth Father	1	2	-8
	c. Step Mother/ Adoptive Mother	1	2	-8
	d. Step Father/ Adoptive Father	1	2	-8
	e. Participant	1	2	-8
	f. Otheri. Specify:	1	2 (Skip to D6)	-8 (Skip to D6)
	i. Specify.			
D6.	Do any of the people, adults or children, living in the routinely smoke cigarettes, cigars, cigarillos or little	•	•	east half the time
	Yes	•		
	No			
	Don't Know	_		
Dele	ted Questions D7 and D8.			



For D9: ALLOW RESPONDENT TO CIRCLE THE NUMBER IN THE FAR RIGHT COLUMN THAT CORRESPONDS TO THEIR TOTAL INCOME.

Please estimate the total income (before taxes) of all members of the **primary household**. Include total income from wages, business, or investments for all members of (name of participant) primary household, by year, month, or week. Do NOT include social security, disability insurance, or other governmental assistance. Circle the number in the FAR RIGHT COLUMN that corresponds to the total income.

<u>YEAR</u>	<u>MONTH</u>	WEEK	<u>*</u>
\$6,000 OR LESS	\$500 OR LESS	\$115 OR LESS	. 1
\$6,001 TO \$12,000	\$501 TO \$1,000	\$116 TO \$231	2
\$12,001 TO \$18,000	\$1,001 TO \$1,500	\$232 TO \$346	3
\$18,001 TO \$24,000	\$1,501 TO \$2,000	\$347 TO \$461	4
\$24,001 TO \$30,000	\$2,001 TO \$2,500	\$462 TO \$577	5
\$30,001 TO \$36,000	\$2,501 TO \$3,000	\$578 TO \$692	6
\$36,001 TO \$75,000	\$3,001 TO \$6,250	\$693 TO \$1442	. 7
MORE THAN \$75,000	MORE THAN \$6,250	MORE THAN \$1442	8
Don't know			-8
What is the surrent ampleumer	at atatua of Inama of narticina	nt MOTHED (including hirt	

D9a.	What is the current employment status of (name of participant) MOTHER (including birth	١,
	adoptive or stepmother) in the primary household ?	

Working full-time (35 hours or more per week)	1	
Working part-time (less than 35 hours per week)	2	

Unemployed but seeking work	→ Skip to D9b
Unemployed not seeking work 4	\rightarrow Skip to D9b
Student 5	
Retired 6	\rightarrow Skip to D9b
Disability 7	\rightarrow Skip to D9b
No such person in household/Not Applicable1	\rightarrow Skip to D9b

L	Jon t Know	·····	8	→ Skib to Dap
i.	Is (name of partic	cipant) MOTHER in the	primary house	ehold self-employed?

Yes	1
No	2
Don't Know	-8

D = 12 1/1 = 1 . . .

D9b. What is the current employment status of (name of participant) FATHER (including birth, adoptive or stepfather) in the primary household?

,		
Working full-time (35 hours or more per week)	1	
Working part-time (less than 35 hours per week)	2	
Unemployed but seeking work	3	ightarrow Skip to D9c
Unemployed not seeking work	4	→ Skip to D9c
Student	5	→ Skip to D9c
Retired	6	→ Skip to D9c
Disability	7	→ Skip to D9c
No such person in household/Not Applicable	-1	→ Skip to D9c
Don't Know	-8	→ Skin to D9c



	i	\	-	ehold s	self-employed	?
		Yes No Don't Know	2			
D9c.	Wha	at is the current employment status of (name of	of participant)?			
			<u>Yes</u>	<u>No</u>	N/A	Don't Know
		Working full-time (35 hours or more per week)	1	2	-1	-8
		Working part-time (less than 35 hours per week)	1	2	-1	-8
		Disability income	1	2	-1	-8
		Student	=	2	-1	-8
		Unemployed but seeking work	1 (skip to D10)	2	-1 (skip to D10)	-8 (skip to D10)
		Unemployed not seeking work	1 (skip to D10)	2	-1 (skip to D10)	-8 (skip to D10)
	į.	. Is (name of participant) self-employed?	. (
		Yes		0		
		No				
		Don't Know	0			
D10.	Wha	at is the zip code where the participant curren	tlv lives at leas	t half c	of the time)?	
-			5 -		,	
		Don't Know	8			
D11.	Has	the participant lived at the current zip code for		-		
		Yes		D12)		
		No				
		Don't Know	8 (Skip to	o F1)		
	a.	Approximately how many months has the pa	articipant lived	at the	current zip cod	de?
		months				
		Don't Know	8			
	b.	What was the zip code where the participan	t previously liv	ed?		
		Q				
		Don't Know	8			
	C.	Approximately, how many years did the part	ticipant live at t	the pre	vious zip code	?
		years (Skip to F1)				
		Don't Know	8 (Skip t	o F1)		
D12.	Аррі	roximately, how many years has the participa	nt lived at the	current	t zip code?	
		years				
		Don't Know	-8			



D13.	Is th	e participant's zip code and their parents/guardians' zip code the same?
		Yes 1 (Skip to F1)
		No
		Don't Know8 (Skip to F1)
D14.		at is the current zip code of the parent(s)/guardian(s) (i.e., the parent(s)/guardian(s) home re the participant used to live at least half the time prior to living independently)?
D15.	Аррі	roximately, how long have the parent(s)/guardian(s) lived at the current zip code?
		year(s) month(s)
		Don't Know8
Delete	d Sec	tion E.
		SECTION F: PARTICIPANT'S DEVELOPMENTAL HISTORY
The fol	lowin	ng questions are to learn more about the participant's development.
F1.		ne last CKiD study visit, was (<i>name of participant</i>) older than 5 years of age?
	Αι ιι	Yes
		No
F2.	a.	Is (name of participant) currently older than 5 years of age?
1 2.	u.	Yes
		No
	b.	Is (name of participant) currently breast-fed?
		Yes
		Don't Know
	C.	Was (name of participant) breast-fed? Yes
	\vdash	No
		Don't Know8 \rightarrow (Skip to F3)
	d.	How old was (name of participant) when he/she was weaned from breast feeding? (Please circle "1" for years, "2" for months, "3" for weeks or "4" for days.)
		Age 1 = year(s) 2 = months 3 = week(s) 4 = days
		Don't Know



F3.	ls (n	ame of participant) currently bottle-fed?
		Yes
		No
		Don't Know8 \rightarrow (Skip to F4)
	a.	Was (name of participant) bottle-fed? Yes
		No
		Don't Know8 → (Skip to F4)
	b.	How old was (name of participant) when he/she was weaned from bottle feeding? (Please circle "1" for years, "2" for months, "3" for weeks or "4" for days)
		Age 1 = year(s) 2 = months 3 = week(s) 4 = days
		Don't Know8
		JESTION F4 – F5, PLEASE PAY CLOSE ATTENTION TO THE SKIP PATTERNS. CH SKIP PATTERN CAREFULLY. IT IS IMPORTANT TO ANSWER EACH QUESTIO ACCORDING TO THE SKIP PATTERN.
F4.		e past year, has (name of participant) had any wetness or leakage of urine (accidents)
	duni	ng the day or night? Yes1
		No
		Don't Know8 → (Skip to c)
	a.	In the past year, is (name of participant) wet during the day?
		Yes 1
		No
	h	Don't Know
	b.	In the past year, is (name of participant) wet during the night?
		Yes
		Don't Know8
	c.	In the past year, has <i>(name of participant)</i> catheterized the bladder (i.e., put a tube in the bladder)?
		Yes 1
	•	No
		i. In the past year, has (name of participant) catheterized through the urethra?
		Yes 1
		No



	ii. In the past year, has (name of participant) catheterized through a stoma?
	Yes 1
	No 2
	Don't Know8
F5. A	e last CKiD study visit, was (<i>name of participant</i>) toilet trained?
	Yes 1 → (Skip to F6)
	No
	Don't Know8 \rightarrow (Skip to F6)
	Is (name of participant) currently toilet trained?
	Yes 1
	No
	Don't Know8 \rightarrow (Skip to F6)
	When was (name of participant) toilet trained?
	Age years
	After tailet training, slid had welling a say 2
	After toilet training, did bed-wetting occur? Yes
	No
	Don't Know8 → (Skip to d)
	(0.14 10 0)
	i. Does bed-wetting still occur?
	Yes 1 \rightarrow (Skip to iii)
	No 2
	Don't Know8 \rightarrow (Skip to c)
	ii. At what age did bed-wetting stop? (Please circle "1" for years and "2" for months)
	Age 1 = years
	2 = months
	Don't Know
	Yes 1
	No 2
	Don't Know -8



d.		et training, did bed-soiling occur	
	No		2 → (END)
	Don't Kn	ow	8 → (END)
	i. Doe	es bed-soiling still occur?	
	Yes)	1 → (Skip to iii)
	No.		2
	Dor	n't Know	8 → (END)
	(Ple	vhat age did bed-soiling stop? ease circle "1" for years and "	"2" for months)
	Age	e 1 = years 2 = months	
	Do	n't Know	8
	iii. We	re medical reasons the cause of	of bed-soiling?
	Yes	S	
	No.		2
	Dor	n't Know	8
Deleted Qu	estions I	F6, F7, F8, F9 and Section (G.
TO BE COMP	LETED BY	CLINICAL SITE:	
DATE:	M / D	D/Y Y Y Y	INITIALS:
ADMINISTRA (Circle "1", "		1 = Interviewer Assisted 2 = Self-Administered 3 = Both	



Chronic Kidney Disease in Children (CKiD)

SECTION A: GENERAL INFORMATION

A1.	PARTICIPANT ID: AFFIX ID LAB	BEL OR ENTER NUMBER IF ID LABEL IS NOT AVAILABLI	E
		- -	
A2.	CKID VISIT #:	<u>0</u> <u>1</u> <u>a</u>	
A3.	FORM VERSION:	0 3 / 0 1 / 1 8	
A4.	DATE OF VISIT:	$\frac{1}{M} \frac{1}{M} \frac{1}{D} \frac{1}{D} \frac{1}{Y} \frac{1}$	
A5.	SITE COORDINATOR'S INITI	ALS:	
A6.	INDICATE PERSON COMPLETI	NG THE FORM Child/young adult 1 Parent or other adult 2	
		Both (Parent and Child/young adult) 3	

For each question, fill in the answer or circle the number that best matches the respondent's answer. Circle -8 for "Don't Know" responses. If a participant declines to answer a question, document -7 to the right of the response choice(s). For missing data, document -9 to the right of the response choice(s). Please document the reason for missing data (i.e., the question was accidentally skipped.)

Read each question and follow skip patterns as they appear on the form. Review the QxQ for detailed descriptions of questions.

INTRODUCTION TO PARTICIPANT:

The following questions are about the participant's health history, including information about the current and past diseases that the participant may have had in life. Dates may be hard to remember. Please take as much time as you need so I can gather information that is as accurate as possible.

As with all study information, your responses will be kept strictly confidential, and the responses you provide will in no way affect the participant's clinical care. The first set of questions asks about the participant's kidney disease. Whenever the term "health care provider" is used, it means any doctor, nurse, physician assistant or nurse practitioner the child has ever seen. If you have trouble understanding anything, please feel free to ask for further clarification.



SECTION B: KIDNEY DISEASE

B1.	When did the mother kidney problem?	or another family me	mbe	r first become aware of (name of participant)
	During Pregnanc	y	. 1	(Skip to B4)
	After Pregnancy.		. 2	
	Don't Know		8	
				•
DI	ELETED D2			
B3.	his/her kidney probler	n?		r another family member first became aware of 3" for weeks or "4" for days.)
	•	1 = years	10,	o for weeks of 4 for days.
	age	2 = months		60
		3 = weeks		
		4 = days		. (2)
	Don't Know		-8	XO
				7
B4.	How old was (name of (Please circle "1" for	of participant) when he years, "2" for mont	e or : hs , "	she was first seen by a pediatric nephrologist? 3" for weeks or "4" for days.)
	age	1 = years		
	5 —— ——	2 = months		
		3 = weeks		
		4 = days		
	Don't Know	. 69	-8	
B5.	Has (name of particip	ant) been seen by a	Urol	ogist (adult or pediatric)?
	Yes	<u> </u>	. 1	
	No		. 2	(Skip to B6)
	a. How old was (na.	me of participant) wh	nen h	e or she was first seen by a Urologist (adult or "for months, "3" for weeks or "4" for days.)
	age	1 = years		
	490 <u> </u>	2 = months		
		3 = weeks		
		4 = days		
	Dan't Know		0	



B6.		at were the methods/procedures performed to determine ticipant) with chronic kidney disease?	the pri	mary diagnosi	s of <i>(name of</i>
	(Ple	ease circle "Yes", "No" or "Don't Know" for EACH of the	e follow	ving.)	
			<u>Yes</u>	<u>No</u>	Don't Know
	a.	Kidney Biopsy	1	2	-8
	b.	Ultrasound/sonogram	1	2	-8
	c.	Voiding Cystourethrogram (VCUG)	1	2	-8
	d.	Nuclear Medicine Study (i.e., DMSA, DTPA, MAG3)	1	2	-8
	e.	Intravenous Pyelogram (IVP)	1	2	-8
	f.	Magnetic Resonance Imaging (MRI)	1	2	-8
	g.	Computed Tomography Scan (Cat/CT Scan)	1	2	-8
	h.	Genetic Testing	1	2	-8
	i.	Other	1	2	-8
				(Skip to B7)	(Skip to B7)
		Specify Other method/procedure:			
Р	RON	MPT: IF ANY OF B7 – B8 = YES, THEN COMPLETE TH	E MED	ICAL ABSTRA	CTION
		KING FORM (MAT).			
B7.		as (<i>name of participant</i>) ever had a urologic procedure, indney problems?	cluding	surgery to trea	at his or her
		Yes 1 → (Com	plete l	MAT)	
		No 2	•	,	
		Don't Know8			
B8.		as (<i>name of participant</i>) ever had a genetic test (i.e., Pode	ocin or	Nephrin) perfo	rmed to help
		Yes 1 → (Com	olete N	ЛАТ)	
		No 2		•	
		Don't Know8			



B9.	Has feve		ame of participant) with a kidney infection with a
		Yes	(Skip to B10)
	a.	How many times did he/she have a kidne times Don't Know8	ey infection with a fever in his/her first year of life?
	b.	How many times did he/she have a kidne times Don't Know	ey infection with a fever during the last year?
B10.	ls p	oarticipant a female? Yes1 No2	(Skin to C4)
B11.	Has	s (<i>name of participant</i>) started her menses Yes	s (i.e. period)? (Skip to C1)
	a.	How old was she when she started her myears Don't Know	



SECTION C: GENERAL MEDICAL HISTORY

The next set of questions asks about diseases/illnesses that the participant had since birth and diseases/illness that the participant has developed.

Has a doctor or any other healthcare professional ever told you that (*name of participant*) has any of the following diseases/illnesses?

PROMPT: IF ANY OF C1 - C4 = "YES", THEN COMPLETE THE MEDICAL ABSTRACTION TRACKING FORM (MAT).

(Please circle "Yes", "No" or "Don't Know" for EACH of the following.)

ıcası	clicle les, NO of Doll (Milow lol)	LACITOI IIIE I	mownig.	• •
		<u>Yes</u>	<u>No</u>	Don't Know
GE				(0)
a.		1	2	9
h			2	-8
		ı		-0
C.	(Lupus, Rheumotid Arthritis)	1	2	-8
CA	RDIOVASCULAR DISEASE			
a.	Heart Failure (Congestive heart failure)	1	2	-8
b.	Stroke	XO	2	-8
C.	Left Ventricular Hypertrophy (LVH)/ Thickened Heart Muscle	1	2	-8
LUI	NG DISEASE			
a.	Asthma	1	2	-8
b.	Chronic Lung Disease	1	2	-8
c.	Bronchopulmonary Dysplasia (BPD)	1	2	-8
GE	NITOURINARY DISEASE			
a.	Urinary Tract Infection	1	2	-8
b.	Blood in urine	1	2	-8
C.	Protein in urine	1	2	-8
d.	Passage of kidney stones	1	2	-8
e.	Recurrent pain on urinating	1	2	-8
GΑ	STROINTESTINAL DISEASE			
a.	Gastroenteritis (stomach flu, food poisonin	g) 1	2	-8
b.	Gastroesophageal Reflux (GERD)	1	2	-8
C.	Gastrointestinal Ulcer	1	2	-8
d.	Gastrointestinal Bleeding	1	2	-8
e.	Liver Inflammation Non-Infectious	1	2	-8
f.	Fatty Liver	1	2	-8
g.	Irritable Bowel	1	2	-8
h.	Encopresis (constipation)	1	2	-8
	GE a. b. c. CA a. b. c. GE a. b. c. d. e. f. g.	GENERAL / METABOLIC DISEASE a. Diabetes Mellitus (Sugar Diabetes, High Blood Sugar) b. Sickle Cell Disease c. Auto-immune Disease (Lupus, Rheumotid Arthritis) CARDIOVASCULAR DISEASE a. Heart Failure (Congestive heart failure) b. Stroke c. Left Ventricular Hypertrophy (LVH)/ Thickened Heart Muscle LUNG DISEASE a. Asthma b. Chronic Lung Disease c. Bronchopulmonary Dysplasia (BPD) GENITOURINARY DISEASE a. Urinary Tract Infection b. Blood in urine c. Protein in urine d. Passage of kidney stones e. Recurrent pain on urinating GASTROINTESTINAL DISEASE a. Gastroenteritis (stomach flu, food poisonin b. Gastroesophageal Reflux (GERD) c. Gastrointestinal Ulcer d. Gastrointestinal Bleeding e. Liver Inflammation Non-Infectious f. Fatty Liver g. Irritable Bowel	GENERAL / METABOLIC DISEASE a. Diabetes Mellitus (Sugar Diabetes, High Blood Sugar) b. Sickle Cell Disease c. Auto-immune Disease (Lupus, Rheumotid Arthritis) 1 CARDIOVASCULAR DISEASE a. Heart Failure (Congestive heart failure) b. Stroke c. Left Ventricular Hypertrophy (LVH)/ Thickened Heart Muscle 1 LUNG DISEASE a. Asthma b. Chronic Lung Disease c. Bronchopulmonary Dysplasia (BPD) 1 GENITOURINARY DISEASE a. Urinary Tract Infection b. Blood in urine c. Protein in urine d. Passage of kidney stones e. Recurrent pain on urinating GASTROINTESTINAL DISEASE a. Gastroenteritis (stomach flu, food poisoning) b. Gastroesophageal Reflux (GERD) c. Gastrointestinal Ulcer d. Gastrointestinal Bleeding e. Liver Inflammation Non-Infectious f. Fatty Liver g. Irritable Bowel	a. Diabetes Mellitus (Sugar Diabetes, High Blood Sugar) b. Sickle Cell Disease c. Auto-immune Disease (Lupus, Rheumotid Arthritis) 1 2 CARDIOVASCULAR DISEASE a. Heart Failure (Congestive heart failure) b. Stroke c. Left Ventricular Hypertrophy (LVH)/ Thickened Heart Muscle 1 2 LUNG DISEASE a. Asthma 1 2 b. Chronic Lung Disease c. Bronchopulmonary Dysplasia (BPD) 1 2 GENITOURINARY DISEASE a. Urinary Tract Infection 1 2 b. Blood in urine c. Protein in urine d. Passage of kidney stones e. Recurrent pain on urinating GASTROINTESTINAL DISEASE a. Gastroesophageal Reflux (GERD) 1 2 c. Gastrointestinal Ulcer d. Gastrointestinal Bleeding e. Liver Inflammation Non-Infectious f. Fatty Liver g. Irritable Bowel 1 2 2 2 2 2 3 2 3 3 4 2 3 4 2 3 4 2 5 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7



C6. Has a doctor or healthcare professional ever told you that (<i>name of participan</i> hypertension (high blood pressure)?					
		Yes	1 - Complete MA	AT	
		No	2 (Skip to C7)		
		Don't Know	-8 (Skip to C7)		
	a.	What is the status hypertension?	,		
		On meds but BP still high (Continued problem)	1		
		No longer hypertensive (Resolved problem)	2		
		On meds and BP controlled (Controlled w/ meds)	3	()	
	b.	Was the hypertension diagnosed within the p	oast year?	X	
		Yes	1		
		No	2		
		Don't Know	-8		
C7.	Has	a doctor or healthcare professional told you t	hat (<i>name of participa</i>	nnt) has hepatitis?	
		Yes	1 Complete MA	ΑΤ	
		No	2 (Skip to C8)		
		Don't Know	-8 (Skip to C8)		
	a.	Which of the following types of hepatitis does	(name of participant)	have?	
		<u>Yes</u>	<u>No</u>	Don't Know	
		Type A 1	2	-8	
		Type B	2	-8	
		Type C 1	2	-8	
		Other type 1 Specify:	2 (Skip to C7b)	-8 (Skip to C7b)	
	b.	Was the hepatitis diagnosed within the past y	/ear?		
		Yes	1		
		No	2		
		Don't Know	-8		
C8.		a doctor or healthcare professional told you t ction(s)?	hat (<i>name of participa</i>	ant) has any other	
		Yes	1 → Complete MA	ΑT	
		No	2 (Skip to C9)		
		Don't Know	-8 (Skip to C9)		
		Specify:		·	
	a.	Was the infection diagnosed within the past y	/ear?		
		No	1		
		Don't Know	2		
		Don't Know	-8		



(Please circle "Yes", "No" or "Don't Know" for EACH of the following.)

(<u>Yes</u>	No	Don't Know
C9.	CA	NCER			
	a.	Leukemia	1	2	-8
	b.	Lymphoma	1	2	-8
	C.	Bone Cancer	1	2	-8
	d.	Liver Cancer	1	2	-8
	e.	Skin Cancer	1	2	-8
	f.	Soft Tissue Sarcomas	1	2	-8
	g.	Other	1	2 (Skip to C10)	-8 (Skip to C10)
		Specify:			
			<u>Yes</u>	<u>No</u>	Don't Know
C10.	NE	UROPSYCHIATRIC DISEASE		0),	
	a.	Attention Deficit Disorder (ADD)	1	2	-8
	b.	Attention Deficit Hyperactivity Disorder (ADH	ID) 1	2	-8
	c.	Depression	x 10	2	-8
	d.	Learning Disability other than ADD or ADH	D 1	2	-8
	e.	Anxiety Disorder	1	2	-8
	f.	Other	1	2 (Skip to C11)	-8 (Skip to C11)
		Specify:			
		(0,)	<u>Yes</u>	<u>No</u>	Don't Know
C11.	СН	ILDHOOD ILLNESSES		_	
	a.	Measles	1	2	-8
	b.	German Measles	1	2	-8
	c.	Mumps	1	2	-8
	d.	Chickenpox	1	2	-8
	e.	Tuberculosis	1	2	-8
	f.	Whooping Cough	1	2	-8
	g.	Scarlet Fever	1	2	-8
	h.	Rheumatic Fever	1	2	-8
	i.	Diphtheria	1	2	-8
	j.	Meningitis	1	2	-8
	k.	Encephalitis	1	2	-8
	I.	Anemia	1	2	-8
	m	Fever above 104° for greater than 2 days	1	2	-8
	n.	Head injury including brain bleed	1	2	-8
	Ο.	Coma or loss of consciousness	1	2	-8
	p.	Other	1	2 (Skip to C10)	-8 (Skip to C10)



_						
C	pecify	,.				
\cdot	Oechy	/				
_	, ,	•		 	 	

Please indicate whether (*name of participant*) has or has had any of the following problems. (Please circle "Yes", "No" or "Don't Know" for EACH of the following.)

			<u>Yes</u>	<u>No</u>	Don't Know
C12.	NEU	ROLOGICAL			
	a.	Seizures/Convulsions	1	2	-8
	b.	Speech Defects	1	2	-8
	C.	Accident Prone	1	2	-8
	d.	Bites Nails	1	2	-8
	e.	Sucks Thumb	1	2	-8
	f.	Grinds Teeth	1	2	-8
	g.	Twitches/Tics	1	2	-8
	h.	Bangs Head	1 (2	-8
	i.	Rocks Back and Forth	1	2	-8
	j.	Bowel Movements in Bed/Pants	X 10	2	-8
C13.	HEA	RING	>		
	a.	Ear Infections	1	2	-8
	b.	Hearing Problems	1	2	-8
	c.	Ear Tubes	1	2	-8
C14.	VISI	ON			
	a.	Vision Problems	1	2	-8
	b.	Wears Glasses/Contacts	1	2	-8
	c.	Color Blindness	1	2	-8



SECTION D: ORTHOPEDIC HISTORY

The next set of questions asks about any orthopedic injuries the participant may currently have or that the participant has had since birth. Orthopedic injuries are injuries to the bones.

to	the bones.	Voc	No	Don't Know
D1.	Has a doctor or any other health professional	<u>Yes</u>	<u>No</u>	DOIT KHOW
	ever told you that (name of participant) has had any broken bones?	1	2 (Skip to D2)	-8 (Skip to D2)
	a. Please indicate which of the following	bones (name of participant) has broken.
	(Please circle "Yes", "No" or "Don	't Know	" for EACH of the f	ollowing.)
		<u>Yes</u>	<u>No</u>	Don't Know
	1. Back	1	2	-8
	2. Shoulder	1	2	-8
	3. Arm/Elbow	1	2	-8
	4. Wrist/Hand	1	2	-8
	5. Hip	1	2	-8
	6. Knee	1	2	-8
	7. Ankle	1	2	-8
	8. Foot	10	2	-8
	9. Leg		2	-8
	10. Fingers	1	2	-8
	11. Toes	1	2	-8
	12. Ribs	1	2	-8
	13. Collar Bone	1	2	-8
	4			
D2.	Does (name of participant) have any bone			
	Yes		1 → (Complet	te MAT)
	No		2 (Skip to F1)	
	Don't Know		-8 (Skip to F1)	
	a. Was the bone disease diagnosed with	hin the p	ast year?	
	Yes		1 → (Complet	te MAT)
	No		2	

DELETED SECTION E

Don't Know.....-8



SECTION F: HEALTHCARE UTILIZATION

These questions ask about all the places the participant may have received care in the last year.

F1.			st year, wher "No" for EA				eceive medio	cal care? (Pleas	se circle
	Did ((nam	e of participa	ant) go to			<u>Yes</u>	<u>No</u>	
	a.	Ас	linic or health	n care center	r		1	2	
	b.	Ар	rivate doctor	's office			1	2	
	c.	Hos	spital Outpati	ent Departm	nent		1	2	•
	d.	The	emergency	room			1	2 (Skip to e)
		1.		mes has (nan mergency roc		ant) received tyear?	. 0		
	e.		—— —— me other plac Please spe				COIILE	2 (Skip to F	2)
the	e term sistar In th inclu stud	n "he nt yo ne pa nding ly? Ir	ealth care probumay go to st year, how this CKID st	ovider" mean for medical many times udy visit or thild visits, si	ans any do al care. did (<i>name</i> d he visit at w ck visits and	octor, nurse portion of participant) which you wer	see a health e screened fo	set of question or physician's care provider, or eligibility into the times when	not the
			times	5					
		Do	n't Know			-8			
F3.	(mor	re tha lical a	an half of the appointments	time) see th	ne same hea	alth care prov		re, did he/she u of providers fo	
		No)			2			
		Do	on't Know			8			



The next questions ask about hospitalizations. Being hospitalized includes staying overnight or being admitted for a procedure that was done in one day. Please include all medical and psychiatric hospitalizations. This does not include being treated in the emergency room and then released the same day.

- 4				
F4.		e past year, has (<i>name of participant</i>) beer ? Do not include overnight stays in the er	nerg	ency room.
		Yes	1 -	→ (Complete MAT)
		No	2	(Skip to F5)
		Don't Know	-8	(Skip to F5)
	a.	How many different times was (name of	parti	icipant) hospitalized during the past year?
		times		
		Don't Know	-8	
		uestions ask some questions about car e received in the last year.	e or	social services that the participant
				20.
F5.		e past year, has (<i>name of participant</i>) beer lp him/her obtain services?	n see	en by a social worker or a case manager
		Yes	1	0
		No	2	
			V	
F6.		e past year, has (<i>name of participant</i>) rece chiatrist, psychiatric nurse, counselor, or of		
		Yes	1	
		Yes	2	
F7.	stam to th	e past year, has an agency assisted (name nps or WIC, meals on wheels, food pantrie e participant's parent/guardian's primary h icipant lives at least half the time or lived p	s, or	arranged to have groceries delivered ehold (i.e., the home in which the
		Yes	1	
		No	2	
F8.		e past year, has a social service agency he to live?	elpe	ed you or (name of participant) find a
		Yes	1	
		No	2	
F9.	In th	e past year, has (name of participant) rece	eive	d care from a dentist or dental hygienist?
		Yes	1	
		No	2	
F10.	In th	ne past year, has (<i>name of participant</i>) see	n a	nutritionist or a dietician?
		Yes	1	
		No	2	



SECTION G: HEALTH INSURANCE

These questions ask about the participant's health care coverage.

G1.	Does (<i>name of participant</i>) currently have any kind of health insurance or health care coverage? This includes both private and public insurance programs (e.g., Medicaid, SCHIP or MCHIP), dental insurance, and programs that help pay for medications.
	Yes 1 (Skip to G1b) No 2
G1a.	How long has it been since (name of participant) last had ANY health insurance or coverage?
	6 months or less
G1b.	In the past year, was there any time when (name of participant) was not covered by ANY health insurance or coverage? Yes
G1c.	In the past year, about how long was (name of participant) without ANY health insurance or coverage? 1 = months 2 = weeks 3 = days
G1d.	In the past year, was (name of participant) not covered by ANY insurance or coverage? Yes



INSTRUCTIONS: ASK QUESTIONS G2 - G QUESTION "A" (FAR RIG					
Does (name of participant) currently have	YES	NO	NA	A. Do	you or your mily members by for any of e insurance emium? NO
G2. *CALIFORNIA ONLY: Medi-CAL?	1	2	99		
G3. *MARYLAND ONLY: Medical Assistance?	1	2	99		
G4. ALL STATES EXCEPT CALIFORNIA and MARYLAND: Medicaid?	1	2	99		
G5. Private Health Insurance plan from employer or workplace?	1	2 (S	kip to G6)	1	2
G6. Private Health Insurance plan purchased directly?	1	2 (S	kip to G7)	1	2
G7. Private Health Insurance plan through a state or local government program or community program?	1	2 (S	kip to G8)	1	2
G8. CHIP (Children's Health Insurance Program)?	1	2 (S	kip to G9)	1	2
G9. Military Health Care/VA?	1	2 (S	kip to G10)	1	2
G10. CHAMPUS or other veteran's health insurance?	1	2 (S	kip to G11)	1	2
G11. Student Health Coverage?	1	2 (S	kip to G12)	1	2
G12. State-Sponsored Health Plan?	1	2 (S	kip to G13)	1	2
G13. Dental Insurance?	1	2			
G14. Vision Insurance?	1	2			
G15. Other types of health insurance? Specify	1	2 (S	kip to G16)		



G16.	Do any of these plans assist with prescriptions/medications?
	Yes 1
	No 2
	Not applicable / No Insurance1
G17.	In the past year, has (name of participant) been without needed prescription medication due to cost?
	Yes 1
	No 2
	Not applicable / No Insurance1
	Don't Know8
G18.	Does the participant's health insurance plan(s) pay for both doctor visits and hospital stays?
	Yes 1
	No 2
	Don't Know8
G19.	In the past year, have you had difficulty filing claims and/or getting reimbursed for medical
	care?
	Yes 1
	No 2
	Did not file any claims / No insurance -1
	Don't Know8
G20.	In the past year, how much of a problem, if any, was it to get care for (name of participant)
020.	that you or a doctor believed necessary?
	A big problem
	No problem 3
	My child had not visits in the last year -1
	Don't Know
004	
G21.	In the past year, how often did (name of participant) doctors or other health providers listen
	carefully to you?
	Never
	Usually
	i una joiniminiminiminiminiminiminiminiminimini
	My child had not visits in the last year -1 Don't Know
	Bon Craiow
G22.	In the past year, how often did (name of participant) doctors or other health providers explain
	things in a way you could understand?
	Never 1
	Sometimes 2
	Usually 3
	Always 4
	My child had not visits in the last year -1
	Don't Know



	respect for what you had to say?		
	Never	. 1	
	Sometimes	2	
	Usually	. 3	
	Always		
	Don't Know		
G24.	In the past year, how often did doctors or other	er health providers spend enough time with y	/ou
G24.	and (name of participant)?		/ou
G24.	and (name of participant)?		/ou
G24.	and (name of participant)? Never	10	/ou
G24.	and (<i>name of participant</i>)? NeverSometimes	1 2	/ou
G24.	and (name of participant)? Never Sometimes Usually	1 2 3	/ou
G24.	and (name of participant)? Never	1 2 3 4	/ou

We want to know your rating of all of (*name of participant*) health care in the last year from all **doctors and other health providers**. Use **any number from 0 to 10** where 0 is the worst health care possible, and 10 is the best health care possible.

G25. How would you rate all (name of participant) health care?

0 Worst health care possible	0
1	1
2	2
3	3
4	
5	5
6	6
7	
8	
9	
10	
My child had not visits in the last year	
Don't Know	



SECTION H: RENAL REPLACEMENT THERAPY

H1.	Have you ever discussed renal replacement therapy (i.e., dialysis or transplantation) with your nephrologist or health care provider?
	Yes
H2.	In the past year, have you discussed renal replacement therapy with your nephrologist or health care provider?
	Yes
	Yes
H3.	Was dialysis discussed?
	Yes 1 No 2 (skip to H5)
H4.	Which modality is preferred?
	Hemodialysis
H5.	Was transplantation discussed? Yes
H6.	Which donor option(s) has/have been discussed?
	(Please circle "Yes", "No" or "Don't Know" for EACH of the following.)
	Yes No Don't Know Living Donor
H7.	Has the participant been listed for deceased donor transplantation?
	Yes 1 No 2 (END)
	a. Date listed:// SITE SHOULD CONFIRM DATE
	M M / D D / Y Y Y
го ве	COMPLETED BY CLINICAL SITE:
DATE:	//
	STRATION: 1 = Interviewer Assisted "1", "2" or "3") 2 = Self-Administered 3 = Both



Chronic Kidney Disease in Children (CKiD)

SECTION A: GENERAL INFORMATION

A1.	PARTICIPANT ID: AFFIX ID LABEL OR E	NIER NUMBER IF ID LABEL IS NOT AVAILABL	Ė
		- -	
A2.	CKID VISIT #:		
A3.	FORM VERSION:	0 3 / 0 1 / 1 8	
A4.	DATE OF VISIT:	$\frac{1}{M} \frac{1}{M} \frac{1}{D} \frac{1}{D} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y}$	
A5.	SITE COORDINATOR'S INITIALS:		
A6.	Is this study visit an irregular (accelerated)	visit? Yes	1 2
A7.	INDICATE PERSON COMPLETING THE		1
		Parent or other adult	2
		Both (Parent and Child/young adult)	3

For each question, fill in the answer or circle the number that best matches the respondent's answer. Circle -8 for "Don't Know" responses. If a participant declines to answer a question, document -7 to the right of the response choice(s). For missing data, document -9 to the right of the response choice(s). Please document the reason for missing data (i.e., the question was accidentally skipped.)

Read each question and follow skip patterns as they appear on the form. Review the QxQ for detailed descriptions of questions.

INTRODUCTION TO PARTICIPANT:

The following questions are about the participant's health history, including information about the current and past diseases that the participant may have had in life. Dates may be hard to remember. Please take as much time as you need so I can gather information that is as accurate as possible.

As with all study information, your responses will be kept strictly confidential, and the responses you provide will in no way affect the participant's clinical care. The first set of questions asks about the participant's kidney disease. Whenever the term "health care provider" is used, it means any doctor, nurse, physician assistant or nurse practitioner the child has ever seen. If you have trouble understanding anything, please feel free to ask for further clarification.



SECTION B: KIDNEY DISEASE

B1.	In the past year, has (name of participant) been seen by a Urologist (adult or pediatric)?
	Yes 1
	No 2
	MPT: IF ANY OF B2 – B3 = YES, THEN COMPLETE THE MEDICAL ABSTRACTION CKING FORM (MAT).
B2.	In the past year, has (<i>name of participant</i>) had a urologic procedure, including surgery to treat his or her kidney problems?
	Yes 1 → (Complete MAT)
	No 2
	Don't Know8
B3.	In the past year, has (name of participant) had a genetic test (i.e., Podocin or Nephrin) performed to help diagnose his or her kidney disease?
	Yes 1 → (Complete MAT)
	No 2
	Don't Know8
B4.	In the past year, has a healthcare provider diagnosed (name of participant) with a kidney infection with a fever?
	Yes 1
	No 2 (Skip to B5)
	Don't Know8 (Skip to B5)
	a. In the past year, how many times did he/she have a kidney infection with a fever?
	times
B5.	Is participant a female?
	Yes 1
<	No 2 (Skip to C1)
B6.	In the past year, has (name of participant) started her menses (i.e. period)? Yes
	No
	Don't Know8 (Skip to C1)
	a. How old was she when she started her first period?
	vears of age
	years of age Don't Know



SECTION C: GENERAL MEDICAL HISTORY

The next set of questions asks about diseases/illnesses that the participant had or developed in the past year.

In the past year, has a doctor or any other healthcare professional told you that (name of participant) had or has developed any of the following diseases/illnesses?

PROMPT: IF ANY OF C1 - C4 = YES, THEN COMPLETE THE MEDICAL ABSTRACTION TRACKING FORM (MAT).

(Please circle "Yes", "No" or "Don't Know" for EACH of the following.)

		,	<u>Yes</u>	<u>No</u>	Don't Know
C1.	GE	NERAL / METABOLIC DISEASE			
	a.	Diabetes Mellitus (Sugar Diabetes, High Blood Sugar)	1	2	-8
	b.	Sickle Cell Disease	1	2	-8
	C.	Auto-immune Disease (Lupus, Rheumotid Arthritis)	1	2	-8
C2.	CA	RDIOVASCULAR DISEASE			
	a.	Heart Failure (Congestive heart failure)	1.0	2	-8
	b.	Stroke		2	-8
	C.	Left Ventricular Hypertrophy (LVH)/ Thickened Heart Muscle	0.1	2	-8
C3.	LUI	NG DISEASE			
	a.	Asthma	1	2	-8
	b.	Chronic Lung Disease	1	2	-8
	c.	Bronchopulmonary Dysplasia (BPD)	1	2	-8
C4.	GE	NITOURINARY DISEASE			
	a.	Urinary Tract Infections	1	2	-8
	b.	Blood in urine	1	2	-8
	C.	Protein in urine	1	2	-8
	d.	Passage of kidney stones	1	2	-8
	e.	Recurrent pain on urinating	1	2	-8
C5.	GA	STROINTESTINAL DISEASE			
	a.	Gastroenteritis (stomach flu, food poisoning)) 1	2	-8
	b.	Gastroesophageal Reflux (GERD)	1	2	-8
	C.	Gastrointestinal Ulcer	1	2	-8
	d.	Gastrointestinal Bleeding	1	2	-8
	e.	Liver Inflammation Non-Infectious	1	2	-8
	f.	Fatty Liver	1	2	-8
	g.	Irritable Bowel	1	2	-8
	h.	Encopresis (constipation)	1	2	-8



C6.		he past year, has a doctor or healthcare profe s hypertension (high blood pressure)?	ssional told you that (name of participant)
		Yes	1 - Complete M	AT
		No	2 (Skip to C7)	
		Don't Know	-8 (Skip to C7)	
	a.	What is the status hypertension?		
		On meds but BP still high (Continued problem)	1	
		No longer hypertensive (Resolved problem)	2	
		On meds and BP controlled (Controlled w/ meds)	3	
	b.	Was the hypertension diagnosed within the	oast year?	
		Yes	1	XI
		No	. 2	
		Don't Know	-8	
C7.		he past year, has a doctor or healthcare profe	ssional told you that (name of participant)
	has	s hepatitis?	~0.	
		Yes		AT
		No	, , ,	
		Don't Know	-8 (Skip to C8)	
	a.	Which of the following types of hepatitis doe	s (name of participant) have?
		<u>Yes</u>	<u>No</u>	Don't Know
		Type A 1	2	-8
		Type B	2	-8
		Type C	2	-8
		Other type 1	2 (Skip to C7b)	-8 (Skip to C7b)
		Specify:		
	b.	Was the hepatitis diagnosed within the past	year?	
		Yes		
		No		
		Don't Know	-8	
C8.		he past year, has a doctor or healthcare profes any other infection(s)?	ssional told you that (name of participant)
		Yes	1 → Complete M	AT
		No	2 (Skip to C9)	
		Don't Know	-8 (Skip to C9)	
		Specify:		
	a.	Was the infection diagnosed within the past		
		Yes	•	
		No	. 2	
		Don't Know	-8	



(Please circle "Yes", "No" or "Don't Know" for EACH of the following.)

			<u>Yes</u>	<u>No</u>	Don't Know
C9.	CAI	NCER			
	a.	Leukemia	1	2	-8
	b.	Lymphoma	1	2	-8
	C.	Bone Cancer	1	2	-8
	d.	Liver Cancer	1	2	-8
	e.	Skin Cancer	1	2	-8
	f.	Soft Tissue Sarcoma	1	2 2 (Chin to C40)	-8
	g.	Other	1	2 (Skip to C10)	-8 (Skip to C10)
		Specify:		- X	
C10.	NE	JROPSYCHIATRIC DISEASE		-C)~.	
	a.	Attention Deficit Disorder (ADD)	1	2	-8
	b.	Attention Deficit Hyperactivity Disorder (ADHD)	1	2	-8
	c.	Depression	1	2	-8
	d.	Learning Disability other than ADD or ADHD	1	2	-8
	e.	Anxiety Disorder	1	2	-8
	f.	Other	1	2 (Skip to C11)	-8 (Skip to C11)
		Specify:			
C11	СП	ILDHOOD ILLNESSES	<u>Yes</u>	<u>No</u>	Don't Know
CII.	a.	Measles	1	2	-8
	b.	German Measles	1	2	-8
	C.	Mumps	1	2	-8
	d.	Chickenpox	1	2	-8
	e.	Tuberculosis	1	2	-8
	f.	Whooping Cough	1	2	-8
	g.	Scarlet Fever	1	2	-8
	h.	Rheumatic Fever	1	2	-8
	i.	Diphtheria	1	2	-8
	j.	Meningitis	1	2	-8
	k.	Encephalitis	1	2	-8
	I.	Anemia	1	2	-8
	m	Fever above 104° for greater than 2 days	1	2	-8
	n.	Head injury including brain bleed	1	2	-8
	0.	Coma or loss of consciousness	1	2	-8
	p.	Other	1	2 (Skip to C12)	-8 (Skip to C12)
		Specify:			



Please indicate whether (*name of participant*) has or has had any of the following problems. (Please circle "Yes", "No" or "Don't Know" for EACH of the following.)

			<u>Yes</u>	<u>No</u>	Don't Know
C12.	NEU	ROLOGICAL			
	a.	Seizures/Convulsions	1	2	-8
	b.	Speech Defects	1	2	-8
	c.	Accident Prone	1	2	-8
	d.	Bites Nails	1	2	-8
	e.	Sucks Thumb	1	2	-8
	f.	Grinds Teeth	1	2	-8
	g.	Twitches/Tics	1	2	-8
	h.	Bangs Head	1	2	-8
	i.	Rocks Back and Forth	1	2	-8
	j.	Bowel Movements in Bed/Pants	1	2	-8
C13.	HEA	RING			
	a.	Ear Infections	1	2	-8
	b.	Hearing Problems	1	2	-8
	C.	Ear Tubes	1	2	-8
C14.	VISI	ON			
	a.	Vision Problems	1	2	-8
	b.	Wears Glasses/Contacts	1	2	-8
	C.	Color Blindness	1	2	-8



SECTION D: ORTHOPEDIC HISTORY

The next set of questions asks about any orthopedic injuries the participant may currently have or that the participant has had in the past year. Orthopedic injuries are injuries to the bones.

		<u>Yes</u>	<u>No</u>	Don't Know
D1.	In the past year, has a doctor or any other health professional told you that (name of	1	2 (Skip to D2)	-8 (Skip to D2)
	participant) has had any broken bones?			

a. Please indicate which of the following bones (name of participant) has broken. (Please circle "Yes", "No" or "Don't Know" for EACH of the following.)

		<u>Yes</u>	<u>No</u>	Don't Know
1.	Back	1	2	-8
2.	Shoulder	1	2	-8
3.	Arm/Elbow	1	2	-8
4.	Wrist/Hand	1	2	-8
5.	Hip	1	2	-8
6.	Knee	1.0	2	-8
7.	Ankle		2	-8
8.	Foot	4	2	-8
9.	Leg	1	2	-8
10.	Fingers	1	2	-8
11.	Toes	1	2	-8
12.	Ribs	1	2	-8
13.	Collar Bone	1	2	-8

D2. Does (name of participant) have any bone disease in the hips?

	Yes		(Complete MAT)
	No	2	(Skip to F1)
	Don't Know	-8	(Skip to F1)
a.	Was the bone disease diagnosed within the p	oast yea	ar?
	Yes	1	(Complete MAT)
	No	2	
	Don't Know	-8	

DELETED SECTION E



SECTION F: HEALTHCARE UTILIZATION

These questions ask about all the places the participant may have received care in the past year.

F1.

Г1.		ase circle "Yes" or "No" for EACH of the follo		
	Did	(name of participant) go to		
			<u>Yes</u>	<u>No</u>
	a.	A clinic or health care center	1	2
	b.	A private doctor's office	1	2
	C.	Hospital Outpatient Department	1	2
	d.	The emergency room	1	2 (Skip to e)
		How many times has (name of participant) received care at the emergency room in the past year? ——————		Cillo
	e.	Some other place 1. Please specify:	COIII	2 (Skip to F2)
the te	rm "he	tions ask about the participant's use of health ealth care provider" means any doctor, nurse ou may go to for medical care.	care. In this practitioner,	set of questions, or physician
F2.	inclu stud	te past year, how many times did (name of participating this CKiD study visit or the visit at which you y? Include well child visits, sick visits and ER visitarticipant) was hospitalized overnight.	were screen	ed for eligibility into the
		times		
		Don't Know8		
F3.	(mo	ne past year, when you or (name of participant) we than half of the time) see the same health care ner medical appointments?		
		Yes 1		
		No 2		
	4	Don't Know8		



The next questions ask about hospitalizations. Being hospitalized includes staying overnight or being admitted for a procedure that was done in one day. Please include all medical and psychiatric hospitalizations in the past year. This does not include being treated in the emergency room and then released the same day.

F4.		ne past year, has (<i>name of participant</i>) been born)? Do not include overnight stays in		
		Yes No Don't Know	2	(Skip to F5)
	a.	How many different times was (name of times		\
		Don't Know	-8	.:.0
		tions ask some questions about care o eceived in the past year.	r so	cial services that the participant
				.10
F5.		ne past year, has (<i>name of participant</i>) been the him/her obtain services?	en se	een by a social worker or a case manager to
		Yes	1	G
		No	2	
F6.		ne past year, has (<i>name of participant</i>) rec chiatrist, psychiatric nurse, counselor, or o		
		Yes	1	
		No	2	
F7.	or W parti	/IC, meals on wheels, food pantries, or an	rang nold	(i.e., the home in which the participants lives
		Yes	1	
		No	2	
F8.	In th		nelpe	ed you or (name of participant) find a place to
		Yes	1	
		No	2	
F9.	In th	ne past year, has (<i>name of participant</i>) rec	eive	d care from a dentist or dental hygienist?
		Yes	2	
		NO	2	
F10.	In th	e past year, has (name of participant) see	en a	nutritionist or a dietician?
		Yes	1	
		No	2	



SECTION G: HEALTH INSURANCE

These questions ask about the participant's health care coverage.

G1.	Does (name of participant) currently have any kind of health insurance or health care coverage? This includes both private and public insurance programs (e.g., Medicaid, SCHIP or MCHIP), dental insurance, and programs that help pay for medications. Yes
G1a.	How long has it been since (name of participant) last had ANY health insurance or coverage? 6 months or less
G1b.	In the past year, was there any time when (name of participant) was not covered by ANY health insurance or coverage? Yes
G1c.	In the past year, about how long was (name of participant) without ANY health insurance or coverage? 1 = months
G1d.	In the past year, was (name of participant) not covered by ANY insurance or coverage? Yes



INSTRUCTIONS: ASK QUESTIONS G2 - G15. IF THE RESPONSE IS YES, CIRCLE "1" AND ASK QUESTION "A" (FAR RIGHT COLUMN) UNLESS THE BOX IS SHADED.							
	YES	NC			A. Do fam pay the	you or your nily members for any of insurance mium? NO	
Does (name of participant) currently have G2. *CALIFORNIA ONLY:	IES				TES	INO	
Medi-CAL?	1	2	99				
G3. *MARYLAND ONLY: Medical Assistance?	1	2	99				
G4. ALL STATES EXCEPT CALIFORNIA and MARYLAND: Medicaid?	1	2	99				
G5. Private Health Insurance plan from employer or workplace?	1	2 ((Skip to G6)		1	2	
G6. Private Health Insurance plan purchased directly?	1	2 ((Skip to G7)		1	2	
G7. Private Health Insurance plan through a state or local government program or community program?	1	2	(Skip to G8)		1	2	
G8. CHIP (Children's Health Insurance Program)?	Ò	2	(Skip to G9)		1	2	
G9. Military Health Care/VA?	1	2 ((Skip to G10)		1	2	
G10. CHAMPUS or other veteran's health insurance?	1	2 ((Skip to G11)		1	2	
G11. Student Health Coverage?	1	2 ((Skip to G12)		1	2	
G12. State-Sponsored Health Plan?	1	2 ((Skip to G13)		1	2	
G13. Dental Insurance?	1	2					
G14. Vision Insurance?	1	2					
G15. Other types of health insurance? a. Specify	1	2 ((Skip to G16)				



G16.	Do any of these plans assist with prescriptions/medications?
	Yes 1
	No 2
	Not applicable / No Insurance1
G17.	In the past year, has (name of participant) been without needed prescription medication due to cost?
	Yes 1
	No 2
	Not applicable / No Insurance1
	Don't Know8
G18.	Does the participant's health insurance plan(s) pay for both doctor visits and hospital stays?
	Yes 1
	No 2
	Don't Know8
G19.	In the past year, have you had difficulty filing claims and/or getting reimbursed for medical care?
	Yes 1
	No 2
	Did not file any claims / No insurance -1
	Don't Know8
G20.	In the past year, how much of a problem, if any, was it to get care for (name of participant)
	that you or a doctor believed necessary?
	A big problem 1
	A small problem 2
	No problem 3
	My child had not visits in the last year -1
	Don't Know8
G21.	In the past year, how often did (name of participant) doctors or other health providers listen
021.	carefully to you?
	Never 1
	Sometimes
	Usually 3
	Always 4
	My child had not visits in the last year -1
	Don't Know
G22.	In the past year, how often did (name of participant) doctors or other health providers explain
OZZ.	things in a way you could understand?
	Never 1
	Sometimes
	Usually 3
	Always 4
	My child had not visits in the last year -1
	Don't Know8
	= · · · · · · · · · · · · · · · · ·



G23.	In the past year, how often did (name of participant) doctors or other health providers show
	respect for what you had to say?
	Never 1
	Sometimes 2
	Usually 3
	Always 4
	My child had not visits in the last year -1
	Don't Know8
G24.	In the past year, how often did doctors or other health providers spend enough time with you and (name of participant)? Never
	Sometimes
	Usually 3
	Always 4
	My child had not visits in the last year -1
	Don't Know8
\\\\a_\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	to know your rating of all of (name of participant) health gars in the last year from all dectars

We want to know your rating of all of (name of participant) health care in the last year from all **doctors** and other health providers. Use any number from 0 to 10 where 0 is the worst health care possible, and 10 is the best health care possible.

G25. How would you rate all (name of participant) health care?

0 Worst health care possible	C
1	1
2	2
3	3
4	
5	5
6	
7	
8	
9	
10	
My child had not visits in the last year	-1



SECTION H: RENAL REPLACEMENT THERAPY

I	\Box	۵	ٔما	te	Ы	Н	11
ı	.,	—	10	ι ←:	u		

H2.			have you discussed renal rovith your nephrologist or he			
		Yes		. 1		
		-		_	(END)	
	a.	Did you dis		nerapy	specifics	(i.e., modality, preference etc.)
					(END)	
H3.	Was	dialysis disc	ussed?			
					(skip to I	15)
H4.	Whi	ch modality is	s preferred?			
		Peritoneal of	islialysisoce	. 2		180
H5.	Was	transplantat	ion discussed?			
110.	vvao	Yes			(END)	
H6.	Whi	ch donor opti	on(s) has/have been discus	ssed?		
	(Ple	ase circle "Y	es", "No" or "Don't Knov	v" for	EACH of t	he following.)
	, -			Υe		Don't Know
		Living Dono Deceased D	or Donor		2	-8 -8
H7.	Has	child been lis	sted for deceased donor tra	nsplar	ntation?	
		Yes		. 1	(END)	
	a.	Date listed:			← SITE S	SHOULD CONFIRM DATE
		, <u>4</u> 0	M M / D D / Y Y	Y Y		
O RE	COI	(D) ETED B	BY CLINICAL SITE:			
O BL	COI		of CLINICAL SITE.		INITIALS:	
AIE.	M	M / D D /	<u> </u>		IIVI I IALS.	
DMINI Circle '		TION: 2" or "3")	1 = Interviewer Assisted 2 = Self-Administered 3 = Both		Was the date I LIST CONFIR 1 = YES 2 = NO	isted on DECEASE DONOR MED by site:
					2 - INO	



Chronic Kidney Disease in Children (CKiD) SECTION A: GENERAL INFORMATION

AI.	AVAILABLE	OR ENTER NUMBER IF ID LABEL IS NOT
	/////IE//DEE	- -
A2.	CKID VISIT #:	
A3.	FORM VERSION:	0 4 / 0 1 / 1 8
A4.	DATE OF VISIT:	$\frac{1}{M} \frac{1}{M} \frac{1}{D} \frac{1}{D} \frac{1}{Y} \frac{1}$
A5.	EXAMINER'S INITIALS:	
A6.	Protocol type:	Regular Study Visit 0 Post-Dialysis Visit 1 (Skip to B1) Post-Transplant Visit 2 (Skip to B1)
A7.	Is this study visit an irregular (accelerated) visit?	Yes 1 No 2
A8.	Is this a V1a or V1b study visit?	Yes 1 No
A9.	Has consent form been signed by participant, parent or legal guardia	y young adult an? Yes 1 No 2 (STOP*)
		SENT MUST BE OBTAINED study related procedures or tasks.
A10.	Date parent, legal guardian or your participant signed consent form:	ng adult///
A11.	Is documented assent required at	Yes
A12.		$\frac{1}{D} \frac{1}{D} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y}$
A13.	Has consent for genetic testing be	een obtained? Yes 1 No 2
A14.	Has consent to store biological spobtained?	vecimen(s) been Yes 1 No 2
SECTIONS B	B – G can be completed by a Nurs	se or other Health Care Provider with CKiD Training

____CKID
Chronic Kidney Disease

SECTION B: VITAL SIGNS

B1.	a.	Temperature:
		1 = °C Typical range: 36.1 – 38.3
		2 = °F Typical range: 94.5 – 100.6
	b.	How was the temperature measured? (Please circle the type of measurement.) Oral
		Axillary
I	DO N	OT CALCULATE HEART RATE. ONLY ENTER NUMBER OF BEATS PER MINUTE
B2.	Puls	e Measurement
	a.	Number of Heart Beats per minute:
B3.	Loca	al Clinical Blood Pressure (i.e. Dinamap)://
B4.	Res	piratory Rate
	a.	Respirations per minute:
		SECTION C: WEIGHT
C1.		d Weight (If weight is measured in pounds (lbs), please convert to kilograms (kg).) = (1/2.2) kg Example: 150 lbs = 150/2.2 = 68.18 = 68.2 kg
	a.	First Measurement:(kg)
	b.	Second Measurement:(kg)
		i. Do the first and second measurements differ by more than 0.2 Kg?
		Yes 1
		No
		ii. Third Measurement: (kg)
	SEC	TION D: HEIGHT, WAIST CIRCUMFERENCE and HIP CIRCUMFERENCE
D4	Chil	d Loweth Wile; alst
DI.		d Length/Height Device used to obtain length/height (Please circle the device used.)
	a.	Measuring table with firm block and moveable footboard 1
		Wall mounted stadiometer
	b.	First Measurement: (cm)
	C.	Second Measurement: (cm)
		i. Do the first and second measurements differ by more than 0.3 cm? Yes 1
		No 2 (Skip to D3)
		ii. Third Measurement:(cm)



Deleted – Leg Length (Anterior Superior Iliac Spine to medial malleolus) questions

D2	Is the	e participant less than 12 months old and/or unable to stand?
	Yes.	1 (Skip to D5)
	No	2
D3.	Child	I Waist Circumference
	a. I	First Measurement:(cm)
	b. \$	Second Measurement:(cm)
		i. Do the first and second measurements differ by more than 0.1 cm? Yes 1
		No
		ii. Third Measurement: (cm)
D4.	Chi	ld Hip Circumference
	a.	First Measurement: (cm)
	b.	Second Measurement: (cm)
		i. Do the first and second measurements differ by more than 0.1 cm?
		Yes 1
		No
		ii. Third Measurement:(cm)
D5.	Par	ental Height
	a.	Was the biological mother's height taken at a previous study visit?
		Yes
		Don't know8
		5
	b.	Is the biological mother present during the study visit?
		Yes
		(Okip to sub-question e)
	C.	Mother's First Measurement: (cm)
	d.	Mother's Second Measurement:(cm)
		i. Do the first and second measurements differ by more than 0.3 cm? Yes 1
		No
		ii. Mother's Third Measurement: (cm)



	e.	Was the biological father's height taken at a previous study visit?
		Yes
		Don't know8
	f.	Is the biological father present during the study visit?
		Yes 1
		No 3 (Skip to E1)
	g.	Father's First Measurement: (cm)
	h.	Father's Second Measurement: (cm)
		i. Do the first and second measurements differ by more than 0.3 cm?
		Yes
		No
		ii. Father's Third Measurement: (cm)
SI	ECT	TION E: BLOOD PRESSURE USING MABIS-MEDIC-KIT ANEROID
		dren who are less than 5 years old may be irritable during the study visit. Therefore, it
•		o measure blood pressure while the child is awake. In such cases, blood pressure
		be performed while the child is sleeping. It is important to accurately document if the ake or sleeping. Please answer E1 appropriately.
-		as the blood pressure measurements obtained while the participant is awake?
		Yes 1
		No, participant was/is sleeping 2
1	Mid	Arm Circumference
	a.	First Measurement:(cm)
	b.	Second Measurement:(cm)
		i. Do the first and second measurements differ by more than 0.2 cm?
		Yes 1
		No 2 (Skip to E2)
		ii. Third Measurement: . (cm)
	7	
USE THE	MID	-ARM CIRCUMFERENCE MEASUREMENTS TO SELECT THE APPROPRIATE BP CUFF.
E2.	a.	Cuff size used (Please circle the cuff size used.)
		Infant (9.0 to 14.0 cm) 1
		Child (>14.0 to 21.0 cm)
		Adult (>21.0 cm to 29.0 cm) 3
		Large Adult (>29.0 cm to 40.0 cm) 4
		Thigh (>40.0 to 52.0cm) 5



- The cuff tubing should be attached to the Mabis Medic-Kit Aneroid sphygmomanometer.
- While palpating the radial pulse (at the wrist), observe sphygmomanometer and inflate the cuff rapidly to 60 mmHg and then slowly inflate in increments of 10 mmHg until the pulse is no longer felt.
- If the pulse is still felt, the cuff pressure should be increased until the pulse disappears. Either the first or the second of these procedures will identify the <u>Observed Pulse Obliteration Pressure</u>.

b.	Observed Pulse Obliteration Value			
ADD 30 mm Hg TO THE OBSERVED PULSE OBLITERATION VALUE TO CALCULATE THE PEAK INFLATION LEVEL				
C.	Peak Inflation Pressure:			
d.	First Blood Pressure Reading:/			
USE PARTICIPANT'S RIGHT ARM TO TAKE BP MEASUREMENT. If right arm cannot be used (i.e., casting), then use left arm. WAIT AT LEAST 30 SECONDS BETWEEN MEASUREMENTS. AFTER FIRST AND SECOND BLOOD PRESSURE READING, RAISE CHILD'S ARM FOR 15 SECONDS (MAKE SURE THE CHILD IS NOT SUPPORTING THE ARM AT ALL.) In some patients, the disappearance of sound, i.e. the fifth Korotkoff sound (K5), never occurs and beats can be heard during the entire deflation period. In these circumstances, the fourth Korotkoff sound (K4) should be used to determine the diastolic blood pressure. The fourth Korotkoff sound at the point during deflation where the quality of the sound changes dramatically (e.g. the quality of the beats become muffled.)				
e.	Second Blood Pressure Reading:/			
f.	Third Blood Pressure Reading:/			
g.	Initials of Blood Pressure Reader:			



SECTION F: HEAD CIRCUMFERENCE

F1.	Is the child less than 3 years old?
	Yes 1
	No
F2.	Head Circumference
	a. First Measurement:(cm)
	b. Second Measurement: (cm)
	i. Do the first and second measurements differ by more than .3 cm?
	Yes 1
	No 2 (Skip to G1)
	ii. Third Measurement:(cm)
	SECTION G: EDEMA
G1.	Edema
G2.	Is this a Visit 1b study visit or is the participant less than 12 months old?
OZ.	Yes 1 (Skip to Section I)
	No 2
	NO 2
	. / /
SECTIO	ON H should be completed by a Pediatrician, Nurse Practitioner, or Physician Assistant
SECTIO	ON H should be completed by a Pediatrician, Nurse Practitioner, or Physician Assistant SECTION H: TANNER STAGING
	SECTION H: TANNER STAGING
	SECTION H: TANNER STAGING a. Was the participant's previous CKiD tanner assessment "Adult (stage 5)"? Yes
	SECTION H: TANNER STAGING a. Was the participant's previous CKiD tanner assessment "Adult (stage 5)"? Yes
	SECTION H: TANNER STAGING a. Was the participant's previous CKiD tanner assessment "Adult (stage 5)"?
	SECTION H: TANNER STAGING a. Was the participant's previous CKiD tanner assessment "Adult (stage 5)"? Yes
	SECTION H: TANNER STAGING a. Was the participant's previous CKiD tanner assessment "Adult (stage 5)"? Yes
	SECTION H: TANNER STAGING a. Was the participant's previous CKiD tanner assessment "Adult (stage 5)"? Yes
H1.	SECTION H: TANNER STAGING a. Was the participant's previous CKiD tanner assessment "Adult (stage 5)"? Yes
H1.	SECTION H: TANNER STAGING a. Was the participant's previous CKiD tanner assessment "Adult (stage 5)"? Yes
H1.	SECTION H: TANNER STAGING a. Was the participant's previous CKiD tanner assessment "Adult (stage 5)"? Yes
H1.	SECTION H: TANNER STAGING a. Was the participant's previous CKiD tanner assessment "Adult (stage 5)"? Yes
H1.	SECTION H: TANNER STAGING a. Was the participant's previous CKiD tanner assessment "Adult (stage 5)"? Yes
H1.	SECTION H: TANNER STAGING a. Was the participant's previous CKiD tanner assessment "Adult (stage 5)"? Yes



H3.	If female participant, what is the developmental stage of her breasts?
	(Stage 1) Pre-pubertal
	(Stage 2) Budding 2 (Skip to I1)
	(Stage 3) Small adult breasts
	(Stage 4) Areola and papilla form secondary mound 4 (Skip to I1)
	(Stage 5) Adult breasts
H4.	If male participant, what is the developmental stage of his testes and scrotum?
	Pre-pubertal1
	Enlargement of testes, scrotal reddening 2
	Increasing length more than width of penis, further scrotal enlargement 3
	Further penile enlargement, darkening of scrotal skin 4
	Adult 5
H5.	If male participant, what is the developmental stage of his pubic hair?
	Pre-pubertal1
	Sparse growth of slightly pigmented hair
	Darker, coarser, beginning to curl and spread over the symphysis 3
	Hair has adult characteristics but not adult distribution
	Adult 5

USE THE ORCHIDOMETER (THE GREEN BEADS) PROVIDED BY CKID.

H6. If male participant, what is the testicular size per the orchidometer?

Bead 1, 2 or 3	
Bead 4	
Bead 5	3
Bead 6	
Bead 8	5
Bead 10	6
Bead 12	7
Bead 15	
Bead 20	9
Dead OF	40



SECTION I: PROBLEMS

l1.	Were there any sections of the physical exam form that were difficult t (i.e., participant was irritable and/or crying during blood pressure mea to obtain 1 of the 3 blood pressure measurements)?				
	Yes 1 (Complete I2 on page 8)				
	No				
l2.	Please indicate the section of the physical exam form that was difficult Please circle yes or no to each section.	t to obt	tain data	or not co	mpleted.
	·	Yes	No		
	a. Section B: Vital Signs	1	2	(skip to	b)
	i. Please specify:				
	b. Section C: Weight	1	2	(skip to	c)
	i. Please specify:				
	c. Section D: Height	1	2	(skip to	d)
	i. Please specify:			` •	·
		4	2	(akin ta	5 \
	d. Section D: Waist Circumference	1	2	(skip to	e)
	i. Please specify:				
	e. Section D: Hip Circumference	1	2	(skip to	f)
	i. Please specify:				
	f. Section E: Blood Pressure Measure using Mabis Medic Kit	1	2	(skip to	g)
	i. Please specify:				
	g. Section F: Head Circumference for children less than 3 years old	1	2 (skip		/A kip to h)
	i. Please specify:		(- F	, (-	,
	h. Section G : Edema	1	2	(skip to	i)
	i. Please specify:				
	i. Section H: Tanner Staging	1	2	(END H	ERE)
	i. Please specify:				



NUTRITIONAL ASSESSMENT (F15)

Chronic Kidney Disease in Children (CKiD)

SECTION A: GENERAL INFORMATION

A1.	PAF	RTICIPANT ID: AFFIX ID LABEL OR E	NTER N	UMBER IF ID LABEL IS NOT AVAILABLE	
				- -	
A2.	CKi	D VISIT #:			
A3.	FOF	RM VERSION:		<u>1</u> <u>0</u> / <u>0</u> <u>1</u> / <u>1</u> <u>4a</u>	
A4.	DAT	TE OF VISIT:		$\frac{1}{M} \frac{1}{M} \frac{1}{D} \frac{1}{D} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y}$	
A5.	INT	ERVIEWER'S INITIALS:			
A6.	ls th	nis study visit an irregular (accelerated)	visit?	Yes	1 2
A7.	IND	ICATE PERSON COMPLETING THE	FORM	Child/Young Adult Parent or other adult Both (Parent and Child/Young Adult)	1 2 3
		SECTION B: NUTRI	TIONAL	ASSESSMENT	
adult nasoç nasor	parti gastri ohary	ing set of questions asks about the participant is completing the form) and use it tube (NG tube) is a tube that is passewax and esophagus into the stomach. A ter the stomach.	of a nasc d throug	h the nose and down through the	
B1.	Dur	Very Good 1	me of pa (Skip to I (Skip to I	•	
	a.	that altered <i>(name of participant)</i> normal a Yes 1		B2)	
	b.	During the past week, on how many days days	was the	child ill?	
		Don't Know8			



NUTRITIONAL ASSESSMENT (F15)

B2.	Does (name of participant) use a gastrostomy tube/button or Nasogastric tube (NG tube) for nutrit purposes?	ional
	Yes 1	
	No 2 (Skip to B3)	
	Don't Know8 (Skip to B3)	
	a. In the past year, how many months has the gastrostomy tube/button or NG tube been used?	
	months	
	Don't Know8	
B3.	In a 24 hour time period, does (<i>name of participant</i>) take any nutritional supplement either by mound bottle or feeding tube to increase the caloric intake (<i>Excludes vitamins and minerals, See MEDS Form</i>)?	ıth,
	Yes 1	
	No 2 (END FORM)	
	Don't Know8 (END FORM)	

Please use the following table to record the type and amount of any nutritional supplement or formula (to increase calories, protein or other nutrient intake) the child usually takes in a <u>24 hour period of time</u>. This should include supplement or formula taken by mouth, bottle or feeding tube.

START F15s1

	a) Name of Formula or Supplement (Ex: Similac PM 60/40, Enfamil LIPIL, Suplena,	Amount of Formula (For pre-made liquid, use ounces; if made from powder, use teaspoons, tablespoons or cups)		d) Additional ingredients/amounts* (Ex: 2 teaspoons Polycose, 1 Tablespoon MCT oil, 2 scoops Beneprotein)
	PediaSure, Nepro, Ensure)	b) Amount	c) Unit	*If there are no additional ingredients/amount, record "N/A"
B4.	~	5	Tsp	
B5.	(40)		Tsp	

END F15s1



OVERALL PHYSICAL ACTIVITY (F17)

Chronic Kidney Disease in Children (CKiD)

SECTION A: GENERAL INFORMATION

A1.	PARTICIPANT ID: AFFIX ID LABEL OR ENTER NUMBER IF ID LABEL IS NOT AVAILABLE

|__| - |__|_ - |__|__|

Both.....

3

A2. CKiD VISIT #: ___ __

A3. FORM VERSION: <u>1 0 / 0 1 / 1 4</u>

A5. INTERVIEWER'S INITIALS: ___ __

Silly Silly

OVERALL PHYSICAL ACTIVITY (F17)

SECTION B: SEDENTARY ACTIVITY

B1.	Over the past 30 days , on average how many hours per day did <i>(name of participant)</i> sit
D	and watch TV or videos?
	None, does not watch TV or videos 1
	Less than 1 hour per day 2
	1 hour per day 3
	2 hours per day 4
	3 hours per day 5
	4 hours per day 6
	5 or more hours per day 7
	Don't know8
	DOTT KITOW
Б.0	
B2.	Over the past 30 days , on average how many hours per day did (name of participant) use a
	computer or play computer games/internet outside of school? Include Facebook or other social networking tools, YouTube, smartphone, Playstation, Nintendo DS, smartphone, iPad
	or other tablet, iPod.
	None, does not use a computer or play computer games 1
	Less than 1 hour per day 2
	1 hour per day 3
	2 hours per day 4
	3 hours per day 5
	4 hours per day 6
	5 or more hours per day 7
	Don't know
	DOITE KITOW6
B3.	How much time does (name of participant) usually spend sitting on a typical day? This
	includes sitting at work/school, at home, getting to and from places, or with friends,
	including time spent sitting at a desk, traveling in a car or bus, reading, playing cards,
	watching television, or using a computer. Do not include time spent sleeping.
	&O *
	hr mins

OVERALL PHYSICAL ACTIVITY (F17)

SECTION C: OVERALL ACTIVITY LEVEL

C1.	During the past 7 days , on how many days was <i>(name of participant)</i> physically active for a total of at least 60 minutes per day? Add up all the time <i>(name of participant)</i> spent in any kind of physical activity that increased {his/her} heart rate and made {him/her} breathe hard some of the time.
	0 days 1 1 day 2
	2 days 3
	3 days 4
	4 days 5
	5 days 6
	6 days 7
	7 days 8
	Don't know8
C2.	On how many of the past 7 days did (name of participant) exercise or participate in physical activity for at least 20 minutes that made {him/her} sweat and breathe hard, such as basketball, soccer, running, swimming laps, fast bicycling, fast dancing, or similar aerobic activities? days
C3.	On how many of the past 7 days did <i>(name of participant)</i> participate in physical activity for at least 30 minutes that did not make {him/her} sweat and breathe hard, such as fast walking, slow bicycling, skating, pushing a lawn mower or mopping floors?
	days
	SECTION D: PAID OR UNPAID WORK ACTIVITY
things t	about the time that <i>(name of participant)</i> spends doing work. Think of work as the that <i>(name of participant)</i> does such as paid or unpaid work, household chores yard work.
	us-intensity activity causes large increases in breathing or heart rate and is done for 10 minutes continuously.
D1.	Does (name of participant) work involve vigorous-intensity activity that causes large increases in breathing or heart rate like carrying or lifting heavy loads for at least 10 minutes continuously?
	Yes
D2.	In a typical week , on how many days does (name of participant) do vigorous-intensity activities as part of {his/her} work?
	days

OVERALL PHYSICAL ACTIVITY (F17)

D3.	How much time does (name of participant) spend doing vigorous-intensity activities at work on a typical day?
	1 = minutes 2 = hours
	erate-intensity sports, fitness or recreational activities cause small increases in thing or heart rate and is done for at <u>least 10 minutes continuously</u> .
D4.	Does (name of participant) work/chores involve moderate-intensity activity that causes small increases in breathing or heart rate such as brisk walking or carrying light loads for at least 10 minutes continuously ?
	Yes 1
	No
D5.	In a typical week , on how many days does (name of participant) do moderate-intensity activities as part of their work/chore?
	days
D6.	How much time does (name of participant) spend doing moderate-intensity activities at work on a typical day?
	1 = minutes 2 = hours
	SECTION E: TRAVELING AND COMMUTING
has a	next questions exclude the physical activity of work (including household chores) that already been mentioned. Now I would like to ask about the usual way that <i>(name of cipant)</i> travels to and from places. For example, travel to school, for shopping, to work.
E1.	Does (name of participant) walk or bicycle for at least 10 minutes continuously to get to and from places?
	Yes
E2.	In a typical week , on how many days does <i>(name of participant)</i> walk or bicycle for at least 10 minutes continuously to get to and from places?
	days
E3.	How much time does (name of participant) spend walking or bicycling for travel on a typical day?
	1 = minutes 2 = hours

OVERALL PHYSICAL ACTIVITY (F17)

SECTION F: SCHOOL, SPORTS AND RECREATIONAL ACTIVITY

The next questions exclude the work and transportation activities that have already been mentioned. Now I would like to ask about school, sports, fitness and recreational activities.

F1. In an average week when <i>(name of participant)</i> is in school, on how many day {he/she} go to physical education (PE) classes?			
	days (If "0", Skip to F3)		
F2.	During an average physical education (PE) class, how many minutes does (name of participant) spend actually exercising or playing sports? Less than 10 minutes per day		
F3.	During the past 12 months , on how many sports teams did (name of participant) play? (Include any teams run by {his/her} school or community groups.) teams		
	rous-intensity activity causes large increases in breathing or heart rate and is done for ast 10 minutes continuously.		
F4.	Does (name of participant) do any vigorous-intensity sports, fitness, or recreational activities that cause large increases in breathing or heart rate like running or basketball for at least 10 minutes continuously? Yes		
F5.	In a typical week , on how many days does (name of participant) do vigorous-intensity sports, fitness or recreational activities? days		
F6.	How much time does (name of participant) spend doing vigorous–intensity sports, fitness or recreational activities on a typical day? 1 = minutes 2 = hours		

OVERALL PHYSICAL ACTIVITY (F17)

Moderate-intensity sports, fitness or recreational activities cause small increases in breathing or heart rate and is done for at <u>least 10 minutes continuously</u>.

⊢/.	activities that cause a sma	all increase in brea	athing or heart rate such as brisk walking, at least 10 minutes continuously?
	Yes	1	
	No	2 (END FORM)	
	Don't know	-8 (END FORM)	
F8.	In a typical week , on how sports, fitness or recreation		(name of participant) do moderate-intensity
	days		11800
F9.	How much time does (name or recreational activities on	, , ,	spend doing moderate-intensity sports, fitnes
		inutes	
	2 = ho	ours	*O*

Chronic Kidney Disease in Children (CKiD)

SECTION A: GENERAL INFORMATION

A1.	PARTICIPANT ID: AFFIX ID LABEL OR ENTER NUM	BER IF ID LABEL IS NOT AVAILABLE
		_ - _ -
A2.	CKID VISIT #:	<u> </u>
A3.	FORM VERSION:	1 0 / 0 1 / 1 4
A4.	DATE OF VISIT:	
		M M D D Y Y Y Y
A5.	FORM COMPLETED BY (INITIALS):	
Instr	uctions:	
The they	purpose of this form is to assess the participant's grip s	trength. Participants should complete this form if
1. Ro 2. As	have at least one hand without visible limitations (i.e paralysis) have not had surgery performed on either hand with	in the past three (3) months d) questionnaire eter for grip size; administer practice test
4 6. :	a. Is participant at least 6 years of age? Yes No	1 2 → (END FORM)
k	b. Are there any visible limitations to the participal paralysis; wearing a cast on wrist or hand; most of than thumb or broken fingers)? No visible limitations	
	Visible limitation to right hand Visible limitation to left hand Visible limitation to both hands	2
(No surgery to hands in the last 3 months Yes, surgery to left hand in the last 3 months Yes, surgery to left hand in the last 3 months Yes, surgery to both hands in the last 3 months	0 1 2



u.	su vi : Ye	rigery has been performed in the last 3 months? (Only complete grip strength of hands with no sible limitation and no surgery in the last 3 months) sible limitation and no surgery in the last 3 months) sible limitation and no surgery in the last 3 months) 2 → (END FORM)
e.	ls Ye	the participant using a wheelchair? es
47.		d the participant complete the Hand Grip Test?
₹7.		es1
		$2 \rightarrow \text{(END FORM)}$
Read t	he p	ore-test script to the participants:
you to	sq	am, we want to get some information about your muscle strength. We will be asking ueeze as hard as possible with each of your hands or at least one of your hands. In this in more detail in a few minutes but first I want to ask you a few questions. SECTION B: PRE-HAND GRIP TEST QUESTIONNAIRE
B1	а	Have you ever had surgery on your hands or wrists for arthritis or carpal tunnel
٥	u.	syndrome?
		Yes
		Don't Know
	b.	Which hand or wrist was the surgery on? Right hand/wrist
B2.	a.	Have you had any pain, aching or stiffness in your hands in the past 7 days?
		Yes
	h	Is the pain, aching or stiffness in your hand(s) caused by arthritis , tendonitis , or carpal
	D.	tunnel syndrome? (Choose only one response.) No, pain is not caused by arthritis, tendonitis or carpal tunnel syndrome
	C.	Has the pain, aching or stiffness in your hand(s) gotten worse in the past 7 days? (Choose only one response.) No pain has not gotten worse



Are you right-handed, left-handed, or do you us	e both hands equally?
Right-handed	. 1
Left-handed	
Use both hands equally	. 3
Don't Know	-8
	Right-handed Left-handed Use both hands equally

- 1. Instruct the participant to remove all hand and wrist jewelry.
- 2. Have the participant complete two warm-up exercises on the hand or hands to be tested
 - a. Shake both hands three (3) times
 - b. Bend and stretch all fingers three (3) times

FOLLOW STEPS 2 – 7 and FIGURES 1.1 – 1.4 of the CHEAT SHEET for details on ADJUSTING GRIP SIZE and obtaining a 90° angle).

Also refer to Section 29 of the Manual of Procedures (MOP) for details.

Introduce the grip size adjustment by reading the following script:

"Next, I am going to adjust this device to fit your hand(s). Please hold this with your (right/left hand)."

B4.	Was the participant able to achieve a 90° angle with the right index finger?
	Yes 1 → (Skip to B5)
	No 2
	Don't Know8 \rightarrow (Skip to B5)
	Please specify, reason:
B5.	Was the participant able to achieve a 90° angle with the left index finger?
	Yes 1 \rightarrow (PRE-TEST ENDS HERE)
	No 2
	Don't Know8 \rightarrow (PRE-TEST ENDS HERE)
	Please specify, reason:

STOP HERE AND PREPARE TO ADMINISTER THE HAND GRIP.
FOLLOW STEPS 9 – 14 and FIGURES 1.5 – 1.6 in the CHEAT SHEET
for details on performing the demo and practice trial.
STEP 9 BEGINS WITH READING THE SCRIPT.

Also refer to Section 29 of the MOP for details.



Read the script to the participant and demonstrate the grip test:

"For the test, I will ask you to squeeze this hand grip as hard as you can. You will stand with your feet hip width apart and your toes pointing forward like this. You will position your hand so that it's not touching your body and squeeze the handle. I want you to stand tall and try not to lean when you squeeze. You will take a breath in, then blow out while you squeeze. You will squeeze as hard as you can until you can't squeeze any harder. Like this.

(Do the squeeze demo)

If testing both hands, say: We will test each hand 3 times.

If testing same hand, say: We will test your hand 6 times."

PERFORM THE DEMO.

Instruct the participant to do the practice trial by reading the script below:

"Now try it once just to get the feel of it. For this practice, just squeeze gently. Ready, take a breath in, let it out, squeeze gently."

SECTION C: HAND GRIP PREPARATION

C1.	a.	Are both hands being tested? (only test hands without visible limitations, and no surgery in the past 3 months)
		Yes 1
		No2
	b.	Which hand was used for the Practice Test*? *Participant only has to perform one practice test. However, additional practice test can be performed if needed. Use the same hand to perform all practice tests.
		Right hand 1
		Left hand 2
	C.	Was the dynamometer cleared by pressing "ON/Clear"?
		Yes 1
		No



Now the participant is ready to do the hand grip strength test. FOLLOW STEPS 16 – 20 IN THE CHEAT SHEET and FIGURES 1.5 – 1.6 for details on administering the grip strength test.

Also refer to Section 29 of the MOP for details.

SECTION D: HAND GRIP TEST

Start the stopwatch after each test. The stopwatch is used to ensure that the participant waits at **least 60 seconds between each test**. After appropriate time has elapsed, reset the stopwatch to zero (i.e., 00:00). If using two hands for the test, then have the participant start the test with the opposite hand than was used during the practice test. Note that "maximal" effort is define as when the hand slightly shakes.

Remember to press "ON/Clear" before starting each test.

	Grip Test	(i) Hand	(ii) Dynamometer Reading	(iii) Effort
D1.	Grip Test #1 Comments:	1 = right 2 = left	~~~ CO,,,	1 = maximal 2 = questionable
D2.	Grip Test #2 Comments:	1 = right 2 = left	99	1 = maximal 2 = questionable
D3.	Grip Test #3 Comments:	1 = right 2 = left	·_	1 = maximal 2 = questionable
D4.	Grip Test #4 Comments:	1 = right 2 = left	·_	1 = maximal 2 = questionable
D5.	Grip Test #5 Comments:	1 = right 2 = left	·_	1 = maximal 2 = questionable
D6.	Grip Test #6 Comments:	1 = right 2 = left	·	1 = maximal 2 = questionable



Chronic Kidney Disease in Children (CKiD)

SECTION A: GENERAL INFORMATION

A1.	PARTICIPANT ID: ENTER NUMBER ONLY IF LABEL IS N	OT AVAILABLE	
		<u></u>	
A2.	CKID VISIT #:		
A3.	FORM VERSION:	<u>1</u> <u>0</u> / <u>0</u> <u>1</u> / <u>1</u> <u>2b</u>	
A4.	DATE OF VISIT:	//	
A5.	INTERVIEWER'S INITIALS:		
A6.	Who completed this form?	Child/young adult	
A7.	Has your child taken any medications in the last 30 days?		dication is in the form of a Pill/Tablet/Patch/Powder A9 on page 2, otherwise skip to A9 on page 3)
A8.	Were there any medications that your child was supposed to take but did not take in the past 30 days?	1 CC	lication is in the form of a Pill/Tablet/Patch/Powder ue to A9 on page 2, otherwise go to A9 on page 3)
	5	No	FORM HERE)

Instructions: The family should have brought the bottles/packages of all medications **and any herbal remedies, health supplements, vitamins, etc.** that the child has taken **in the last 30 days prior** to the baseline study visit. The interviewer should confirm that all medications are present, and examine the medication and supplement packages to complete this form.

Please complete Section B for each of the medications the participant has taken, or was supposed to take in the last 30 days.

If medication is in the form of a Pill, Tablet, Patch, or Powder complete **Question A9 and Section B on page 2**.

If medication is in the form of Drops, Inhaler/Spray, Nebulizer, Rectal Formulation or Liquid (syrup, gel, cream, lotion, injection), complete **Question A9 on page 3** and **Section B on page 3**.

Only one medication may be recorded on each page. Therefore, additional copies are provided in the binder. Please note that sites may have to make more copies, as needed.

Pill/Tablet/Patch/Powder

What is the DRUG's form? A9.

Pill/Tablet/Patch/Powder.... 1 (If drug form is NOT a Pill/Tablet/Patch/Powder, go to page 3)

Section B: Pill/Tablet/Patch/Powder

	B1a. Medication (Brand Name and/or Generic)	B1b. Drug Code: (see medication coding sheets provided in the binder)	B1c. How is the drug taken ^a ? (see ADMINISTRATION codes on page 4)	B2. Individual Dose	on page 4)	B5. What is the frequency ^c that drug suppose be taken? (see FREQUENCY codes on page 4)
1						

B6. Is (DRUG) a prescribed	B7. How many times did (name of participant)	B8. Has (name of participant) missed	B9. Has (DRUG) been
medication?	take prescribed medication in the past 30	taking (DRUG) in the past 30 days?	taken as prescribed in
	days?		the past 7 days?
Yes1		Yes 1	Yes 1(END)
No 2 (END)		No 2 (END)	No2

Section C: Medication Adherence for Prescribed Medication

d BOTHER:	1 = Neve	2 = Sometimes	3 = Often	4 = Always	e RATE: 1 = V	ery Well 2 = Somewhat	3 = Not at all	-8 = Don't know			
C2. In the past 7 damany times was dramissed? (If "0" skip	rug	C2a. For the times when r many times was this due t refusing to take medication	to the child	C3. Does drug bother ^d child? (see codes listed above)	C4. How well ^e do you think the drug helps? (see codes listed above)	C5. Please answer the following EACH statement. Remember 0 = Never (N), 1 = Someting	your answers will		es" or "a	lot" for	•
				~ \		a. The medication causes si	ide effects.		0	1	2
	_					b. It is hard to remember to	give (name of p	participant) the (DRUG).	0	1	2
				5		c. It is hard to get to the pha	armacy to pick u	up the (DRUG).	0	1	2
						d. It is hard to open the (DR	(UG) container.		0	1	2
			C			e. It is hard to get the (DRU	G) refill on time		0	1	2
			×			f. It is hard to remember to give weekends.	e (name of particip	pant) the (DRUG) on	0	1	2
						g. It is hard to pay for the (D	RUG).		0	1	2
						h. The (DRUG) tastes bad.			0	1	2
						i. It hurts/is painful to take ([DRUG).		0	1	2
						j. Other reason, specify:			0	1	2

Drop/Inhaler/Nebulizer/Rectal Formulation/Liquid (syrup, gel, cream, lotion, injection)

A9.	What is	s the DRUG's form?	Drop	2	Inhaler/Spray Nebulizer	3 (Skip to B1a) 4 (Skip to B1a)	Liquid (syrup/gel/cream/lotion/injections)5 (Skip to B1a) Rectal Formulation
	A9a.	If drops, where is dose	delivered?				
		Right1	Left	.2		Both3	Other99

Section B: Drop/Inhaler/Nebulizer/Rectal Formulation/Liquid (syrup, gel, cream, lotion, injection)

ecotion B. Brop/initiale//tebalize//testarr officialisticity/Elquid (eyrap; ger, orealis, injection)						_		
	B1a. Medication	B1b. Drug Code:	B1c. How is the	B1e. Volume of the	B1f. Concentration	B5. What is the		
	(Brand Name and/or Generic)		drug taken ^a ? (see ADMINISTRATION codes on page 4)	dose (or number of drops/puffs /nebulizer treatment/suppository) and indicated the units ^{b1} (see VOLUME UNITS codes on page 4)	This is a measurement unit per a specific volume. (Refer to the medication label) Indicate the measuring unit ^{b2} in the 1 st column and the volume unit ^{b3} in the 2 nd column. (see CONCENTRATION UNITS codes on page 4)	frequency ^c that drug suppose be taken? (see FREQUENCY codes on page 4)		
1				Unit:				

B6. Is (DRUG) a prescribed medication?	B7. How many times did (name of participant) take prescribed medication in the past 30 days?	B8. Has (name of participant) missed taking (DRUG) in the past 30 days?	B9. Has (DRUG) been taken as prescribed in the past 7 days?
Yes1		Yes 1	Yes 1(END)
No2 (END)		No 2 (END)	No2

Section C: Medication Adherence for Prescribed Medication

d BOTHER: 1 = Nev	er 2 = Sometimes 3 = Often	4 = Always	^e RATE: 1 = V	ery Well 2 = Somewhat 3 = Not at all -8 = Don't know			
C2. In the past 7 days, how many times was drug missed? (If "0" skip to C3)	C2a. For the times when missed, how many times was this due to the child refusing to take medication?	C3. Does drug bother ^d child? (see codes listed above)	C4. How well ^e do you think the drug helps? (see codes listed above)	C5. Please answer the following questions by responding "never", "sometime EACH statement. Remember your answers will be kept private. 0 = Never (N), 1 = Sometimes (S), 2 = A lot (A)	es" or "a	lot" for	
				a. The medication causes side effects.	0	1	2
	×			b. It is hard to remember to give (name of participant) the (DRUG).	0	1	2
	*			c. It is hard to get to the pharmacy to pick up the (DRUG).	0	1	2
				d. It is hard to open the (DRUG) container.	0	1	2
				e. It is hard to get the (DRUG) refill on time.	0	1	2
				f. It is hard to remember to give (name of participant) the (DRUG) on weekends.	0	1	2
	, and the second			g. It is hard to pay for the (DRUG).	0	1	2
				h. The (DRUG) tastes bad.	0	1	2
				i. It hurts/is painful to take (DRUG).	0	1	2
				j. Other reason, specify:	0	1	2

CODES AND EXAMPLES

Codes for page 2 medication that is in the form of a Pill/Tablet/Patch/Powder

a A	DMINISTRATION	Code:	1 = oral			nalation	4 = intranasal	10 = trans	sdermal	Injection:	5 = intravenous	12 = intramuscular
		97 = other	6 = nasogasi	tric	7 = pe	r rectal	9 = sublingual	11 = topic	cal		8 = subcutaneous	13 = intradermal
b L	JNITS Code:		1 = mg	2 = mcg	9 =	vitamins	s 10 = g 11	= %	98 = other	Specify:		
•												
	REQUENCY Cod	•	3 / tid (every 8 h			•	= qod (every other day)	•	ek (every weel	•	qmonth (every month)
	q4 (every 4 hours)		2 / bid (every 1				= triweek (3 times/week)	_	eek (every 2 w		PRN (as needed)	
2 =	q6 (every 6 hours)	5 = q2	24 / qday (every	day or one	ce/day)	14 :	= biweek (2 times/week)	12 = q3w	eek (ever 3 we	eeks) 8 =	other: Specify Other:	
		Medicatio me and/or G		B1b.	Drug	Code:	B1c. How is the contaken ^a ? (see ADMINISTRATION		B2. Indivi	dual Dose	B3. Units ^b (see UNITS codes)	B5. What is the frequency that drug suppose be taken? (see FREQUENCY codes)
0	Tums Ultra			<u>1</u> 2 -	01-	<u>0</u> 0	_ 1		<u>1 00 0</u>	. <u>0</u>	<u>1</u>	_ <u>3</u>
									· = 		_	
	Codes for page 3 medication that is in the form of a Drop/Inhale/Nebulizer/ Rectal Formulation/ Liquid (syrup, gel, cream, lotion, injection)											
			tion that is i	n the for	m of a	Drop/Ir	hale/Nebulizer/ Recta	I Formu	ilation/ Liqu	ııd (syrup, g	el, cream, lotion,	injection)
^a A	DMINISTRATION		1 = oral			nalation	4 = intranasal	10 = trans		Injection:	5 = intravenous	12 = intramuscular
		99 = other	6 = nasogast	tric	7 = pe	r rectal	9 = sublingual	11 = topic	cal		8 = subcutaneous	13 = intradermal
b1 ,	Volume UNITS Co	ode: 1 = n	nl/cc 2 = L	3 = drop	1 -nı	ıff/nebuli	zer 5 = suppository	6 = grams	e _1 = N//	(topical cream)	99 = Other Spec	sife
	Volume Olario Ol	Jue. 1 – 11	111/CC Z = L	3 = ulop	4 –μι	iii/iiebuii	zei 3 – suppository	0 – grains	5 -1 - 14/ <i>F</i>	(topical cream)	39 - Other Spec	:y
b2 (Concentration UNIT	S (1st Column	n): 1 = mcg	2 = mg	3 = g	4 :	= % 5 = units	99 = Othe	er Specify	r:		_
							XV		<u> </u>			
b3	Concentration U	NITS (2 nd Colu	umn): 1 = ml/cc	2 = L	3 = g		=per actuation (spray/puff)	-1 = N	I/A (topical cre	eam) 99 = (Other Specify:	
° F	REQUENCY Cod	e: 3 = a8	3 / tid (every 8 h	ours or 3 ti	imes/day	v) 6 =	god (every other day)	7 = gwe	ek (every weel	k) 13 =	gmonth (every month)
	q4 (every 4 hours)	•	2 / bid (every 1		•		= triweek (3 times/week)	-	eek (every 2 w	•	PRN (as needed)	,
	q6 (every 6 hours)		24 / qday (every	day or one	ce/day)	14:	= biweek (2 times/week)	12 = q3w	eek (ever 3 we	eks) 8 =	other: Specify Other:	
	_			X								
		. Medicatio me and/or G		B1b	. Drug (Code:	B1c. How is the drug taken ^a ? (see ADMINISTRATION codes)	dose (drops/potreatment	olume of the or number of uffs /nebulizer nt/suppository) dicated the (see VOLUME codes)	This is a m volume. (F Indicate the column and column.	ncentration peasurement unit per a selefer to the medication land measuring unit be in the land the volume unit be in the colume unit be in the colume unit be column to the column to t	suppose be taken? (see FREQUENCY codes)
0	Amoxicillin sus	pension		<u>0</u> <u>2</u> -	<u>0</u> <u>1</u> -	<u> </u>	_1	5 Unit:	1	2 5 0 Unit		_ <u>5</u> _ <u>3</u>

	A	10-02-00	Bisacodyl (Ducolax)
99-01-99	Acetaminophen (Tylenol)	01-03-00	Bisoprolol (Zebata)
01-09-99	Acetazolamide (Diamox)	06-01-00	Budesonide (Pulmicort)
13-03-00	Acidophilus	07-01-00	Bupropion (Wellbutrin, Zyban)
02-02-00	Acyclovir (Zovirax)		С
06-03-01	Albuterol (Ventolin, Preventil)	13-02-01	Calcitriol (Rocaltrol)
13-02-01	Alfacalcidol (One-alpha)	12-01-00	Calcium Carbonate (TUMS)
15-00-00	Allopurinol (Zyloprim)	13-02-02	Calcium Carbonate with Vitamin D Supplement
01-09-02	Amiloride (Midamor)	12-01-00	Calcium salts (PhosLo)
01-10-00	Amiloride-Hydrochlorothiazide (Moduretic)	13-02-02	Calcium Vitamin D Supplement
13-05-00	AMINO ACID SUPPLEMENT	13-06-00	CALORIC NUTRITIONAL SUPPLEMENT
01-06-00	Amlodipine (Norvasc)	01-02-00	Candesartan (Atacand)
02-01-00	Amoxicillin (Amoxil, Augmentin)	01-01-00	Captopril (Capoten)
07-02-00	Amphetamine-Dextroamphetamine (Adderall)	09-00-00	Carbamazepine (Tegretol)
03-99-00	Anemia Medication - Other	01-05-00	Carvedilol (Coreg)
10-03-99	Antacid - Other	02-01-00	Cefuroxime (Ceftin)
99-99-00	Antitussive - Dextromethorphan (Delsym)	13-01-99	Centrium Etc.
07-03-00	Aripiprazole (Abilify)	02-01-00	Cephalexin (Keflex)
13-01-02	Ascorbic Acid	02-01-00	Cephalosporins
99-01-99	Aspirin	06-02-00	Cetirizine (Zyrtec)
01-03-00	Atenolol (Tenormin)	13-01-99	Children's Multivitamin
08-00-00	Atorvastatin (Lipitor)	13-03-00	Chlorophil
99-99-00	Aurodex	01-09-03	Chlorothiazide (Diuril)
04-02-00	Azathioprine (Imuran)	06-02-00	Chlorpheniramine (Rynatan, Rondec-DM, R-Tannate)
06-02-00	Azelastine (Astelin)	10-03-01	Cimetidine (Tagamet)
02-01-00	Azithromycin (Zithromax)	07-01-00	Citalopram (Celexa)
	В	10-05-02	CITRATE AND CITRIC ACID (Bicitra, Polycitra)
01-01-00	Benazepril (Lotensin)	02-01-00	Clarithromycin (Biaxin)
11-01-00	Bethanechol (Urecholine)	02-01-00	Clindamycin (Cleocin)

01-07-00	Clonidine (Catapres)		E
02-03-00	Clotrimazole (Betamethasone, Lotrimin, Lotrisone, Mycelex)	01-01-00	Enalapril (Vasotec)
13-07-00	Complete Omega	06-03-99	Epinephrine (Adrenalin, Epipen)
99-99-00	Contraceptive - Medroxyprogesterone (Depo- Provera)	13-02-02	Ergo Calciferol (Drisdol)
13-01-99	Cranberry Tablet	03-01-01	Erythropoeitin (Epogen, Procrit)
04-02-00	Cyclophosphamide (Cytoxan)	03-01-99	ESA – Other
04-02-00	Cyclosporine (Sandimmune, Neoral)	07-01-00	Escitalopram (Lexapro)
06-02-00	Cyproheptadine (Periactin)	10-03-02	Esomeprazole (Nexium)
13-04-02	CYSTEAMINE (CYSTAGON)		F
	D	10-03-01	Famotidine (Pepcid)
03-01-02	Darbepoeitin alfa (Aranesp)	01-06-00	Felodipine (Plendil)
99-99-00	Depo-Provera	03-02-00	Ferrous Sulphate (Fer-in-sol)
06-02-00	Desloratadine (Clarinex)	06-02-00	Fexofenadine (Allegra, Allegra-D)
04-01-00	Desonide (DesOwen, Tridesilon)	13-07-00	Fish Oil
07-02-00	Dexmethylphenidate (Focalin)	13-03-00	Floranex Lactobacillus
13-99-00	Dietary Supplement – Other	04-01-00	Fludrocortisone (Florinef)
10-99-00	Digestive System Medication – Other	02-01-00	Fluoroquinolones (Ciprofloxacin, Cipro)
01-06-00	Diltiazem (Cardizem, Tiazac)	06-01-00	Fluticasone (Advair, Flovent)
06-02-00	Diphenhydramine (Benadryl)	13-01-02	Folic Acid (Niferex, Leucovorin)
10-04-00	Diphenoxylate and Atropine (Lomotil)	01-01-00	Fosinopril (Monopril)
13-02-02	Di-Vi-Sol	01-09-01	Furosemide (Lasix)
10-02-00	Docusate (Colace, Senna)		G
01-04-00	Doxazosin (Cardura)	13-01-02	Glyco-Bears Dietary Supplement
13-02-02	Doxercalciferol (Hectorol)	11-01-00	Glycopyrrolate (Robinol)
13-02-02	Doxercaldreron Nectrol	01-07-00	Guanfacine (Intuniv, Tenex)
02-01-00	Doxycycline (Vibramycin)		Н
07-01-00	Duloxetine (Cymbalta)	01-08-00	Hydralazine (Apresoline)
		01-09-03	Hydrochlorothiazide

04-02-00	Hydroxychloroquine (Plaquenil)	01-02-00	Losartan (Cozaar)
11-01-00	Hyoscyamine (Levsin)	01-10-00	Losartan-Hydrochlorothiazide (Hyzaar)
	I	08-00-00	Lovastatin (Advicor, Altoprev, Mevacor)
99-01-01	Ibuprofen (Motrin, Advil, Midol)		M
07-01-00	Imipramine (Tofranil)	13-04-01	Maginate (OTC magnesium supplement)
04-99-00	Immunosuppressive Meds - Other	13-04-01	Magnesium (Maginex)
14-01-00	Insulin Aspart (NovoLog)	13-04-01	Magnesium Chloride
14-01-00	Insulin Lispro (Humalog Insulin)	13-04-01	Magnesium Gluconate (Magonate)
01-02-00	Irbesartan (Avapro)	13-04-01	Magnesium Oxide (Mag-Ox)
03-02-00	IRON SUPPLEMENTATION	07-04-00	Melatonin
01-06-00	Isradipine (DynaCirc)	04-02-00	Mesalamine (Asacol, Pentasa)
	J	14-01-00	Metformin (Fortamet)
13-04-01	Joules (Joules Solution)	04-02-00	Methotrexate (Amethopterin, Rheumatrex, Trexall)
	K	07-02-00	Methylphenidate (Concerta, Metadate)
40.04.04			
13-04-01	K-Phos-Neutral	04-01-00	Methylprednisolone
13-04-01	K-Phos-Neutral L	04-01-00 10-01-00	Methylprednisolone Metoclopramide (Reglan)
01-05-00			• •
	L	10-01-00	Metoclopramide (Reglan)
01-05-00	L Labetolol (Normodyne)	10-01-00 01-09-99	Metoclopramide (Reglan) Metolazone (Zaroxolyn)
01-05-00 09-00-00 10-03-02	L Labetolol (Normodyne) Lamotrigine (Lamictal)	10-01-00 01-09-99 01-03-00	Metoclopramide (Reglan) Metolazone (Zaroxolyn) Metoprolol (Lopressor, Toprol XL)
01-05-00 09-00-00 10-03-02	L Labetolol (Normodyne) Lamotrigine (Lamictal) Lansoprazole (Prevacid)	10-01-00 01-09-99 01-03-00 02-01-00	Metoclopramide (Reglan) Metolazone (Zaroxolyn) Metoprolol (Lopressor, Toprol XL) Metronidazole (Flagyl)
01-05-00 09-00-00 10-03-02 13-01-02	L Labetolol (Normodyne) Lamotrigine (Lamictal) Lansoprazole (Prevacid) L-Carnitine (Carnitor)	10-01-00 01-09-99 01-03-00 02-01-00 07-01-00	Metoclopramide (Reglan) Metolazone (Zaroxolyn) Metoprolol (Lopressor, Toprol XL) Metronidazole (Flagyl) Mirtazapine (Remeron)
01-05-00 09-00-00 10-03-02 13-01-02	L Labetolol (Normodyne) Lamotrigine (Lamictal) Lansoprazole (Prevacid) L-Carnitine (Carnitor) Leucovorin Calcium (Wellcovorin)	10-01-00 01-09-99 01-03-00 02-01-00 07-01-00 06-01-00	Metoclopramide (Reglan) Metolazone (Zaroxolyn) Metoprolol (Lopressor, Toprol XL) Metronidazole (Flagyl) Mirtazapine (Remeron) Mometasone Furoate (Nasonex)
01-05-00 09-00-00 10-03-02 13-01-02 13-01-02 06-03-01	L Labetolol (Normodyne) Lamotrigine (Lamictal) Lansoprazole (Prevacid) L-Carnitine (Carnitor) Leucovorin Calcium (Wellcovorin) Levalbuterol (Xopenex)	10-01-00 01-09-99 01-03-00 02-01-00 07-01-00 06-01-00 06-99-00	Metoclopramide (Reglan) Metolazone (Zaroxolyn) Metoprolol (Lopressor, Toprol XL) Metronidazole (Flagyl) Mirtazapine (Remeron) Mometasone Furoate (Nasonex) Montelukast (Singulair)
01-05-00 09-00-00 10-03-02 13-01-02 13-01-02 06-03-01 09-00-00	L Labetolol (Normodyne) Lamotrigine (Lamictal) Lansoprazole (Prevacid) L-Carnitine (Carnitor) Leucovorin Calcium (Wellcovorin) Levalbuterol (Xopenex) Levetiracetam (Keppra)	10-01-00 01-09-99 01-03-00 02-01-00 07-01-00 06-01-00 06-99-00	Metoclopramide (Reglan) Metolazone (Zaroxolyn) Metoprolol (Lopressor, Toprol XL) Metronidazole (Flagyl) Mirtazapine (Remeron) Mometasone Furoate (Nasonex) Montelukast (Singulair) Mood/Behavior Medication – Other
01-05-00 09-00-00 10-03-02 13-01-02 13-01-02 06-03-01 09-00-00 14-02-00	L Labetolol (Normodyne) Lamotrigine (Lamictal) Lansoprazole (Prevacid) L-Carnitine (Carnitor) Leucovorin Calcium (Wellcovorin) Levalbuterol (Xopenex) Levetiracetam (Keppra) Levothyroxine (Levoxyl, L-Thryoxine)	10-01-00 01-09-99 01-03-00 02-01-00 07-01-00 06-01-00 06-99-00	Metoclopramide (Reglan) Metolazone (Zaroxolyn) Metoprolol (Lopressor, Toprol XL) Metronidazole (Flagyl) Mirtazapine (Remeron) Mometasone Furoate (Nasonex) Montelukast (Singulair) Mood/Behavior Medication – Other Mycophenolate mofetil (Cellcept)
01-05-00 09-00-00 10-03-02 13-01-02 13-01-02 06-03-01 09-00-00 14-02-00	L Labetolol (Normodyne) Lamotrigine (Lamictal) Lansoprazole (Prevacid) L-Carnitine (Carnitor) Leucovorin Calcium (Wellcovorin) Levalbuterol (Xopenex) Levetiracetam (Keppra) Levothyroxine (Levoxyl, L-Thryoxine) Levothyroxine Sodium (Synthroid)	10-01-00 01-09-99 01-03-00 02-01-00 07-01-00 06-01-00 06-99-00 07-99-00 04-02-00	Metoclopramide (Reglan) Metolazone (Zaroxolyn) Metoprolol (Lopressor, Toprol XL) Metronidazole (Flagyl) Mirtazapine (Remeron) Mometasone Furoate (Nasonex) Montelukast (Singulair) Mood/Behavior Medication – Other Mycophenolate mofetil (Cellcept)

02-01-00	Nitrofurantoin (Furadantin, Macrobid, Macrodantin)	04-01-00	Prednisone
10-03-01	Nizatidine (Axid)	10-01-00	Promethazine (Phenergan)
13-03-00	Noni Juice	01-03-00	Propranolol (Inderal)
99-99-00	Nutritional Supplement		Q
02-03-00	Nystatin (Mycostatin, Pedi-Dri)	07-03-00	Quetiapine (Seroquel)
	0	01-01-00	Quinapril (Accupril)
07-03-00	Olanzapine (Zyprexa)		R
01-02-00	Olmesartan (Benicar)	01-01-00	Ramipril (Altace)
13-07-00	Omega 3 Fatty Acid	10-03-01	Ranitidine (Zantac)
10-03-02	Omeprazole (Priolsec)	07-03-00	Risperidone (Risperdal)
10-01-00	Ondansetron (Zofran)	08-00-00	Rosuvastatin (Crestor)
99-01-99	Opioids - Tylenol with Codeine		S
02-02-00	Oseltamivir (Tamiflu)	07-01-00	Sertaline (Zoloft)
99-99-00	OTC Cough and Cold Products	12-01-00	Sevelamer (Renagel)
99-99-00	Otic Analgesic - Antipyrine and Benzocaine (Aurodex)	10-02-00	Simethicone (Maalox, Mylanta, Gas-X, Milk of Magnesia, Lactobacillus)
09-00-00	Oxcarbazepine (Trileptal)	99-99-00	Similac 6040 (Formula)
11-01-00	Oxybutynin (Ditropan, Ditropan XL, Oxytrol)	08-00-00	Simvastatin (Zocor)
	P	10-05-01	SODIUM BICARBONATE
10-03-02	Pantoprazole (Protonix)	13-04-01	Sodium Chloride
02-01-00	Penicillin (Bicillin)	99-99-00	Sodium Chloride Inhalation
02-01-00 11-01-00	Penicillin (Bicillin) Phenazopyridine (Pyridium)	99-99-00 13-01-03	
			Sodium Chloride Inhalation
11-01-00	Phenazopyridine (Pyridium)	13-01-03	Sodium Chloride Inhalation Sodium Fluoride (Ethedent Chewable, Fluoritab, Fluor-A-Day)
11-01-00 12-02-00	Phenazopyridine (Pyridium) Phosphate/Potassium Binder Meds – Other	13-01-03 13-04-01	Sodium Chloride Inhalation Sodium Fluoride (Ethedent Chewable, Fluoritab, Fluor-A-Day) Sodium Phosphate (Na Phosphate)
11-01-00 12-02-00 14-01-00	Phenazopyridine (Pyridium) Phosphate/Potassium Binder Meds – Other Pioglitazone Hydrochloride (Actos)	13-01-03 13-04-01 12-02-00	Sodium Chloride Inhalation Sodium Fluoride (Ethedent Chewable, Fluoritab, Fluor-A-Day) Sodium Phosphate (Na Phosphate) Sodium Polystyrene Sulfonate (Kayexalate)
11-01-00 12-02-00 14-01-00 10-02-00	Phenazopyridine (Pyridium) Phosphate/Potassium Binder Meds – Other Pioglitazone Hydrochloride (Actos) Polyethylene (Lactulose, Miralax, Glycolax)	13-01-03 13-04-01 12-02-00 05-00-00	Sodium Chloride Inhalation Sodium Fluoride (Ethedent Chewable, Fluoritab, Fluor-A-Day) Sodium Phosphate (Na Phosphate) Sodium Polystyrene Sulfonate (Kayexalate) Somatren (Protropin)
11-01-00 12-02-00 14-01-00 10-02-00 13-04-01	Phenazopyridine (Pyridium) Phosphate/Potassium Binder Meds – Other Pioglitazone Hydrochloride (Actos) Polyethylene (Lactulose, Miralax, Glycolax) Potassium Chloride (K-Dur, Klorconr)	13-01-03 13-04-01 12-02-00 05-00-00	Sodium Chloride Inhalation Sodium Fluoride (Ethedent Chewable, Fluoritab, Fluor-A-Day) Sodium Phosphate (Na Phosphate) Sodium Polystyrene Sulfonate (Kayexalate) Somatren (Protropin) Somatropin (Genotropin Humatrope, Nutropin)

01-02-00	Telmisartan (Micardis)
14-02-00	Thynoxine (Thyroid Supplement)
02-01-00	Tobramycin (Nebcin)
11-01-00	Tolterodine (Detrol, Detrol LA)
06-01-00	Triamcinolone (Allernaze, Nasacort, Tri-nasal)
11-01-00	Trihexyphenidyl (Artane)
02-01-00	Trimethoprim-Sulfamethoxazole (Bactrim, Sulfatrim, Septra)
	U
99-99-99	UNKNOWN MEDICATION
	V
09-00-00	Valproic Acid (Depakene, Depakote, Divalproex sodium)
01-02-00	Valsartan (Diovan)
11-01-00	Vasopress in analog Desmopressin (DDAVP)
07-01-00	Venlafaxine (Effexor)
01-06-00	Verapamil (Isoptin, Calan, Nu-Verap, Novo- Veramil)
13-01-99	Vitamin B
13-01-99	Vitamin C
13-02-02	Vitamin D 25, D3
13-01-02	Vitamin E
	X
99-99-00	Xanthine Oxidase Inhibitor - Allopurinol (Zyloprim)
	Z
13-02-01	Zemplar (Paricalcitol)
13-01-02	Zinc

	ANTIHYPERTENSIVE MEDICATION	01-08-00	DIRECT VASODILATORS
01-00-00	ACE INHIBITORS	01-08-00	Hydralazine (Apresoline)
01-01-00	Benazepril (Lotensin)	01-09-01	DIURECTIC – LOOP
01-01-00	Captopril (Capoten)	01-09-01	Furosemide (Lasix)
01-01-00	Enalapril (Vasotec)	01-09-02	DIURETIC - POTASSIUM-SPARING
01-01-00	Fosinopril (Monopril)	01-09-02	Amiloride (Midamor)
01-01-00	Lisinopril (Prinivil, Zestril)	01-09-03	DIURECTIC – THIAZIDE
01-01-00	Quinapril (Accupril)	01-09-03	Chlorothiazide (Diuril)
01-01-00	Ramipril (Altace)	01-09-03	Hydrochlorothiazide
01-02-00	ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	01-09-99	DIURECTIC - OTHER
01-02-00	Candesartan (Atacand)	01-09-99	Acetazolamide (Diamox)
01-02-00	Irbesartan (Avapro)	01-09-99	Metolazone (Zaroxolyn)
01-02-00	Losartan (Cozaar)	01-10-00	COMBINATION ANTIHYPERTENSIVE MEDS
01-02-00	Olmesartan (Benicar)	01-10-00	Amiloride/Hydrochlorothiazide (Moduretic)
01-02-00	Telmisartan (Micardis)	01-10-00	Lisnopril/Hydrochlorothiazide (Lisinop/Hcz, Prinizide, Zestoretic)
01-02-00	Valsartan (Diovan)	01-10-00	Losartan/Hydrochlorothiazide (Hyzaar)
01-03-00	BETA BLOCKERS		ANTI-INFECTIOUS AGENTS
01-03-00	Atenolol (Tenormin)	02-01-00	ANTIBIOTICS - UTI PROPHYLAXIS
01-03-00	Bisoprolol (Zebata)	02-01-00	Amoxicillin (Amoxil, Augmentin)
01-03-00	Metoprolol (Lopressor, Toprol XL)	02-01-00	Azithromycin (Zithromax)
01-03-00	Propranolol (Inderal)	02-01-00	Cefuroxime (Ceftin)
01-04-00	ALPHA BLOCKERS	02-01-00	Cephalexin (Keflex)
01-04-00	Doxazosin (Cardura)	02-01-00	Cephalosporins
01-04-00	Prazosin (Minipress)	02-01-00	Clarithromycin (Biaxin)
01-04-00	Tamsulosin (Flomax)	02-01-00	Clindamycin (Cleocin)
01-05-00	ALPHA/BETA BLOCKERS	02-01-00	Doxycycline (Vibramycin)
01-05-00	Carvedilol (Coreg)	02-01-00	Fluoroquinolones (Ciprofloxacin, Cipro)
01-05-00	Labetolol (Normodyne)	02-01-00	Metronidazole (Flagyl)
01-06-00	CALCIUM CHANNEL BLOCKER	02-01-00	Nitrofurantoin (Furadantin, Macrobid, Macrodantin)
01-06-00	Amlodipine (Norvasc)	02-01-00	Penicillin (Bicillin)
01-06-00	Diltiazem (Cardizem, Tiazac)	02-01-00	Tobramycin (Nebcin)
01-06-00	Felodipine (Plendil)	02-01-00	Trimethoprim-Sulfamethoxazole (Bactrim, Sulfatrim, Septra)
01-06-00 01-06-00	Felodipine (Plendil) Isradipine (DynaCirc)	02-01-00 02-02-00	Trimethoprim-Sulfamethoxazole (Bactrim, Sulfatrim, Septra) ANTIVIRAL
	, ,		
01-06-00	Isradipine (DynaCirc)	02-02-00	ANTIVIRAL
01-06-00 01-06-00	Isradipine (DynaCirc) Nifedipine (Adalat, Procardia)	02-02-00 02-02-00	ANTIVIRAL Acyclovir (Zovirax)
01-06-00 01-06-00 01-06-00	Isradipine (DynaCirc) Nifedipine (Adalat, Procardia) Verapamil (Isoptin, Calan, Nu-Verap, Novo-Veramil)	02-02-00 02-02-00 02-02-00	ANTIVIRAL Acyclovir (Zovirax) Oseltamivir (Tamiflu)

	ANEMIA MEDICATION
03-01-01	ESA – ERYTHOPOIETIN
03-01-01	Erythropoeitin (Epogen, Procrit)
03-01-02	ESA – DARBEPOETIN ALFA
03-01-02	Darbepoeitin alfa (Aranesp)
03-01-99	ESA – OTHER
03-02-00	IRON SUPPLEMENTATION
03-02-00	Ferrous Sulphate (Fer-in-sol)
03-02-00	Niferex
03-99-00	OTHER ANEMIA MEDICATION

	IMMUNOSUPPRESSIVES
04-01-00	CORTICOSTEROIDS
04-01-00	Desonide (DesOwen, Tridesilon)
04-01-00	Fludrocortisone (Florinef)
04-01-00	Methylprednisolone
04-01-00	Prednisone
04-02-00	ANTINEOPLASTIC / CHEMOTHERAPEUTIC AGENTS
04-02-00	Azathioprine (Imuran)
04-02-00	Cyclophosphamide (Cytoxan)
04-02-00	Cyclosporine (Sandimmune, Neoral)
04-02-00	Hydroxychloroquine (Plaquenil)
04-02-00	Mesalamine (Asacol, Pentasa)
04-02-00	Methotrexate (Amethopterin, Rheumatrex, Trexall)
04-02-00	Mycophenolate mofetil (Cellcept)
04-02-00	Tacrolimus, (FK506, Prograf)
04-99-00	OTHER IMMUNOSUPPRESSIVE MED

GROWTH HORMONES			
05-00-00	Somatren (Protropin)		
05-00-00	Somatropin (Genotropin Humatrope, Nutropin)		

	ASTHMA/ALLERGY MEDICATIONS
06-01-00	INHALED CORTICOSTEROIDS
06-01-00	Budesonide (Pulmicort)
06-01-00	Fluticasone (Advair, Flovent)
06-01-00	Mometasone Furoate (Nasonex)
06-01-00	Triamcinolone (Allernaze, Nasacort, Tri-nasal)
06-02-00	ANTIHISTAMINES (OTC & PRESCRIPTION MEDS)
06-02-00	Azelastine (Astelin)
06-02-00	Cetirizine (Zyrtec)
06-02-00	Chlorpheniramine (Rynatan, Rondec-DM, R-Tannate)
06-02-00	Cyproheptadine (Periactin)
06-02-00	Desloratadine (Clarinex)
06-02-00	Diphenhydramine (Benadryl)
06-02-00	Fexofenadine (Allegra, Allegra-D)
06-02-00	Loratadine (Claritin)
06-03-01	SHORT ACTING B2 AGONIST
06-03-01	Albuterol (Ventolin, Preventil)
06-03-01	Levalbuterol (Xopenex)
06-03-99	OTHER BRONCHODILATOR
06-03-99	Epinephrine (Adrenalin, Epipen)
06-99-00	OTHER ASTHMA/ALLERGY MEDICATION
06-99-00	Montelukast (Singulair)

	MOOD/BEHAVIOR MEDICATIONS
07-01-00	ANTIDEPRESSANT
07-01-00	Bupropion (Wellbutrin, Zyban)
07-01-00	Citalopram (Celexa)
07-01-00	Duloxetine (Cymbalta)
07-01-00	Escitalopram (Lexapro)
07-01-00	Imipramine (Tofranil)
07-01-00	Mirtazapine (Remeron)
07-01-00	Sertaline (Zoloft)
07-01-00	Venlafaxine (Effexor)
07-02-00	CNS STIMULANTS (ADD and ADHD MEDICATIONS)
07-02-00	Amphetamine/Dextroamphetamine (Adderall)
07-02-00	Dexmethylphenidate (Focalin)
07-02-00	Methylphenidate (Concerta, Metadate)

07-03-00 07-03-00			
07-03-00	ANTIPSYCHOTICS	10-03-01	Nizatidine (Axid)
07-03-00	Aripiprazole (Abilify)	10-03-01	Ranitidine (Zantac)
07-03-00	Olanzapine (Zyprexa)	10-03-02	ANTACIDS - PROTON-PUMPINHIBITORS
07-03-00	Quetiapine (Seroquel)	10-03-02	Esomeprazole (Nexium)
07-03-00	Risperidone (Risperdal)	10-03-02	Lansoprazole (Prevacid)
07-04-00	SLEEP MEDICATION	10-03-02	Omeprazole (Priolsec)
07-04-00	Melatonin	10-03-02	Pantoprazole (Protonix)
07-99-00	OTHER MOOD/BEHAVIOR MEDICATIONS	10-03-99	OTHER ANTACIDS
	LIPID LOWERING MEDICATIONS	10-04-00	ANTIDIARRHEALS
08-00-00	Atorvastatin (Lipitor)	10-04-00	Diphenoxylate and Atropine (Lomotil)
08-00-00	Lovastatin (Advicor, Altoprev, Mevacor)		101
08-00-00	Pravastatin (Proavachol, Pravigard)	10-05-01	SODIUM BICARBONATE
08-00-00	Rosuvastatin (Crestor)		-0,
08-00-00	Simvastatin (Zocor)	10-05-02	CITRATE AND CITRIC ACID (Bicitra, Polycitra)
	SEIZURE/ANTIEPILEPTIC MEDICATIONS	10-99-00	OTHER DIGESTIVE SYSTEM MEDICATIONS
09-00-00	Carbamazepine (Tegretol)	10	
09-00-00	Lamotrigine (Lamictal)		BLADDER/URINARY SYSTEM MEDICATIONS
09-00-00	Levetiracetam (Keppra)	11-01-00	ANTICHOLINGERGICS
09-00-00 09-00-00	Levetiracetam (Keppra) Oxcarbazepine (Trileptal)	11-01-00 11-01-00	ANTICHOLINGERGICS Bethanechol (Urecholine)
	, , ,		
09-00-00	Oxcarbazepine (Trileptal)	11-01-00	Bethanechol (Urecholine)
09-00-00	Oxcarbazepine (Trileptal)	11-01-00 11-01-00	Bethanechol (Urecholine) Glycopyrrolate (Robinol)
09-00-00	Oxcarbazepine (Trileptal)	11-01-00 11-01-00 11-01-00	Bethanechol (Urecholine) Glycopyrrolate (Robinol) Hyoscyamine (Levsin)
09-00-00	Oxcarbazepine (Trileptal) Valproic Acid (Depakene, Depakote, Divalproex sodium)	11-01-00 11-01-00 11-01-00 11-01-00	Bethanechol (Urecholine) Glycopyrrolate (Robinol) Hyoscyamine (Levsin) Oxybutynin (Ditropan, Ditropan XL, Oxytrol)
09-00-00	Oxcarbazepine (Trileptal) Valproic Acid (Depakene, Depakote, Divalproex sodium) DIGESTIVE SYSTEM MEDICATIONS	11-01-00 11-01-00 11-01-00 11-01-00	Bethanechol (Urecholine) Glycopyrrolate (Robinol) Hyoscyamine (Levsin) Oxybutynin (Ditropan, Ditropan XL, Oxytrol) Phenazopyridine (Pyridium)
09-00-00 09-00-00	Oxcarbazepine (Trileptal) Valproic Acid (Depakene, Depakote, Divalproex sodium) DIGESTIVE SYSTEM MEDICATIONS ANTIEMETICS & GI MOTILITY AGENTS	11-01-00 11-01-00 11-01-00 11-01-00 11-01-00	Bethanechol (Urecholine) Glycopyrrolate (Robinol) Hyoscyamine (Levsin) Oxybutynin (Ditropan, Ditropan XL, Oxytrol) Phenazopyridine (Pyridium) Tolterodine (Detrol, Detrol LA)
09-00-00 09-00-00 10-01-00 10-01-00	Oxcarbazepine (Trileptal) Valproic Acid (Depakene, Depakote, Divalproex sodium) DIGESTIVE SYSTEM MEDICATIONS ANTIEMETICS & GI MOTILITY AGENTS Metoclopramide (Reglan)	11-01-00 11-01-00 11-01-00 11-01-00 11-01-00 11-01-00	Bethanechol (Urecholine) Glycopyrrolate (Robinol) Hyoscyamine (Levsin) Oxybutynin (Ditropan, Ditropan XL, Oxytrol) Phenazopyridine (Pyridium) Tolterodine (Detrol, Detrol LA) Trihexyphenidyl (Artane)
09-00-00 09-00-00 10-01-00 10-01-00	Oxcarbazepine (Trileptal) Valproic Acid (Depakene, Depakote, Divalproex sodium) DIGESTIVE SYSTEM MEDICATIONS ANTIEMETICS & GI MOTILITY AGENTS Metoclopramide (Reglan) Ondansetron (Zofran)	11-01-00 11-01-00 11-01-00 11-01-00 11-01-00 11-01-00	Bethanechol (Urecholine) Glycopyrrolate (Robinol) Hyoscyamine (Levsin) Oxybutynin (Ditropan, Ditropan XL, Oxytrol) Phenazopyridine (Pyridium) Tolterodine (Detrol, Detrol LA) Trihexyphenidyl (Artane)
09-00-00 09-00-00 10-01-00 10-01-00 10-01-00	Oxcarbazepine (Trileptal) Valproic Acid (Depakene, Depakote, Divalproex sodium) DIGESTIVE SYSTEM MEDICATIONS ANTIEMETICS & GI MOTILITY AGENTS Metoclopramide (Reglan) Ondansetron (Zofran) Promethazine (Phenergan)	11-01-00 11-01-00 11-01-00 11-01-00 11-01-00 11-01-00	Bethanechol (Urecholine) Glycopyrrolate (Robinol) Hyoscyamine (Levsin) Oxybutynin (Ditropan, Ditropan XL, Oxytrol) Phenazopyridine (Pyridium) Tolterodine (Detrol, Detrol LA) Trihexyphenidyl (Artane) Vasopress in analog Desmopressin (DDAVP)
10-01-00 10-01-00 10-01-00 10-01-00 10-02-00	Oxcarbazepine (Trileptal) Valproic Acid (Depakene, Depakote, Divalproex sodium) DIGESTIVE SYSTEM MEDICATIONS ANTIEMETICS & GI MOTILITY AGENTS Metoclopramide (Reglan) Ondansetron (Zofran) Promethazine (Phenergan) LAXATIVES & STOOL SOFTNERS	11-01-00 11-01-00 11-01-00 11-01-00 11-01-00 11-01-00	Bethanechol (Urecholine) Glycopyrrolate (Robinol) Hyoscyamine (Levsin) Oxybutynin (Ditropan, Ditropan XL, Oxytrol) Phenazopyridine (Pyridium) Tolterodine (Detrol, Detrol LA) Trihexyphenidyl (Artane) Vasopress in analog Desmopressin (DDAVP) PHOSPHATE AND POTASSIUM BINDERS
10-01-00 10-01-00 10-01-00 10-01-00 10-02-00 10-02-00	Oxcarbazepine (Trileptal) Valproic Acid (Depakene, Depakote, Divalproex sodium) DIGESTIVE SYSTEM MEDICATIONS ANTIEMETICS & GI MOTILITY AGENTS Metoclopramide (Reglan) Ondansetron (Zofran) Promethazine (Phenergan) LAXATIVES & STOOL SOFTNERS Bisacodyl (Ducolax)	11-01-00 11-01-00 11-01-00 11-01-00 11-01-00 11-01-00	Bethanechol (Urecholine) Glycopyrrolate (Robinol) Hyoscyamine (Levsin) Oxybutynin (Ditropan, Ditropan XL, Oxytrol) Phenazopyridine (Pyridium) Tolterodine (Detrol, Detrol LA) Trihexyphenidyl (Artane) Vasopress in analog Desmopressin (DDAVP) PHOSPHATE AND POTASSIUM BINDERS PHOSPHATE BINDER
10-01-00 10-01-00 10-01-00 10-01-00 10-02-00 10-02-00 10-02-00	Oxcarbazepine (Trileptal) Valproic Acid (Depakene, Depakote, Divalproex sodium) DIGESTIVE SYSTEM MEDICATIONS ANTIEMETICS & GI MOTILITY AGENTS Metoclopramide (Reglan) Ondansetron (Zofran) Promethazine (Phenergan) LAXATIVES & STOOL SOFTNERS Bisacodyl (Ducolax) Docusate (Colace, Senna)	11-01-00 11-01-00 11-01-00 11-01-00 11-01-00 11-01-00 11-01-00	Bethanechol (Urecholine) Glycopyrrolate (Robinol) Hyoscyamine (Levsin) Oxybutynin (Ditropan, Ditropan XL, Oxytrol) Phenazopyridine (Pyridium) Tolterodine (Detrol, Detrol LA) Trihexyphenidyl (Artane) Vasopress in analog Desmopressin (DDAVP) PHOSPHATE AND POTASSIUM BINDERS PHOSPHATE BINDER Calcium Carbonate (TUMS)
09-00-00 09-00-00 10-01-00 10-01-00 10-02-00 10-02-00 10-02-00 10-02-00	Oxcarbazepine (Trileptal) Valproic Acid (Depakene, Depakote, Divalproex sodium) DIGESTIVE SYSTEM MEDICATIONS ANTIEMETICS & GI MOTILITY AGENTS Metoclopramide (Reglan) Ondansetron (Zofran) Promethazine (Phenergan) LAXATIVES & STOOL SOFTNERS Bisacodyl (Ducolax) Docusate (Colace, Senna) Polyethylene (Lactulose, Miralax, Glycolax) Simethicone (Maalox, Mylanta, Gas-X, Milk of	11-01-00 11-01-00 11-01-00 11-01-00 11-01-00 11-01-00 11-01-00 12-01-00	Bethanechol (Urecholine) Glycopyrrolate (Robinol) Hyoscyamine (Levsin) Oxybutynin (Ditropan, Ditropan XL, Oxytrol) Phenazopyridine (Pyridium) Tolterodine (Detrol, Detrol LA) Trihexyphenidyl (Artane) Vasopress in analog Desmopressin (DDAVP) PHOSPHATE AND POTASSIUM BINDERS PHOSPHATE BINDER Calcium Carbonate (TUMS) Calcium salts (PhosLo)
09-00-00 09-00-00 10-01-00 10-01-00 10-02-00 10-02-00 10-02-00 10-02-00	Oxcarbazepine (Trileptal) Valproic Acid (Depakene, Depakote, Divalproex sodium) DIGESTIVE SYSTEM MEDICATIONS ANTIEMETICS & GI MOTILITY AGENTS Metoclopramide (Reglan) Ondansetron (Zofran) Promethazine (Phenergan) LAXATIVES & STOOL SOFTNERS Bisacodyl (Ducolax) Docusate (Colace, Senna) Polyethylene (Lactulose, Miralax, Glycolax) Simethicone (Maalox, Mylanta, Gas-X, Milk of Magnesia, Lactobacillus)	11-01-00 11-01-00 11-01-00 11-01-00 11-01-00 11-01-00 11-01-00 12-01-00 12-01-00	Bethanechol (Urecholine) Glycopyrrolate (Robinol) Hyoscyamine (Levsin) Oxybutynin (Ditropan, Ditropan XL, Oxytrol) Phenazopyridine (Pyridium) Tolterodine (Detrol, Detrol LA) Trihexyphenidyl (Artane) Vasopress in analog Desmopressin (DDAVP) PHOSPHATE AND POTASSIUM BINDERS PHOSPHATE BINDER Calcium Carbonate (TUMS) Calcium salts (PhosLo) Sevelamer (Renagel)

	DIETARY SUPPLEMENT	13-03-00	HERBAL SUPPLEMENT
13-01-01	MULTIVITAMINS FOR KIDNEY DISEASE	13-03-00	Acidophilus
13-01-01	Nephro-Vite, Nephrocaps, Nephro, Replavite	13-03-00	Chlorophil
13-01-02	VITAMIN/MINERAL SUPPLEMENT	13-03-00	Floranex Lactobacillus
13-01-02	Ascorbic Acid	13-03-00	Noni Juice
13-01-02	Folic Acid (Niferex, Leucovorin)	13-04-01	ELECTROLYTE REPLACEMENT
13-01-02	Glyco-Bears Dietary Supplement	13-04-01	Joules (Joules Solution)
13-01-02	L-Carnitine (Carnitor)	13-04-01	K-Phos-Neutral
13-01-02	Leucovorin Calcium (Wellcovorin)	13-04-01	Maginate (OTC magnesium supplement)
13-01-02	Vitamin E	13-04-01	Magnesium (Maginex)
13-01-02	Zinc	13-04-01	Magnesium Chloride
13-01-03	FLUORIDE	13-04-01	Magnesium Gluconate (Magonate)
13-01-03	Sodium Fluoride (Ethedent Chewable, Fluoritab, Fluor-A-Day)	13-04-01	Magnesium Oxide (Mag-Ox)
13-01-99	OTHER MULTIVITAMINS	13-04-01	Potassium Chloride (K-Dur, Klorconr)
13-01-99	Centrium Etc.	13-04-01	Potassium Phosphate (Neutra-Phos)
13-01-99	Children's Multivitamin	13-04-01	Sodium Chloride
13-01-99	Cranberry Tablet	13-04-01	Sodium Phosphate (Na Phosphate)
13-01-99	Vitamin B	13-04-02	CYSTEAMINE (CYSTAGON)
13-01-99	Vitamin C		
13-02-01	ACTIVE VITAMIN D	13-05-00	AMINO ACID SUPPLEMENT
13-02-01	Alfacalcidol (One-alpha)		
13-02-01	Calcitriol (Rocaltrol)	13-06-00	CALORIC NUTRITIONAL SUPPLEMENT
13-02-01	Zemplar (Paricalcitol)		
13-02-02	INACTIVE VITAMIN D	13-07-00	FISH OILS
13-02-02	Calcium Vitamin D Supplement	13-07-00	Complete Omega
13-02-02	Calcium Carbonate with Vitamin D Supplement	13-07-00	Fish Oil
13-02-02	Di-Vi-Sol	13-07-00	Omega 3 Fatty Acid
13-02-02	Doxercalciferol (Hectorol)		
13-02-02	Doxercaldreron Nectrol	13-99-00	OTHER DIETARY SUPPLEMENTS
13-02-02	Ergo Calciferol (Drisdol)		
13-02-02	Vitamin D 25, D3		

	ENDOCRINE SYSTEM MEDICATION
14-01-00	INSULIN AND ORAL HYPOGLYCEMICS
14-01-00	Insulin Aspart (NovoLog)
14-01-00	Insulin Lispro (Humalog Insulin)
14-01-00	Metformin (Fortamet)
14-01-00	Pioglitazone Hydrochloride (Actos)
14-02-00	THYROID REPLACEMENT
14-02-00	Levothyroxine (Levoxyl, L-Thryoxine)
14-02-00	Levothyroxine Sodium (Synthroid)
14-02-00	Thynoxine (Thyroid Supplement)
	XANTHINE OXIDASE INHIBITOR
15-00-00	Allopurinol (Zyloprim)
	OTHER MEDICATIONS
99-01-01	ANALGESICS, IBUPROPHEN (NSAID)
99-01-01	Ibuprofen (Motrin, Advil, Midol)
00 04 00	
99-01-99	ANALGESICS, ASPIRIN/ACETAMINOPHEN
99-01-99 99-01-99	ANALGESICS, ASPIRIN/ACETAMINOPHEN Acetaminophen (Tylenol)
	· · · · · · · · · · · · · · · · · · ·
99-01-99	Acetaminophen (Tylenol)
99-01-99 99-01-99	Acetaminophen (Tylenol) Aspirin
99-01-99 99-01-99 99-01-99	Acetaminophen (Tylenol) Aspirin Opioids - Tylenol with Codeine
99-01-99 99-01-99 99-01-99 99-99-00	Acetaminophen (Tylenol) Aspirin Opioids - Tylenol with Codeine OTHER MEDICATION SUPPLEMENT
99-01-99 99-01-99 99-01-99 99-99-00 99-99-00	Acetaminophen (Tylenol) Aspirin Opioids - Tylenol with Codeine OTHER MEDICATION SUPPLEMENT Antitussive - Dextromethorphan (Delsym)
99-01-99 99-01-99 99-01-99 99-99-00 99-99-00	Acetaminophen (Tylenol) Aspirin Opioids - Tylenol with Codeine OTHER MEDICATION SUPPLEMENT Antitussive - Dextromethorphan (Delsym) Aurodex
99-01-99 99-01-99 99-01-99 99-99-00 99-99-00 99-99-00	Acetaminophen (Tylenol) Aspirin Opioids - Tylenol with Codeine OTHER MEDICATION SUPPLEMENT Antitussive - Dextromethorphan (Delsym) Aurodex Contraceptive - Medroxyprogesterone (Depo-Provera)
99-01-99 99-01-99 99-01-99 99-99-00 99-99-00 99-99-00 99-99-00	Acetaminophen (Tylenol) Aspirin Opioids - Tylenol with Codeine OTHER MEDICATION SUPPLEMENT Antitussive - Dextromethorphan (Delsym) Aurodex Contraceptive - Medroxyprogesterone (Depo-Provera) Depo-Provera
99-01-99 99-01-99 99-01-99 99-99-00 99-99-00 99-99-00 99-99-00	Acetaminophen (Tylenol) Aspirin Opioids - Tylenol with Codeine OTHER MEDICATION SUPPLEMENT Antitussive - Dextromethorphan (Delsym) Aurodex Contraceptive - Medroxyprogesterone (Depo-Provera) Depo-Provera Nutritional Supplement
99-01-99 99-01-99 99-01-99 99-99-00 99-99-00 99-99-00 99-99-00 99-99-00	Acetaminophen (Tylenol) Aspirin Opioids - Tylenol with Codeine OTHER MEDICATION SUPPLEMENT Antitussive - Dextromethorphan (Delsym) Aurodex Contraceptive - Medroxyprogesterone (Depo-Provera) Depo-Provera Nutritional Supplement OTC Cough and Cold Products Otic Analgesic - Antipyrine and Benzocaine
99-01-99 99-01-99 99-01-99 99-99-00 99-99-00 99-99-00 99-99-00 99-99-00	Acetaminophen (Tylenol) Aspirin Opioids - Tylenol with Codeine OTHER MEDICATION SUPPLEMENT Antitussive - Dextromethorphan (Delsym) Aurodex Contraceptive - Medroxyprogesterone (Depo-Provera) Depo-Provera Nutritional Supplement OTC Cough and Cold Products Otic Analgesic - Antipyrine and Benzocaine (Aurodex)

99-99-99 UNKNOWN MEDICATION

CKiD Chronic Kidney Disease in Children Cohort Study (CKiD) SECTION A: GENERAL INFORMATION

A1.	F	PARTICIPANT ID: AFFIX ID LABEL OR ENTER NUMBER IF ID LABEL IS NOT AVAILABLE			
			- -		
A2.	(CKID VISIT #:	<u>0 1 a</u>		
A3.	ŀ	FORM VERSION:	0 3 / 0 1 / 1 8		
A4.	Ī	DATE OF VISIT:/			
A5.	ſ	FORM COMPLETED BY (INITIALS	s):		
The follo	owi	ng samples should be collected.			
Samples	<u>s:</u>	Shipped to:	Shipped:		
Serum		CBL	IMMEDIATELY		
Serum		CBL	Batched (Ship in Jan, Apr, Jul or Oct)		
Urine		CBL	IMMEDIATELY		
lohexol	Blo	od* CBL	IMMEDIATELY		
			f Cohort 3 participants who consent to iohexol		
protoco	l or	Cohorts 1 & 2 participants had p	previous iGFR>90		
	ВА		SHIPPED QUARTERLY (Jan, Apr, July or Oct) IRED BY THE SITE COORDINATOR!		
		-	oe stored for more than one year. ontact your CCC prior to shipment.		
	5	SECTION B: PREGNANCY TEST	AND FIRST MORNING URINE COLLECTION		
B1.	-	articipant a female of child-bearing po			
		5 1 (•		
	No.	2 (Skip to B3)		
_			RTICIPANTS OF CHILD-BEARING POTENTIAL ONLY.		
_			. WITHIN 72 HOURS BEFORE STUDY VISIT DATE.		
It pert		• •	COMPLETED BEFORE IOHEXOL TESTING IS		
774777					
B2.	a.	Urine pregnancy test date:	//		
		1	$\frac{1}{M} \frac{1}{M} \frac{1}{D} \frac{1}{D} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y}$		
	b.	Urine pregnancy results:	(END. COMPLETE TRANSITIONAL (TRASA) FORM		
			(END; COMPLETE TRANSITIONAL (TRS01) FORM)		
		Negative 2			
			Or ha		



FIRST MORNING URINE COLLECTION

Obtain urine collected at home in the specimen container that was shipped to the family before the visit. If URINE WAS NOT COLLECTED at home, collect FRESH urine sample during CKiD visit.

Pour at least 1 mL of urine into the CBL transport tube.

Check that all information is correct on the urine collection tube and follow packaging instructions and ship to CBL.

Reasons Code List*: 1= Not required 3 = Participant Refused 5 = Inadvertently Destroyed 7=Insufficient Volume 2 = Difficult Urine Collection 4 = Collection Contamination 6 = Oversight

Sample Type (Required Volume):	(a) Sample Obtained:		(b) If No, specify reason *SEE CODE LIST ABOVE	(c) Additional Requirements:	
	<u>Yes</u>	<u>No</u>	SEE CODE LIST ABOVE		
B3. Urine Creatinine, Urine Protein, Urine Albumin (1 mL-10 mL)	1 (skip to c→)	2	(skip to C1)	i. Is this a first morning urine sample? Yes	

SECTION C: Visit 1a BLOOD DRAW (Select the Type of Consent Obtained, option 1 or 2)

1 If participant is completing study visit, without iohexol protocol: Collect 4.5-5.5 mL from all participants (regardless of weight)

If < 30 kg, immediately transfer (using 18 gauge needle) or draw:

- 2 mL into Tiger-Top SSTs for CBL
- 1 mL in lavender-top tube for local CBC (tube not provided in CBL kit)
- 1.5 mL in appropriate tube (not provided) for local Renal Panel
- 1 mL of additional blood in SST for CBL (if initial sample is GROSSLY HEMOLYZED)


9 For Participant Completing Iohexol Study Visit:

For IOHEXOL study visits, collect:

• 1mL of additional blood into Tiger Top SST for CBL Iohexol Blank (B0) blood sample

Iohexol is infused at the time of initial blood draw. Refer to page 6 for Instructions for Iohexol Infusion and GFR Blood Draws.

SECTION C: Visit 1a BLOOD DRAW PROCESSING



When pickup has been scheduled, complete "On-line Shipping Form" on CKiD website: http://www.statepi.jhsph.edu/ckid/admin/ to notify appropriate personnel that sample(s) have been shipped to CBL.

\cap 1	ACTUAL	OF BI	000	DDVW
UI.	ACTUAL		טטט.	DRAW

•	1 = AM	2 = PM
•	/	

PROMPT: IF SUSPECTED BLOOD DRAW ADVERSE EVENT (i.e., infection), complete Adverse Event (ADVR) Form

Reasons Code List*: 1= Not required 4 = Red Blood Cell Contamination 7 = Exceeds maximum allowable volume 5 = Inadvertently Destroyed 3 = Participant Refused 6 = Oversight

	Sample Type	(a)		(b)	(c)
(Rec	uired Volume in Top Color Tube	Sample Obtained:		If No, specify reason	Additional Requirements:
	Type):	<u>Yes</u>	<u>No</u>	*SEE CODE LIST ABOVE	
C2.	Renal/ Uric Acid Chemistries (2.0 mL in Tiger Top SST)	1 (skip to c→)	2	(skip to C3)	Indicate the appearance of the serum after centrifuging. Grossly (Dark Red)
C3.	Cystatin C (1.0 mL in Tiger Top SST)	1 (skip to c→)	2	(skip to C4)	Date Frozen:/
C4.	Local CBC (1.0 mL in Lavender Top tube)	1 (skip to C5)	2	 (skip to C5)	N/A
C5.	Local Renal Panel (1.5 mL in Local SST)	1 (skip to D2)	2	(skip to D2)	N/A

Sites can obtain results for lab values that have been identified as "KEY VARIABLES". To obtain results, go the CKiD Nephron Website: https://statepiaps8.jhsph.edu/nephron/groups/aspproc/, click on "Report Menu" and choose the appropriate lab report (i.e., Selected Renal Panel Lab Variables Report.)

SECTION D: OPTIONAL TESTS LOCAL LAB TEST (IF CLINICALLY INDICATED)

Check with the PI at your clinical site to determine whether or not it is **CLINICALLY INDICATED** to obtain urine for local lab. These are instances when the PI needs results immediately and/or the participant needs additional local labs performed (i.e., local Urine Creatinine and Urine Protein).

QUES	STION	D1	HAS	BEEN	DELE	TED.
------	-------	----	-----	------	------	------

	QU	ESTION D1 HAS BEEN DELETED.		
D2.	Wa	as a urine protein to creatinine ratio assay perf	ormed at the clinical s	ite's local laboratory?
		Yes 1 → No 2	Complete Local Urion CLINICALLY INDICALLY	ne Assay Results Form L06 ONLY if local labs are ATED
			IOHEXOL PROTO	COL
D3.	ls t	he participant completing iohexol study visit?	-	ed 1 2 → (End Form)
(ONL	Y COMPLETE SECTIONS E & F IF	PARTICIPANT	IS COMPLETING IOHEXOL STUDY VISIT.
O,	niy C	should complete iohexol prote For an iohexol study visit, additional should be	ocol. If you have a	
E1.		ALE MUST BE FIRST ZEROED BEFORE WEIGH ST BE USED TO WEIGH THE SYRINGE <u>PRE AN</u>		IUM FOIL PRIOR TO WEIGHING THE SYRINGE. THE <u>SAME</u> SCAL USION.
	a.	Syringe Weight Pre- lohexol Infusion:	(g)	
	b.	Syringe Weight Post- Iohexol Infusion : _	(g)	(Post-Infusion Weight should be at least 6.0g less than Pre Infusion Weight. If Post-Infusion Weight is not at least 6g less, please confirm.)
:	PRE	AND POST SYRINGE WEIGHT MUS	T BE OBTAINED	IN ORDER TO CALCULATE PARTICIPANT'S GFR.

SECTION F: IOHEXOL - Refer to Instructions for Iohexol Infusion and GFR Blood Draws Flow Chart on Page 6

- > BEFORE INFUSING 5 mL of IOHEXOL, SET TIMER = 0. SIMULTANEOUSLY START TIMER AND BEGIN IOHEXOL INFUSION
- **COMPLETE INFUSION BETWEEN 1 TO 2 MINS.**
- > LEAVE TIMER RUNNING THROUGHOUT IOHEXOL INFUSION AND SUBSEQUENT BLOOD DRAWS

Instructions for Iohexol Infusion and GFR Blood Draws

Place two IV lines (18-22 gauge polyethylene catheters) using two separate vascular access sites ---OR---

Place one butterfly and one IV line (18-22 gauge polyethylene catheter) using two separate vascular access sites; use tape to stabilize butterfly for iohexol infusion

--OR---

Use butterfly for pre-iohexol and individual blood draw sticks; use tape to stabilize butterfly for Iohexol infusion

Complete pre-iohexol infusion blood draw according to instructions

Start timer and infuse iohexol over 1-2 minutes

If infusion site for iohexol IV or butterfly infiltrates, study MUST BE DISCONTINUED

Must wait at least 48 hours to repeat study, and repeat visit should occur within 3 months of initial

Flush with 10 mL normal saline to ensure infusion of all of the iohexol; IOHEXOL IV OR BUTTERFLY MAY NOW BE REMOVED

10 minutes post-infusion CHECK POST-INFUSION VITALS DO NOT DRAW BLOOD AT 10 MINUTES

Obtain post-infusion weight of syringe on the same scale as prior to infusion. Record weight on the Specimen Collection Form prior to shipment to the CCC

Draw 1 ml of blood into SST at 120 mins (B1), and 300 mins (B2).

*For IV ONLY: Discard initial 1 mL blood waste at each blood draw (or per device guidelines)

*For IV ONLY: Flush after each blood draw with at least 3 mL normal saline

*Record the time each blood draw is completed

If rash develops, consider it a reaction to iohexol and **notify PI immediately**. Consider administering 1mg/kg Benadryl IV (maximum dose 50mg).

If systolic BP decreases > 25 mm Hg, diastolic BP decreases > 20 mm Hg or pulse increases > 20 beats per min, consider this an anaphylactic reaction to iohexol and **notify PI immediately**; consider administering 1 mg/kg Benadryl IV (maximum dose 50 mg) and draw up to 0.1 mL 1:1000 Epinephrine for SQ injection and 2 mg/kg Solumedrol IV if necessary.

COMPLETE ADVERSE EVENT FORM and send to CCC for data entry

......

If blood draw is difficult with poor volume delivery, repeat draw 5 minutes later; record time on Specimen Collection Form and tube. If blood draw is impossible, repeat with new venipuncture.

Following each blood draw: gently invert tube 5-10 times

Stand SST upright at room temp for 30 minutes, but no longer than 1 hour

Centrifuge at MAX SPEED between 1100-1300 g for 10 minutes in swinghead or 15 minutes in fixed angle*

Transfer serum into the cryovial labeled "Iohexol Serum."

Following packaging and shipping instructions; send urine, blood and copies of completed shipping form(s) & confirmation of written consent to CBL

Physician should be immediately available (in person or by phone) during Iohexol Infusion Encourage fluids throughout the visit.

*1100-1300 g = 3000 rpm with 10 cm radius rotor



F1.	IOH	EXOL INFUSION		
	a.	INFUSION START TIME:	:	1 = AM 2 = PM

- DO NOT DRAW BLOOD FROM THE IV SITE WHERE IOHEXOL WAS INFUSED. ANOTHER IV SITE MUST BE USED.
- > WASTE 1 mL OF BLOOD IF DRAWING FROM A SALINE/HEPARIN LOCK (OR PER DEVICE GUIDELINES).
- > COLLECT 1 mL OF BLOOD FOR EACH IOHEXOL BLOOD DRAW IN THE PROVIDED SST.
- > RECORDING THE EXACT NUMBER OF MINUTES ON THE TIMER IS MORE IMPORTANT THAN DRAWING THE BLOOD EXACTLY AT 120 & 300 MINUTES AFTER IOHEXOL INFUSION. FOR EXAMPLE, IF BLOOD IS DRAWN AT 133 MINS INSTEAD OF 120 MINS, DOCUMENT BLOOD DRAWN @ 133 MINS.
- > TIME SHOULD BE RECORDED IMMEDIATELY AFTER EACH BLOOD SAMPLE IS OBTAINED (i.e., B1, B2).

POST VITALS SHOULD BE TAKEN 10 MINUTES AFTER INFUSION USING LOCAL BLOOD PRESSURE MEASUREMENT (i.e. DINAMAP)

- If rash develops after lohexol Infusion, consider it a reaction to lohexol and notify PI immediately. Consider administration of 1 mg/kg Benadryl IV (maximum dose: 50 mg Benadryl IV).
- In the rare event that systolic BP decreases more than 25 mm Hg, diastolic BP decreases more than 20 mmHg, or pulse increases more than 20 beats per min, notify PI immediately to evaluate reaction and complete the Adverse Event (ADVR) Form. Consider the possibility of an anaphylactic reaction to lohexol. Consider administration of 1 mg/kg Benadryl IV (maximum dose: 50 mg Benadryl IV). Draw up to 0.1 mL 1:1000 Epinephrine for SQ injection and 2 mg/kg Solumedrol IV for administration as ordered by physician.

	(i) Post Vitals:								
F2a.	Post- infusion blood pressure:	/							
b.	Post-infusion temperature:	1 = °C Typical range: 36.1 – 38.3 2 = °F Typical range: 94.5 – 100.6							
c.	Post-infusion number of heart beats per minute:								
d.	Post-infusion respirations per minute:								

CKiD (Baseline Visit) L01: Specimen Collection Form for V1a – 03/01/18

INVERT TUBE 5-10 TIMES AFTER EACH BLOOD DRAW LET SST TUBE STAND 30 MINUTES (BUT NO LONGER THAN 1 HOUR) CENTRIFUGE AT MAX SPEED BETWEEN 1100-1300g (3000rpm with 10cm radius rotor) for 10 MINUTES IN SWING HEAD OR 15 MINUTES IN FIXED ANGLE (BALANCE TUBES IN CENTRIFUGE)

	ALL TIMES should be documented from the initial infusion time	ACTUAL HOURS/ MINUTES on TIMER		(ii) ONLY if Timer malfunctions, record Clock Time using the same clock used for G1a	(iii) Difficult Blood Draw: Yes No		(iv) Blood Drawn via Venipuncture Yes No		(v) Blood Volume Collected (1 mL):	(v Centri at Clinio Yes	fuged
F3a.	B1 2 hrs (120 min):	hr	mins	: 1 = AM 2 = PM	1 (Skip to b)	2	1	2	mL	1 (Skip to F4a)	2 (Skip to F4a)
b.	B1 2 nd attempt:	hr	mins	: 1 = AM 2 = PM	9	2	1	2	mL	1	2
F4a.	B2 5 hrs (300 min):	hr	mins	: 1 = AM 2 = PM	1 (Skip to b)	2	1	2	mL	1 (END FORM)	2 (END FORM)
b.	B2 2 nd attempt:	hr	mins	: 1 = AM 2 = PM	1	2	1	2	mL	1	2

CKiD Chronic Kidney Disease in Children Cohort Study SECTION A: GENERAL INFORMATION

A1. PARTICIPANT ID: AFFIX ID LABEL OR ENTER NUMBER IF ID LABEL IS NOT AVAILABLE

|__| - |__| - |__|

A2. CKiD VISIT #: <u>0 1 b</u>

A3. FORM VERSION: <u>0 3 / 0 1 / 1 8</u>

A4. SPECIMEN COLLECTION DATE:

M M D D Y Y Y Y

A5. FORM COMPLETED BY (INITIALS): ____ ___

The following sample should be collected.

Samples: Shipped to: Shipped:

Serum CBL BATCHED (Ship in Jan, Apr, Jul or Oct)

Plasma CBL BATCHED (Ship in Jan, Apr, Jul or Oct)

Please refer to questions 26 and 27 on the Eligibility Form to determine if genetic and/or biological consent was obtained.

Depending on the type of consent, the following samples may or may not be collected:

Samples: Shipped to: Shipped:

Whole Blood (Genetic) NIDDK Biorepository IMMEDIATELY

Nail Clippings (Biological) NIDDK Biorepository IMMEDIATELY

Hair (Biological) NIDDK Biorepository IMMEDIATELY

Serum (Biological) NIDDK Biorepository Batched (Jan, Apr, Jul or Oct)

Plasma (Biological) NIDDK Biorepository Batched (Jan, Apr, Jul or Oct)

Urine (Biological) NIDDK Biorepository Batched (Jan, Apr, Jul or Oct)

BATCHED SAMPLES SHOULD BE SHIPPED QUARTERLY (Jan, Apr, July or Oct) OR MORE OFTEN IF DESIRED BY THE SITE COORDINATOR!

Samples should NOT be stored for more than one year. For specific questions, contact your CCC prior to shipment.



SECTION B: Visit V1B BLOOD DRAW

For Initial Blood Draw with Syringe, Vacutainer OR Butterfly Method:

Select the Type of Consent Obtained (options 1 through 4) That Pertains to the CKiD Participant:

If participant consented to both BIOLOGICAL AND GENETIC samples:

Collect 15 mL if participant is < 30 kg OR 19 mL if participant is $\ge 30 \text{ kg}$.

If < 30 kg, immediately transfer (using 18 gauge needle) or draw:

- 6 mL into (1) 6mL ACD tubes for Genetic sample (ACD Tube must be COMPLETELY FILLED)
- 5 mL into (1) Tiger-Top SST for CBL and NIDDK Biorepository
- 4 mL into two (2) PSTs for CBL and NIDDK Biorepository

If ≥ 30 kg, immediately transfer (using 18 gauge needle) or draw:

- 6 mL into (1) 6mL ACD tubes for Genetic sample (ACD Tube must be COMPLETELY FILLED)
- 7 mL into (1) Tiger-Top SST for CBL and NIDDK Biorepository
- 6 mL into two (2) PSTs for CBL and NIDDK Biorepository

If participant consented to BIOLOGICAL samples ONLY:

Collect 9 mL if participant is < 30 kg OR 13 mL if participant is $\ge 30 \text{ kg}$.

If < 30 kg, immediately transfer or draw:

2

3

- 5 mL into (1) Tiger-Top SST for CBL and NIDDK Biorepository
- 4 mL into two (2) PSTs for and CBL NIDDK Biorepository

If ≥ 30 kg, immediately transfer or draw:

- 7 mL into (1) Tiger-Top SST for CBL and NIDDK Biorepository
- 6 mL into two (2) PSTs for CBL and NIDDK Biorepository

If participant consented to GENETIC samples ONLY:

Collect 9 mL from all participants (regardless of weight)

Immediately transfer or draw:

- 6 mL into (1) 6mL ACD tube for Genetic sample (ACD Tubes must be COMPLETELY FILLED)
- 2 mL into (1) Tiger-Top SST for CBL
- 1 mL into (1) PST for CBL

If participant did NOT consent to BIOLOGICAL AND GENETIC samples:

Collect 3 mL from all participants (regardless of weight). Immediately transfer or draw 2 mL into (1) Tiger-Top SST for CBL and 1 mL into PST for CBL.

SECTION B: Visit 1B BLOOD DRAW PROCESSING PROCESSING BLOOD FOR CBL AND NIDDK BR SAMPLES



Invert the Tiger Top SST 5 times gently to mix.

Stand SST upright to allow clotting at room temperature for 30 mins and not more than 1 hour (60 mins).

Centrifuge SST at MAX SPEED between 1100-1300g (3000rpm with 10cm radius rotor) for 10 mins in swinghead OR 15 mins in fixed angle. *If incomplete separation, centrifuge again 10-15 mins.

NIDDK (Serum)

Pipette 1.5mL (<30kg) or 2.5mL (≥30kg) serum into clear top cryovial (use different pipettes for serum and plasma). *If there is any extra serum, then pipette the extra serum into the clear top cryovial marked "NIDDK BR SERUM".

Store sample(s) in freezer at -70°C or lower, batch up to 40 samples and ship during **January**, **April**, **July and October**. When shipper is needed, complete "NIDDK BR Shipper Request Form" on the CKiD website:

http://www.statepi.jhsph.edu/ckid/admin/. Then, follow packaging instructions.

Pipette 0.5 mL of serum into red top cryovial tube for CBL iPTH &. hsCRP

<u>iPTH/hsCRP</u>

Pipette 0.5 mL of serum into red top cryovial for CBL Vitamin D

Vitamin D

Store sample in freezer at -70°C or lower and batch up to 20 samples and ship quarterly during the months of **January**, **April**, **July and October**. When shipper is needed, complete "CBL Dry Ice Shipper Request Form" on the CKiD website: http://www.statepi.jhsph.edu/ckid/admin/ Then, follow packaging instructions and ship to CBL with accompanying forms. No FRIDAY shipments. Refrigerate and ship on next business day.

CBL & NIDDK BR (Plasma)

Invert each PST 8-10 times gently to mix.

Centrifuge each PST at MAX SPEED between 1100-1300g for 10 mins (swinghead) **OR** 15 mins (fixed angle).

FGF-23

Pipette 0.5 mL of plasma into a cryovial with a green cap insert for CBL FGF-23

green cap insert (use different pipettes for serum and plasma).

*If there is any extra plasma, then pipette the extra plasma into the green cap insert cryovial marked "PLASMA (Extra)".

Pipette 1.5mL (<30kg) or 2.5mL

(≥30kg) plasma into cryovial with

Store sample(s) in freezer at -70°C or lower, batch up to 40 samples and ship during the months of **January**, **April**, **July and October**. When shipper is needed, complete "NIDDK BR Shipper Request Form" on the CKiD website: http://www.statepi.jhsph.edu/ckid/admin/. Then, follow packaging instructions.

NIDDK BR (Whole Blood for DNA)

Invert ACD Tube 6 times gently to mix blood with additives.

Keep tube at room temperature. **DO NOT FREEZE.**

Follow packaging instructions, complete DNA Collection Form and ship immediately to NIDDK Biorepository with accompanying forms. Specimen can be shipped on Friday.

Complete "On-line Shipping Form" on CKiD website to notify KIDMAC that sample(s) have been shipped.

When pickup has been scheduled, complete "On-line Shipping Form" on CKiD website: http://www.statepi.jhsph.edu/ckid/admin/ to notify the appropriate personnel from the CBL and the NIDDK BR.

SECTION B: Visit 1B BLOOD DRAW AND PROCESSING

: $1 = AM \quad 2 = PM$

B1. ACTUAL TIME OF BLOOD DRAW

Reason	s Code List [*] :	1= Not required	4 = Red Blood (Cell Contamination 7 = Ex	cceed maximum allowable volume				
		2 = Difficult Blood Draw	5 = Inadvertent	/ Destroyed					
		3 = Participant Refused	6 = Oversight						
		mple Type in Top Color Tube Type):	(a) Sample Obtained: <u>Yes</u> <u>No</u>	(b) If No, specify reason *SEE CODE LIST ABOVE	(c) Additional Requirements:				
B2a.	32a. Serum for iPTH, hsCRP & Vitamin D (2.0 mL of blood in Tiger Top SST)		1 (skip to c→) (skip to B2b)		Date Frozen://				
B2b.	Plasma for FGF-2 (1.0 mL of blood i		1 2 (skip to c→)	(skip to B3)	Date Frozen://				
B3.									
		mple Type in Top Color Tube Type):	(a) Sample Obtained: <u>Yes</u> <u>No</u>	(b) If No, specify reason *SEE CODE LIST ABOVE	(c) Additional Requirements:				
B4.		NIDDK Biorepository 1 (6 mL) ACD tube)	1 2 (skip to c→)	(skip to B5)	i. Date of Blood Draw: //				

B5.	Did the participant consent to have biological samples (i	i.e., serum,	, plasma, ι	urine, nai	iil clippings and	d hair	(samples)	stored at NII	DDK
	Biorepository?								

Reasons Code List*:	1= Not required 2 = Difficult Blood Draw	4 = Red Blood Cell Contamination 7 = Exceed maximum allowable volume 5 = Inadvertently Destroyed
	3 = Participant Refused	6 = Oversight

	Sample Type (Required Volume in Top Color Tube Type):	(a) Sample Obtained: Yes No	(b) If No, specify reason *SEE CODE LIST ABOVE	(c) Additional Requirements:
В6.	Serum for NIDDK Biorepository (**3.0 mL or **5.0 mL of blood in Tiger Top SST)	1 (skip to c→)	(skip to B7)	Date Frozen: //
B7.	Plasma for NIDDK Biorepository (**3.0 mL of blood (1) Green Top or **5.0 mL (2) Green Top PSTs)	1 2 (skip to c→)	(skip to C1)	Date Frozen://

^{**} Collect 3.0 mL of whole blood for participants < 30 kg and 5.0 mL for participants \ge 30 kg

SECTION C: Visit 1B URINE COLLECTION AND PROCESSING FOR REPOSITORY

Collect FRESH urine into an initial urine collection cup or hat (provided by the site).

Pour 15-60 mL (preferably 60 mL) of FRESH urine into 90 mL urine collection cup with 4 protease inhibitor tablets. Do not fill the urine past the 60 mL mark on the collection cup. One protease inhibitor tablet should be used for 10-15 mL of urine (see **Table A**). For example if 30 mL of urine is collected, ONLY 2 PI tablets are needed. (Like all unused supplies, unused protease inhibitor tablets should be returned to the CBL.)

Invert the urine cup gently 5 - 10 times.

TABLE A:

of Protease
Inhibitor Tablets

10 - 15 mL
16 - 30 mL
31 - 45 mL
46 - 60 mL

4 minimized in a protection in a prote

The PROTEASE INHIBITOR TABLET(s) MUST BE COMPLETELY DISSOLVED in the urine.

Once the protease inhibitor tablet(s) are completely dissolved, pour urine into up to six (6) 10 mL urine centrifuge tubes. (**For each tube:** remove yellow top cap, pour urine into tube and SCREW cap back onto tube.) Place no more than 10 mL in each tube.

-- OR -

Sites may also substitute with tubes normally used to centrifuge urine at site.

Centrifuge urine tube(s) at MAX SPEED between 1100-1300g (3000rpm with 10cm radius rotor) for 10 mins (swinghead units) – **OR** – 15 mins (fixed angle units).

Decant (pour off) the supernates (liquid reaction) into up to seven (7) 10 mL urine cryovials. Pour no more than 9 mL of urine into each 10 mL cryovial to allow for expansion.

Check that all information is correct on the urine cryovials, promptly freeze and store sample(s) at -70°C or lower. Batch samples and ship at least quarterly (include maximum of 36 cryovials per shipper). When shipper(s) is needed, complete "NIDDK Shipper Request Form" on CKiD website: http://www.statepi.jhsph.edu/ckid/admin/. Then, follow packaging instructions.

When pickup has been scheduled, complete "Online Shipping Form" on CKiD website to notify the NIDDK and KIDMAC that sample(s) have been shipped to NIDDK BR.

Reasons Code List*: 1= Not required 2 = Difficult Urine 3 = Participant 4 = Collection 5 = Inadvertently 6 = Oversight 7 = Insufficient volume

Sample Type (Required Volume in Top Color Tube Type):	(a) Sample Obtained:		(b) If No, specify reason	(c) Additional Requirements:	
	<u>Yes</u>	<u>No</u>	*SEE CODE LIST ABOVE		
C1. Urine for NIDDK Biorepository (15.0 - 60.0 mL of urine in specimen container and transferred into collection cup with protease inhibitors)	1 (skip to c→)	2	 (skip to D1)	i. Was supernate decanted into urine transport cryovials? Yes1 No2	
				ii. Date Frozen: / /	

SECTION D: NAIL CLIPPING COLLECTION

Collection of fingernails is preferred. DO NOT collect fingernail clippings if the participant has acrylic nails, nail fungus, or discoloration
causing pain or discomfort. If the participant cannot provide fingernail clippings, the Study Coordinator may clip the participant's toenails
instead. FINGERNAILS AND TOENAILS SHOULD NOT BE COLLECTED IN THE SAME CRYOVIAL (collect one or the other).

• STAINLESS STEEL NAIL CLIPPERS MUST BE USED TO COLLECT NAIL CLIPPINGS. Use small (pediatric size) stainless steel nail clippers (see Figure A) for younger participants and large stainless steel nail clippers (see Figure B) for older participants. Both sizes are included in the CKiD starter package.

Clean the blades of the nail clippers with SaniZide Plus prior to use (provided by the CBL).

- Whenever possible, the Study Coordinator should clip all (10) fingernails, removing approximately 1 millimeter from each nail (See Figure C). Be prepared to collect flyaway nails.
- ➤ (To use nail clippers, see Figures A D). Refer to CKiD MOP Section 12 for further details.
- Carefully place the nail clippings into the cryovial (see Figure D). After using the nail clipper, spray the clipper with SaniZide Plus and wipe clean with clean cloth.

Figure A









Figure D

Provide 10 nail clippings that are at least 1 mm tall

D1.	Do	Does the participant have acrylic nails?	
		Yes 1 (Skip to	D3)
		No	
D2.	We	Were 10 fingernail clippings collected?	. 0
		Yes 1 (Skip to	E1)
		No 2	
	a.	a. How many fingernail clippings were collected?	E1)
	b.	1 7	CO,
		Nails not long enough 1 (Skip to	
		Participant Refused	D3)
		Other 2	
		i. Specify:	
D3.	We	Were 10 toenail clippings collected?	
		Yes	E1)
		No	
	a.	a. How many toenail clippings were collected? —————	
	b.	b. Specify reason "10" toenail clippings were not collected: (e.g., Nail fu	ngus or discoloration causing pain or discomfort
		Nail fungus or discoloration 1 (Skip to	E1)
		Nails not long enough	E1)
		Participant Refused7 (Skip to	E1)
		Other	

SECTION E: HAIR SAMPLE COLLECTION

- STAINLESS STEEL SCISSORS MUST BE USED TO COLLECT HAIR SAMPLE. The scissors are included in the CKiD starter package.
- DO NOT collect hair sample if the participant has colored, or chemically altered hair
- Clean blades of stainless steel scissors with SaniZide Plus prior to use.
- Use powder-free gloves.
- Refer to CKiD MOP Section 12 for further details.
 - Lift up the top layer of hair from the **occipital** region of the scalp (see Figure A). Isolate a small thatch of hair (at least 20 fibers) from this region (see Figure B).
 - Place the label with the participant's KID ID # tightly around all 20 strands of hair located at the distal end (furthest from the scalp) (see Figure C).
 - > Cut the hair sample off the participant's head as close to the scalp as possible (see Figure D).
 - > Place cut thatch of hair inside aluminum foil (4 X 4) and fold the top of the foil to completely enclose the hair sample.
 - Place the aluminum foil inside a Ziplock bag (4 X 4) with the gel desiccant pellets in it and seal.
 - Store sample at room temperature in a dark place prior to shipment.
 - After using the scissors, spray scissors with SaniZide Plus and wipe clean with clean cloth.

Figure A

Occipital Region of Scalp

Figure B



Place the KID ID label tightly around all 20 strands.

Figure C



Figure D



Cut the hair sample off the participant's head as close to the scalp as possible.

E1.	Does the participant have permed, dyed, colored, or ch	nemically altered hair?
	Yes	1 (End Form)
	No	2
E2.	Was the Study Coordinator able to cut at least 20 fibers	s of hair from the occipital region?
	Yes	1 (End Form)
	No	2
	a. Specify reason "20" hair fibers were not collected:	
	Hair not long enough	1 (End Form)
	Participant Refused	7 (End Form)
	Other	2
	i. Specify:	
	•	

CKiD Chronic Kidney Disease in Children Cohort Study SECTION A: GENERAL INFORMATION

PARTICIPANT ID: AFFIX ID LABEL OR ENTER NUMBER IF ID LABEL IS NOT AVAILABLE

A1.

			- -				
A2.	CKiD VISIT #:						
A3.	FORM VERSION:		0 3 / 0 1 / 1 8				
A4. SPECIMEN COLLECTION DATE:		DLLECTION DATE:	$\frac{1}{M} \frac{1}{M} \frac{1}{D} \frac{1}{D} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y}$				
A5. FORM COMPLETED BY (INITIALS):		LETED BY (INITIALS):					
The	following sam	ples should be collecte	ed.				
<u>Sar</u>	<u>nples:</u>	Shipped to	Shipped:				
Ser	um	CBL	IMMEDIATELY				
Ser	um	CBL	Batched (Ship in Jan, Apr, Jul or Oct)				
Uri	Urine CBL		IMMEDIATELY				
loh	Iohexol Blood* CBL		IMMEDIATELY				
* Co	* COLLECT IOHEXOL BLOOD DRAW: Only if Cohort 3 participants who consent to iohexol protocol or Cohorts 1 & 2 participants had previous iGFR>90						
If c	If consent is obtained for biological samples, collect the following:						

Samples: Shipped to: Shipped: Serum (Biological) **NIDDK Biorepository Batched**

(Ship in Jan, Apr, Jul or Oct)

Plasma (Biological) **NIDDK Biorepository Batched**

(Ship in Jan, Apr, Jul or Oct)

Urine (Biological) NIDDK Biorepository Batched

(Ship in Jan, Apr, Jul or Oct)

Nail Clippings (Biological) **NIDDK Biorepository IMMEDIATELY**

Hair (Biological) **NIDDK Biorepository IMMEDIATELY**

BATCHED SAMPLES SHOULD BE SHIPPED QUARTERLY (Jan, Apr, July or Oct) OR MORE OFTEN IF DESIRED BY THE SITE COORDINATOR!

> Samples should NOT be stored for more than one year. For specific questions, contact your CCC prior to shipment.



SECTION B: PREGNANCY TEST AND FIRST MORNING URINE COLLECTION

B1.	ls p	participant a female of child-bearing potential?					
		S					
PROMPT: QUESTION B2 IS FOR FEMALE PARTICIPANTS OF CHILD-BEARING POTENTIAL ONLY. URINE PREGNANCY TEST DATE MUST FALL WITHIN 72 HOURS BEFORE STUDY VISIT DATE.							
If per INITI		ning iohexol protocol, B2 MUST BE COMPLETED BEFORE IOHEXOL TESTING IS D.					
B2.	a.	Urine pregnancy test date: M M D D Y Y Y Y					
	b.	Urine pregnancy results:					
		Positive					
		Negative2					

FIRST MORNING URINE COLLECTION

Obtain urine collected at home in the specimen container that was shipped to the family before the visit. IF URINE WAS NOT collected at home, collect FRESH urine sample during CKiD visit.

(Refer to MOP Section 11 and/or CBL flowchart for additional information and directions)

Pour at least1 mL of urine into the CBL transport tube.

1

Check that all information is correct on the urine collection tube and follow packaging instructions and ship to CBL.

Reasons Code List*: 1= Not required 4 = Collection Contamination 7 = Insufficient Volume 5 = Inadvertently Destroyed

3 = Participant Refused 6 = Oversight

	Sample Type (Required Volume):	(a) Sample Obtained: Yes No	(b) If No, specify reason *SEE CODE LIST ABOVE	(c) Additional Requirements:
B3.	Urine Creatinine, Urine Protein, Urine Albumin (CBL) (1.0 mL–10 mL)	1 2 (skip to c→)	(okin to C1)	i. Is this a first morning urine sample? Yes1 No2
	(1.0 IIIL=10 IIIL)		(skip to C1)	ii. Time of Collection: : 1 = am, 2 = pm

SECTION C: Visit 2 BLOOD DRAW

For Initial Blood Draw with <u>Syringe</u>, <u>Vacutainer</u> OR <u>Butterfly</u> Method: Select the Type of Consent Obtained (options 1 through 3):

If participant consented to BIOLOGICAL samples:

Collect 14-15 mL if participant is < 30 kg OR 20-21 mL if participant is $\ge 30 \text{ kg}$.

If < 30 kg, immediately transfer (using 18 gauge needle) or draw:

- 8.5 mL into (2) Tiger-Top SSTs for CBL & NIDDK Biorepository
- 3 mL into (1) PST for NIDDK Biorepository
- 1 mL in lavender-top tube for local CBC (tube not provided in CBL kit)
- 1.5 mL in appropriate tube (not provided) for local Renal Panel
- 1 mL of additional blood in SST for CBL (if initial sample is GROSSLY HEMOLYZED)

If ≥ 30 kg, immediately transfer (using 18 gauge needle) or draw:

- 12.5 mL into (2) Tiger-Top SSTs for CBL & NIDDK Biorepository
- 5 mL into (2) PST for NIDDK Biorepository
- 1 mL in lavender-top tube for local CBC (tube not provided in CBL kit)
- 1.5 mL in appropriate tube (not provided) for local Renal Panel
- 1 mL of additional blood in SST for CBL (if initial sample is GROSSLY HEMOLYZED)

2 If participant did NOT consent to BIOLOGICAL samples:

Collect 5-6 mL from all participants (regardless of weight) as specified below.

Immediately transfer (using 18 gauge needle) or draw:

- 2.5 mL into (1) Tiger-Top SSTs for CBL
- 1 mL in lavender-top tube for local CBC (tube not provided in CBL kit)
- 1.5 mL in appropriate tube (not provided) for local Renal Panel
- 1 mL of additional blood in SST for CBL (if initial sample is GROSSLY HEMOLYZED)

For Participant Completing Iohexol Study Visit

Only Cohort 3 participants who consent to iohexol protocol or Cohorts 1 & 2 participants with previous iGFR>90

For IOHEXOL study visits:

• ImL of additional blood into Tiger Top SST for CBL Iohexol Blank (B0) blood sample Iohexol is infused at the time of initial blood draw.

Refer to page 10 for **Instructions for Iohexol Infusion and GFR Blood Draws**.

SECTION C: Visit 2 BLOOD DRAW PROCESSING

Invert the SST 5 times & PST 8-10 times gently to mix. Stand SST upright to allow clotting at room temperature for 30 mins and not more than 1 hour (60 mins). Centrifuge SST & PST at MAX SPEED between 1100-1300g (3000rpm with 10cm radius rotor) for 10 minutes in swinghead units **OR** 15 minutes in fixed angle units (balance tube in centrifuge).*If incomplete separation, centrifuge again for 10-15 minutes. If sample is moderately, slightly or NOT HEMOLYZED, proceed with CBL and NIDDK BR preparation. If sample is GROSSLY HEMOLYZED. You must send hemolyzed **Cystatin C** sample to CBL. If **NIDDK BR** For IOHEXOL STUDY **CBL Studies** Using the disposable pipette, pipette (Serum & Plasma) Using the disposable pipette, participant has eaten, VISITS ONLY: 0.5 mL of serum into Blue Screwpipette 0.75 mL of serum Pipette 3 mL (<30kg) or 5 mL (>30kg) aliquot hemolyzed sample B0 sample Top Cryovial for Cystatin C. into Orange Top Transport of serum into clear top cryovial & 1.5 for fasting lipid profile Using the disposable pipette, Store sample in freezer at -70°C or Tube labeled "Serum CBL" mL (<30kg) or 2.5 mL (> 30kg) of and send to CBL. Also, if pipette 0.5 mL of serum into lower, batch up to 20 samples and for CBL renal/uric acid and plasma into cryovial into green cap Round-bottom Orange Top the sample is **GROSSLY** ship on dry ice every four months to lipids. Follow packaging insert (use different pipettes for serum Transport Tube labeled "B0" for HEMOLYZED (Dark the CBL. When shipper is needed, instructions and ship to CBL and plasma). Iohexol Blank (B0) sample. complete "CBL Dry Ice Shipper **Red),** collect 1 mL of with accompanying forms, *If there is any extra serum and/or Follow packaging instructions Request Form" on the CKiD iohexol blood draws and additional blood in a SST. plasma, then pipette the extra serum and ship to CBL with website: urine. No FRIDAY into the clear top cryovial marked Centrifuge and then accompanying forms, iohexol http://www.statepi.jhsph.edu/ckid/admin/ shipments. Refrigerate "NIDDK BR SERUM" and the extra transfer serum into the blood draws and urine. No Then, follow packaging specimen and ship on next plasma in green cap insert cryovial FRIDAY shipments. extra Orange Top instructions and ship to CBL with business day. marked "PLASMA (Extra)." Refrigerate specimen and ship Transport Tube provided. accompanying forms. No Store samples in freezer at -70°C or on next business day. FRIDAY shipments. lower, & batch up to 40 samples and Ship on next business day. ship on dry ice in January, April, July or October to the NIDDK BR. When shipper is needed, complete "NIDDK BR Shipper Request Form" on the CKiD website: http://www.statepi.jhsph.edu/ckid/admin/. Then, follow packaging instructions. When pickup has been scheduled, complete "On-line Shipping Form" on CKiD website: http://www.statepi.jhsph.edu/ckid/admin/ to notify the appropriate personnel from the CBL and the NIDDK BR.

C1. ACTUAL TIME OF BLOOD DRAW : : 1 = AM 2 =
--

PROMPT: IF SUSPECTED BLOOD DRAW ADVERSE EVENT (i.e., infection), complete ADVERSE EVENT (ADVR) Form

Reasons Code List*: 1= Not required 4 = Red Blood Cell Contamination 7 = Exceed maximum allowable volume 2 = Difficult Blood Draw 5 = Inadvertently Destroyed 3 = Participant Refused 6 = Oversight

Sample Type (Required Volume in Top Color Tube Type):		(a) Sample Obtained:		(b) If No, specify reason	(c) Additional Requirements:	
		<u>Yes</u>	<u>No</u>	*SEE CODE LIST ABOVE	O *	
C2.	Renal/Uric Acid Chemistries (2.0 mL in Tiger Top SST)	1 (skip to c→)	2	(skip to C3)	Indicate the appearance of the serum after centrifuging. Grossly (Dark Red)	
C3.	Cystatin C (1.0 mL in Tiger Top SST)	1 (skip to c→)	2	(skip to C4a)	Date Frozen: //	
C4a.	Local CBC (1.0 mL in Lavender Top tube)	1 (skip to C4b)	2	(skip to C4b)	N/A	
C4b.	Local Renal Panel (1.5 mL in Local SST)	1 (skip to C5)	2	(skip to C5)	N/A	
C5.	Serum for Fasting Lipid Panel (0.5 mL in Tiger Top SST)	1 (skip to c→)	2	(skip to C6)	Did the participant fast after midnight? Yes1 No2*	

^{*}If the participant did not fast, the Nephron Lipid Report will indicate that the participant did not fast.

Sites can obtain results for lab values that have been identified as "KEY VARIABLES". To obtain results, go the CKiD Nephron Website: https://statepiaps8.jhsph.edu/nephron/groups/aspproc/, click on "Report Menu" and choose the appropriate lab report (i.e., Selected Renal Panel Lab Variables Report.)

C6.	Did the participant consent to have biological samples (i.e., serum, plasma and urine samples) stored at the NIDDK Biorepository?				
	Yes	1			
	No	2 (Skip to E2)	.:.0		

Reasons Code List*:	1= Not required	4 = Red Blood Cell Contamination	7 = Exceed maximum allowable volume
	2 = Difficult Blood Draw	5 = Inadvertently Destroyed	
	3 = Participant Refused	6 = Oversight	

	Sample Type (Required Volume in Top Color Tube Type):	(a) Sample Ob <u>Yes</u>	tained:	(b) If No, specify reason *SEE CODE LIST ABOVE	(c) Additional Requirements:
C7.	Serum for NIDDK Biorepository (**6.0 mL or **10.0 mL of blood in Tiger Top SST)	1 (skip to c→)	2	 (skip to C8)	Date Frozen: ///
C8.	Plasma for NIDDK Biorepository (***3.0 mL of blood in one Green Top or ***5.0 mL in two Green Top PSTs)	1 (skip to c→)	2	(skip to D1)	Date Frozen: ///

^{**} Collect 6.0 mL of whole blood for participants < 30 kg and 10.0 mL for participants \ge 30 kg

^{***} Collect 3.0 mL of whole blood for participants < 30 kg and 5.0 mL for participants ≥ 30 kg

SECTION D: URINE COLLECTION AND PROCESSING FOR REPOSITORY

Collect FRESH urine into an initial urine collection cup or hat (provided by the site).

Pour 15-60 mL (preferably 60 mL) of FRESH urine into 90 mL urine collection cup with 4 protease inhibitor tablets. Do not fill the urine past the 60 mL mark on the collection cup. One protease inhibitor tablet should be used for 10-15 mL of urine (see **Table A**). For example if 30 mL of urine is collected, ONLY 2 PI tablets are needed. (Like all unused supplies, unused protease inhibitor tablets should be returned to the CBL.)

Invert the urine cup gently 5 - 10 times.

The PROTEASE INHIBITOR TABLET(s) MUST BE COMPLETELY DISSOLVED in the urine.

Once the protease inhibitor tablet(s) are completely dissolved, pour urine into up to six (6) 10 mL urine centrifuge tubes. (For each tube: remove yellow top cap, pour urine into tube and SCREW cap back onto tube.) Place no more than 10 mL in each tube.

-- OR –

Sites may also substitute with tubes normally used to centrifuge urine at site.

Centrifuge urine tube(s) at MAX SPEED between 1100-1300g (3000rpm with 10cm radius rotor) for 10 mins (swinghead units) – **OR** – 15 mins (fixed angle units).

Decant (pour off) the supernates (liquid reaction) into up to seven (7) 10 mL urine cryovials. Pour no more than 9 mL of urine into each 10 mL cryovial to allow for expansion.

Check that all information is correct on the urine cryovials, promptly freeze and store sample(s) at -70°C or lower. Batch samples and ship at least quarterly (include maximum of 36 cryovials per shipper). When shipper(s) is needed, complete "NIDDK Shipper Request Form" on CKiD website: http://www.statepi.jhsph.edu/ckid/admin/. Then, follow packaging instructions.

When pickup has been scheduled, complete "Online Shipping Form" on CKiD website to notify the NIDDK BR and KIDMAC that sample(s) have been shipped to NIDDK BR.

Reasons Code List*: 1= Not required 2 = Difficult Urine 3 = Participant 4 = Collection 5 = Inadvertently 6 = Oversight 7 = Insufficient volume

Sample Type (Required Volume in Top Color Tube Type):	(a) Sample Obtained: Yes No	(b) If No, specify reason *SEE CODE LIST ABOVE	(c) Additional Requirements:
D1. Urine for NIDDK Biorepository (15.0 - 60.0 mL of urine in specimen container and transferred into collection cup with protease inhibitors)	1 2 (skip to c→)	 (skip to E2)	i. Was supernate decanted into urine transport cryovials? Yes1 No2 ii. Date Frozen: /

SECTION E: OPTIONAL TESTS LOCAL LAB TEST (IF CLINICALLY INDICATED)

Check with the PI at your clinical site to determine whether or not it is **CLINICALLY INDICATED** to obtain urine for local lab. These are instances when the PI needs results immediately and/or the participant needs additional local labs performed (i.e., local Urine Creatinine and I Irina Protain)

and	Omic	1 10(011).		
E2.	Was	a urine protein to creatinine ratio assay perfe	ormed at the clinical site	e's local laboratory?
		Yes	Complete Local Urine CLINICALLY INDICAT	Assay Results Form L06, ONLY if local labs are ED
			IOHEXOL PROTOCO	OL O
E3.	Is the	e participant completing iohexol study visit?		ed 1 2 → (Skip to Section H)
<u>O</u>	NLY	COMPLETE SECTIONS F & G IF	PARTICIPANT IS	COMPLETING IOHEXOL STUDY VISIT.
		For an iohexol study visit, additional should be	-	
F1.		ALE MUST FIRST BE ZEROED BEFORE W E <u>SAME</u> SCALE MUST BE USED TO WEIGI		LUMINUM FOIL PRIOR TO WEIGHING THE SYRINGE. AND POST IOHEXOL INFUSION.
	a.	Syringe Weight Pre-Iohexol Infusion:	(g)	
	b.	Syringe Weight Post-Iohexol Infusion : _	(g)	(Post-Infusion Weight should be at least 6.0g less than Pre-Infusion Weight. If Post-Infusion Weight is not at least 6g less, please confirm.)
PRF	ΔΝΓ	D POST SYRINGE WEIGHT MUST R	E ORTAINED IN OF	DER TO CALCUL ATE PARTICIPANT'S GER

SECTION G: IOHEXOL - Refer to Instructions for Iohexol Infusion and GFR Blood Draws Flow Chart on Page 10

- > BEFORE INFUSING 5 mL OF IOHEXOL, SET TIMER = 0. SIMULTANEOUSLY START TIMER AND BEGIN IOHEXOL INFUSION
- **COMPLETE INFUSION BETWEEN 1 TO 2 MINS**
- LEAVE TIMER RUNNING THROUGHOUT IOHEXOL INFUSION AND SUBSEQUENT BLOOD DRAWS

Instructions for Iohexol Infusion and GFR Blood Draws

Place two IV lines (18-22 gauge polyethylene catheters) using two separate vascular access sites ---OR---

Place one butterfly and one IV line (18-22 gauge polyethylene catheter) using two separate vascular access sites; use tape to stabilize butterfly for iohexol infusion

--OR---

Use butterfly for pre-iohexol and individual blood draw sticks; use tape to stabilize butterfly for Iohexol infusion

Complete pre-iohexol infusion blood draw according to instructions

Start timer and infuse iohexol over 1-2 minutes

If infusion site for iohexol IV or butterfly infiltrates, study MUST BE DISCONTINUED

Must wait at least 48 hours to repeat study, and repeat visit should occur within 3 months of initial

Flush with 10 mL normal saline to ensure infusion of all of the iohexol; IOHEXOL IV OR BUTTERFLY MAY NOW BE REMOVED

10 minutes post-infusion CHECK POST-INFUSION VITALS DO NOT DRAW BLOOD AT 10 MINUTES

Obtain post-infusion weight of syringe on the same scale as prior to infusion. Record weight on the Specimen Collection Form prior to shipment to the CCC

Draw 1 ml of blood into SST at 120 mins (B1), and 300 mins (B2).

*For IV ONLY: Discard initial 1 mL blood waste at each blood draw (or per device guidelines)

*For IV ONLY: Flush after each blood draw with at least 3 mL normal saline

*Record the time each blood draw is completed

If rash develops, consider it a reaction to inhexol and **notify PI immediately**. Consider administering 1mg/kg Benadryl IV (maximum dose 50mg).

If systolic BP decreases > 25 mm Hg, diastolic BP decreases > 20 mm Hg or pulse increases > 20 beats per min, consider this an anaphylactic reaction to iohexol and **notify PI immediately**; consider administering 1 mg/kg Benadryl IV (maximum dose 50 mg) and draw up to 0.1 mL 1:1000 Epinephrine for SQ injection and 2 mg/kg Solumedrol IV if necessary.

COMPLETE ADVERSE EVENT FORM and send to CCC for data entry

If blood draw is difficult with poor volume delivery, repeat draw 5 minutes later; record time on Specimen Collection Form and tube. If blood draw is impossible, repeat with new venipuncture.

Following each blood draw: gently invert tube 5-10 times

Stand SST upright at room temp for 30 minutes, but no longer than 1 hour

Centrifuge at MAX SPEED between 1100-1300 g for 10 minutes in swinghead or 15 minutes in fixed angle*

Transfer serum into the cryovial labeled "Iohexol Serum."

Following packaging and shipping instructions; send urine, blood and copies of completed shipping form(s) & confirmation of written consent to CBL

Physician should be immediately available (in person or by phone) during Iohexol Infusion Encourage fluids throughout the visit.

*1100-1300 g = 3000 rpm with 10 cm radius rotor



G1.	IOI	HEXOL INFUSION		
	а	INFUSION START TIME:	•	1 = AM 2 = PM

- > DO NOT DRAW BLOOD FROM THE IV SITE WHERE IOHEXOL WAS INFUSED. ANOTHER IV SITE MUST BE USED.
- > WASTE 1 mL OF BLOOD IF DRAWING FROM A SALINE/HEPARIN LOCK (OR PER DEVICE GUIDELINES).
- COLLECT 1 mL OF BLOOD FOR EACH IOHEXOL BLOOD DRAW IN THE PROVIDED SST.
- RECORDING THE EXACT NUMBER OF MINUTES ON THE TIMER IS MORE IMPORTANT THAN DRAWING THE BLOOD EXACTLY AT 120 & 300 MINUTES AFTER IOHEXOL INFUSION. FOR EXAMPLE, IF BLOOD IS DRAWN AT 133 MINS INSTEAD OF 120 MINS, DOCUMENT BLOOD DRAWN @ 133 MINS.
- ➤ TIME SHOULD BE RECORDED IMMEDIATELY <u>AFTER</u> EACH BLOOD SAMPLE IS OBTAINED (i.e., B1, B2).

POST VITALS SHOULD BE TAKEN 10 MINUTES AFTER INFUSION USING LOCAL BLOOD PRESSURE MEASUREMENT (i.e. DINAMAP)

- If rash develops after lohexol Infusion, consider it a reaction to lohexol and notify PI immediately. Consider administration of 1 mg/kg Benadryl IV (maximum dose: 50 mg Benadryl IV).
- In the rare event that systolic BP decreases more than 25 mm Hg, diastolic BP decreases more than 20 mmHg, or pulse increases more than 20 beats per min, notify PI immediately to evaluate reaction and complete the Adverse Event (ADVR) Form. Consider the possibility of an anaphylactic reaction to lohexol. Consider administration of 1 mg/kg Benadryl IV (maximum dose: 50 mg Benadryl IV). Draw up to 0.1 mL 1:1000 Epinephrine for SQ injection and 2 mg/kg Solumedrol IV for administration as ordered by physician.

	(i) Post Vitals:	
G2a.	Post- infusion blood pressure:	
		/
b.	Post-infusion temperature:	
		·_
		1 = °C Typical range: 36.1 – 38.3
		$2 = {}^{0}F$ Typical range: 94.5 – 100.6
C.	Post-infusion number of heart beats per minute:	
d.	Post-infusion respirations per minute:	

INVERT TUBE 5-10 TIMES AFTER EACH BLOOD DRAW LET SST TUBE STAND 30 MINUTES (BUT NO LONGER THAN 1 HOUR) CENTRIFUGE AT MAX SPEED BETWEEN 1100-1300g (3000rpm with 10cm radius rotor) for 10 MINUTES IN SWING HEAD OR 15 MINUTES IN FIXED ANGLE (BALANCE TUBES IN CENTRIFUGE)

	ALL TIMES should be documented from the initial infusion time	HOURS/	i) UAL MINUTES IMER	(ii) ONLY if Timer malfunctions, record Clock Time using the same clock used for G1a	(iii) Difficult Blood Drav Yes		Blood D	v) rawn via uncture No	(v) Blood Volume Collected (1 mL):	(v Centri at Clinic Yes	fuged
G3a.	B1 2 hrs (120 min):	hr	mins	: 1 = AM 2 = PM	1 (Skip to b)	2	1	2	mL	1 (Skip to G4a)	2 (Skip to G4a)
b.	B1 2 nd attempt:	hr	mins	: 1 = AM 2 = PM	1	2	1	2	mL	1	2
G4a.	B2 5 hrs (300 min):	hr	mins	: 1 = AM 2 = PM	1 (Skip to b)	2	1	2	mL	1 (Skip to H2)	2 (Skip to H2)
b.	B2 2 nd attempt:	hr	mins	: 1 = AM 2 = PM	1	2	1	2	mL	1	2

SECTION H:

H2.	Were nail clippings and hair samples previously collected and shipped at V1b?
	Yes
	No
	Did the participant consent to have biological samples (i.e., nail clippings and hair samples) stored at NIDDK Biorepository?
	Yes 1
	No



NAIL CLIPPING COLLECTION

- Collection of fingernails is preferred. DO NOT collect fingernail clippings if the participant has acrylic nails, or nail fungus or discoloration causing pain or discomfort. If the participant cannot provide fingernail clippings, the Study Coordinator may clip the participant's toenails instead. FINGERNAILS AND TOENAILS SHOULD NOT BE COLLECTED IN THE SAME CRYOVIAL (collect one or the other).
- STAINLESS STEEL NAIL CLIPPERS MUST BE USED TO COLLECT NAIL CLIPPINGS. Use small (pediatric size) stainless steel nail clippers (see Figure A) for younger participants and large stainless steel nail clippers (see Figure B) for older participants. Both sizes are included in the CKiD starter package.
- Clean the blades of the nail clippers with SaniZide Plus prior to use (provided by the CBL).
- Whenever possible, the Study Coordinator should clip all (10) fingernails, removing approximately 1 millimeter from each nail (See Figure C). Be prepared to collect flyaway nails.
- ➤ (To use nail clippers, see Figures A D). Refer to CKiD MOP Section 12 for further details.
- Carefully place the nail clippings into the cryovial (see Figure D). After using the nail clipper, spray the clipper with **SaniZide Plus** and wipe with clean cloth.

Figure A









Figure C

Provide 10 nail clippings that are at least 1 mm tall

Figure D

H4.	Doe	es the participant have acrylic nails?
		Yes 1 (Skip to H6)
		No
H5.	We	re 10 fingernail clippings collected?
		Yes
		No
	a.	How many fingernail clippings were collected?
	b.	Specify reason "10" fingernail clippings were not collected.
		Nails not long enough 1 (Skip to H6)
		Participant Refused7 (Skip to H6)
		Other
		i. Specify:
H6.	We	re 10 toenail clippings collected?
		Yes 1 (Skip to I1)
		No 2
	a.	How many toenail clippings were collected?
	b.	Specify reason "10" toenail clippings were not collected: (e.g., Nail fungus or discoloration causing pain or discomfort)
		Nail fungus or discoloration
		Nails not long enough
		Participant Refused7 (Skip to I1)
		Other
		i. Specify:
		discomfort)1 (Skip to I1)Nails not long enough

SECTION I: HAIR SAMPLE COLLECTION

- STAINLESS STEEL SCISSORS MUST BE USED TO COLLECT HAIR SAMPLE. The scissors are included in the CKID starter package.
- DO NOT collect hair sample if the participant has colored, or chemically altered hair
- Clean blades of stainless steel scissors with SaniZide Plus prior to use.
- Use powder-free gloves.
- Refer to CKiD MOP Section 12 for further details.
 - Lift up the top layer of hair from the occipital region of the scalp (see Figure A). Isolate a small thatch of hair (at least 20 fibers) from this region (see Figure B).
 - > Place the label with the participant's KID ID # tightly around all 20 strands of hair located at the distal end (furthest from the scalp) (see Figure C).
 - > Cut the hair sample off the participant's head as close to the scalp as possible (see Figure D).
 - Place cut thatch of hair inside aluminum foil (4 X 4) and fold the top of the foil to completely enclose the hair sample.
 - Place the aluminum foil inside a Ziplock bag (4 X 4) with the gel desiccant pellets in it and seal.
 - > Store sample at room temperature in a dark place prior to shipment.
 - After using the scissors, spray scissors with SaniZide Plus and wipe with clean cloth.

Figure A



Occipital Region of Scalp

Figure B





Figure C



Place the KID ID label tightly around all 20 strands.

Figure D



Cut the hair sample off the participant's head as close to the scalp as possible.

l1.	Doe	s the participant have permed, dyed, colored, or chemically alte	red hair?
		Yes	1 (END)
		No	2
l2.	Was	s the Study Coordinator able to cut at least 20 fibers of hair from	the occipital region?
		Yes	1 (END)
		No	2
	a.	Specify reason "20" hair fibers were not collected:	
		Hair not long enough	1 (END)
		Participant Refused	-7 (END)
		Other	2
		i. Specify:	

CKiD Chronic Kidney Disease in Children Cohort Study SECTION A: GENERAL INFORMATION

A1.	PARTICIPANT ID: AFFIX ID LABEL OR ENTER NUMBER IF ID LABEL IS NOT AVAILABLE					
		- -				
A2.	CKiD VISIT #:					
A3.	FORM VERSION:	0 3 / 0 1 / 1 8				
A4.	SPECIMEN COLLECTION DATE:	$\frac{1}{M} \frac{1}{M} \frac{1}{D} \frac{1}{D} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y}$				
A5.	FORM COMPLETED BY (INITIALS):					

The following sample should be collected.

Samples:	Shipped to:	Shipped:
Serum	CBL	IMMEDIATELY
Serum	CBL	BATCHED (Ship in Jan, Apr, Jul or Oct)
Plasma	CBL	BATCHED (Ship in Jan, Apr, Jul or Oct)
Urine	CBL	IMMEDIATELY

Please refer to questions 27 on the Eligibility Form to determine if biological consent was obtained.

Depending on the type of consent, the following samples may or may not be collected:

Samples:	Shipped to:	Shipped:
Serum (Biological)	NIDDK Biorepository	BATCHED
		(Ship in Jan, Apr, Jul or Oct)
Plasma (Biological)	NIDDK Biorepository	BATCHED
XC)	(Ship in Jan, Apr, Jul or Oct)

Urine (Biological) **NIDDK Biorepository BATCHED**

(Ship in Jan, Apr, Jul or Oct)

*Whole Blood (Genetic) NIDDK Biorepository **IMMEDIATELY**

*ONLY collect whole blood for NIDDK Biorepository, if sample was not collected at V1b OR if sample collected at V1b was inadequate.

BATCHED SAMPLES SHOULD BE SHIPPED QUARTERLY (Jan, Apr, July or Oct) OR MORE OFTEN IF DESIRED BY THE SITE COORDINATOR!

> Samples should NOT be stored for more than one year. For specific questions, contact your CCC prior to shipment.

SECTION B: PREGNANCY TEST AND FIRST MORNING URINE COLLECTION

B1.	le i	participant a female of child	-hearing notes			
υ 1.		•	•		IDT Polow)	
		S	•		•	
	110		2 (01	"P to Do	,	
		: QUESTION B2 IS FOR F REGNANCY TEST DATE I				
B2.	a.	Urine pregnancy test date	: <u> </u>	/_ M D	D Y Y Y	S
	b.	Urine pregnancy results:				
		Positive	1 (E	ND; CO	MPLETE TRANSITION	AL FORM)
		Negative	2			
		EIDC	r Maddait	NICI TIT	INE COLLECTI	ON
					RINE COLLECTI	
					ontainer that was shipped t collect FRESH urine samp	to the family before the visit. The during CKiD visit.
		Pou	ır at least 1 ml	L of urin	e into the CBL transpor	t tube.
CI	hack	that all information is corre	oct on the urin	a collecti	on tube and follow pac	kaging instructions and ship to CBL.
Ci	ICCK	that all information is corre	et on the urm	Conce	on tube and follow pac	kaging instructions and simp to CBL.
ns Cod	e List	•			ollection Contamination	7 = Insufficient Volume
		2 = Difficult Urine Co			advertently Destroyed	
		3 = Participant Refu	sed	6 = O	versight	
		Sample Type	(a)		(b)	(c)
		(Required Volume):	Sample Ob	tained:	If No, specify reason	Additional Requirements:
			<u>Yes</u>	<u>No</u>	*SEE CODE LIST ABOVE	
B3.		ne Creatinine, Urine Protein,	1	2		i. Is this a first morning urine sample?
		ne Albumin (CBL) mL–10 mL)	(skip to c→)		(skip to C1)	Yes1 No2

ii. Time of Collection:

___: __ 1 = am, 2 = pm

SECTION C: Visit 3 BLOOD DRAW

For Initial Blood Draw with <u>Syringe</u>, <u>Vacutainer</u> OR <u>Butterfly</u> Method: Select the Type of Consent Obtained (options 1 through 4): <u>ONLY collect whole blood for NIDDK Biorepository, if sample was not collected at V1b or sample collected at V1b was inadequate.</u>

If participant consented to both BIOLOGICAL AND GENETIC samples:

Collect 22.5-23.5 mL if participant is < 30 kg OR 28.5-29.5 mL if participant is $\ge 30 \text{ kg}$.

If < 30 kg, immediately transfer (using 18 gauge needle) or draw:

- If not collected at V1b 6 mL into (1) 6mL ACD tube for Genetic sample (ACD Tube must be COMPLETELY FILLED)
- 10 mL into (2) Tiger-Top SST for CBL and NIDDK Biorepository
- 4 mL into two (2) PSTs for CBL and NIDDK Biorepository
- 1 mL in lavender-top tube for local CBC (tube not provided in CBL kit)
- 1.5 mL in appropriate tube (not provided) for local Renal Panel
- 1 mL of additional blood in SST for CBL (if initial sample is grossly hemolyzed)

If ≥ 30 kg, immediately transfer (using 18 gauge needle) or draw:

- If not collected at V1b 6 mL into (1) 6mL ACD tube for Genetic sample (ACD Tube must be COMPLETELY FILLED)
- 14 mL into (2) Tiger-Top SST for CBL and NIDDK Biorepository
- 6 mL into two (2) PSTs for NIDDK Biorepository
- 1 mL in lavender-top tube for local CBC (tube not provided in CBL kit)
- 1.5 mL in appropriate tube (not provided) for local Renal Panel
- 1 mL of additional blood in SST for CBL (if initial sample is grossly hemolyzed)

2 If participant consented to BIOLOGICAL samples ONLY:

Collect 16.5-17.5 mL if participant is < 30 kg OR 22.5-23.5 mL if participant is $\ge 30 \text{ kg}$.

If < 30 kg, immediately transfer (using 18 gauge needle) or draw:

- 10 mL into (2) Tiger-Top SSTs for CBL & NIDDK Biorepository
- 4 mL into one (1) PSTs for CBL and NIDDK Biorepository
- 1 mL in lavender-top tube for local CBC (tube not provided in CBL kit)
- 1.5 mL in appropriate tube (not provided) for local Renal Panel
- 1 mL of additional blood in SST for CBL (if initial sample is GROSSLY HEMOLYZED)

If ≥ 30 kg, immediately transfer (using 18 gauge needle) or draw:

- 14 mL into (2) Tiger-Top SSTs for CBL & NIDDK Biorepository
- 6 mL into (2) PST for NIDDK Biorepository
- 1 mL in lavender-top tube for local CBC (tube not provided in CBL kit)
- 1.5 mL in appropriate tube (not provided) for local Renal Panel
- 1 mL of additional blood in SST for CBL (if initial sample is GROSSLY HEMOLYZED)

3 If participant consented to GENETIC samples ONLY, collect 13.5-14.5 mL from all participants (regardless of weight):

Immediately transfer or draw:

- If not collected at V1b 6 mL into (1) 6mL ACD tube for Genetic sample (ACD Tube must be COMPLETELY FILLED)
- 4mL into (1) Tiger-Top SST for CBL
- 1 mL into PST for CBL
- 1 mL in lavender-top tube for local CBC (tube not provided in CBL kit)
- 1.5 mL in appropriate tube (not provided) for local Renal Panel
- 1 mL of additional blood in SST for CBL (if initial sample is GROSSLY HEMOLYZED)

4 If participant did NOT consent to BIOLOGICAL samples and Genetic samples:

Collect 7.5-8.5 mL from all participants (regardless of weight) as specified below.

Immediately transfer (using 18 gauge needle) or draw:

- 4 mL into (1) Tiger-Top SSTs for CBL
- 1 mL into PST for CBL
- 1 mL in lavender-top tube for local CBC (tube not provided in CBL kit)
- 1.5 mL in appropriate tube (not provided) for local Renal Panel
- 1 mL of additional blood in SST for CBL (if initial sample is GROSSLY HEMOLYZED)

SECTION C: Visit 3 BLOOD DRAW PROCESSING

CBL & NIDDK BR (Serum)

Invert the Tiger Top SST 5 times gently to mix.

Stand SST upright to allow clotting at room temperature for 30 mins and not more than 1 hour (60 mins).

Centrifuge SST at MAX SPEED between 1100-1300g (3000rpm with 10cm radius rotor) for 10 mins in swinghead OR 15 mins in fixed angle. *If incomplete separation, centrifuge again 10-15 mins.

You must send hemolyzed sample to CBL. Also if the sample is **GROSSLY** HEMOLYZED (Dark **Red),** then collect 1 mL of additional blood in a SST. Centrifuge and then transfer serum into the extra Orange Top Transport Tube provided.

CBL Studies

Using the disposable pipette, pipette 0.5 of serum into Orange Top Transport Tube labeled "Serum CBL" for CBL renal/uric acid). Follow packaging instructions and ship to CBL with accompanying forms and urine. No FRIDAY shipments. Refrigerate specimen and ship on next business day.

If sample is moderately, slightly or NOT HEMOLYZED, proceed with CBL and NIDDK BR preparation.

NIDDK (Serum)

Pipette 3mL (<30kg) or 5mL (≥30kg) serum into clear top cryovial for NIDDK BR (use different pipettes for serum and plasma).

*If there is any extra serum, then pipette the extra serum into the clear top cryovial marked "NIDDK BR SERUM"

Store sample in freezer at -70°C or lower, batch up to 40 samples and ship during Jan, Apr, Jul and Oct. When shipper is needed, complete "NIDDK BR Shipper Request Form" on CKiD website:

http://www.statepi.ihsph. Then, follow packaging instructions.

iPTH/hsCRP Pipette 0.5 mL of serum into a red top cryovial tube for CBL iPTH &, hsCRP

Vitamin D Pipette 0.5 mL of serum into a red top cryovial for CBL Vitamin D

for Cystatin

Cystatin C

pipette 0.5 mL

of serum into

Blue Screw-

Top Cryovial

Using the

disposable

pipette,

Store sample in freezer at -70°C or lower and batch up to 20 samples and ship quarterly during the months of January, April, July and October. When shipper is needed, complete "CBL Dry Ice Shipper Request Form" on the CKiD website:

http://www.statepi.jhsph.edu/ckid/admin/

Then, follow packaging instructions and ship to CBL with accompanying forms. No FRIDAY shipments. Ship on next business day.

CBL & NIDDK BR (Plasma) Invert each PST 8-10

Centrifuge each PST at 1100-1300g for 10 mins (swinghead) **OR** 15 mins (fixed angle).

FGF-23

0.5 mL of

Pipette

plasma

cryovial

green cap

insert for

into a

with

CBL

FGF-23

times gently to mix.

Keep tube at room temperature.

Pipette 1.5mL (<30kg) or 2.5mL (≥30kg) plasma into cryovial with green cap insert (use different pipettes for serum and plasma).

*If there is any extra plasma, then pipette the extra plasma into the green cap insert cryovial marked "PLASMA (Extra)".

Store sample in freezer at -70°C or lower, batch up to 40 samples and ship during the months of Jan, April, July and Oct. When shipper is needed, complete "NIDDK BR Shipper Request Form" on the CKiD website: http://www.statepi.jhsph.edu/ckid/admin/

Then, follow packaging instructions.

Follow packaging instructions, complete DNA Collection Form and ship immediately to **NIDDK** Biorepository with accompanying forms. Specimen can be shipped on

NIDDK BR

(Whole Blood for DNA)

Invert the ACD Tube 6 times gently

DO NOT FREEZE.

to mix blood with additives.

Complete "On-line Shipping Form" on CKiD website to notify KIDMAC that sample(s) have been shipped.

When pickup has been scheduled, complete "On-line Shipping Form" on CKiD website: http://www.statepi.jhsph.edu/ckid/admin/ to notify the appropriate personnel from the CBL and the NIDDK BR.

SECTION C: Visit 3 BLOOD DRAW AND PROCESSING

C1. ACTUAL TIME OF BLOOD DRAW ____ : ___ : ___ 1 = AM 2 = PM

Reasons Code List*: 1= Not required 4 = Red Blood Cell Contamination 7 = Exceed maximum allowable volume 5 = Inadvertently Destroyed 3 = Participant Refused 6 = Oversight

	Sample Type (Required Volume in Top Color Tube Type):	(a) Sample Obt <u>Yes</u>	ained:	(b) If No, specify reason *SEE CODE LIST ABOVE	(c) Additional Requirements:
C2a.	Renal/Uric Acid Chemistries (1.0 mL in Tiger Top SST)	1 (skip to c→)	2	(skip to C2b)	Indicate the appearance of the serum after centrifuging. Grossly (Dark Red)
C2b.	Cystatin C (1.0 mL in Tiger Top SST)	1 (skip to c→)	2	(skip to C3)	Date Frozen://
C3a.	Serum for iPTH, hsCRP & Vitamin D (2.0 mL of blood in Tiger Top SST)	(skip to c→)	2	(skip to C3b)	Date Frozen: /
C3b.	Plasma for FGF-23 (1.0 mL of blood in PST)	1 (skip to c→)	2	(skip to C4a)	Date Frozen: /
C4a.	Local CBC (1.0 mL in Lavender Top tube)	1 (skip to C4b)	2	(skip to C4b)	N/A
C4b.	Local Renal Panel (1.5 mL in Local SST)	1 (skip to C5)	2	(skip to C5)	N/A

Sites can obtain results for lab values that have been identified as "KEY VARIABLES". To obtain results, go the CKiD Nephron Website: https://statepiaps8.jhsph.edu/nephron/groups/aspproc/, click on "Report Menu" and choose the appropriate lab report (i.e., Selected Renal Panel Lab Variables Report.)

C5. Did the participant consent to have biological samples (i.e., serum, plasma and urine) stored at NIDDK Biorepository?

Yes...... 1

Reasons Code List*:	1= Not required	4 = Red Blood Cell Contamination	7 = Exceed maximum allowable volume
	2 = Difficult Blood Draw	5 = Inadvertently Destroyed	
	3 = Participant Refused	6 = Oversight	

	Sample Type (Required Volume in Top Color Tube Type):	(a) Sample Obtained: Yes No	(b) If No, specify reason *SEE CODE LIST ABOVE	(c) Additional Requirements:
C6.	Serum for NIDDK Biorepository (**6.0 mL or **10.0 mL of blood in Tiger Top SST)	$ \begin{array}{ccc} 1 & 2 \\ \text{(skip to c} \rightarrow) \end{array} $	(skip to C7)	Date Frozen: //
C7.	Plasma for NIDDK Biorepository (***3.0 mL of blood (1) Green Top or ***5.0 mL (2) Green Top PSTs)	1 2 (skip to c→)	(skip to D1)	Date Frozen: //

^{**} Collect 6.0 mL of whole blood for participants < 30 kg and 10.0 mL for participants ≥ 30 kg

^{***} Collect 3.0 mL of whole blood for participants < 30 kg and 5.0 mL for participants \ge 30 kg

SECTION D: Visit 3 URINE COLLECTION AND PROCESSING FOR REPOSITORY

Collect FRESH urine into an initial urine collection cup or hat (provided by the site).

Pour 15-60 mL (preferably 60 mL) of FRESH urine into 90 mL urine collection cup with 4 protease inhibitor tablets. Do not fill the urine past the 60 mL mark on the collection cup. One protease inhibitor tablet should be used for 10-15 mL of urine (see **Table A**). For example if 30 mL of urine is collected, ONLY 2 PI tablets are needed. (Like all unused supplies, unused protease inhibitor tablets should be returned to the CBL.)

Invert the urine cup gently 5 - 10 times.

TABLE A:

of Protease
Urine Volume Inhibitor Tablets

10 - 15 mL
16 - 30 mL
2
31 - 45 mL
3
46 - 60 mL
4

The PROTEASE INHIBITOR TABLET(s) MUST BE COMPLETELY DISSOLVED in the urine.

Once the protease inhibitor tablet(s) are completely dissolved, pour urine into up to six (6) 10 mL urine centrifuge tubes. (**For each tube:** remove yellow top cap, pour urine into tube and SCREW cap back onto tube.) Place no more than 10 mL in each tube.

-- OR -

Sites may also substitute with tubes normally used to centrifuge urine at site.

Centrifuge urine tube(s) at MAX SPEED between 1100-1300g (3000rpm with 10cm radius rotor) for 10 mins (swinghead units) – \mathbf{OR} – 15 mins (fixed angle units).

Decant (pour off) the supernates (liquid reaction) into up to seven (7) 10 mL urine cryovials. Pour no more than 9 mL of urine into each 10 mL cryovial to allow for expansion.

Check that all information is correct on the urine cryovials, promptly freeze and store sample(s) at -70°C or lower. Batch samples and ship at least quarterly (include maximum of 36 cryovials per shipper). When shipper(s) is needed, complete "NIDDK Shipper Request Form" on CKiD website: http://www.statepi.jhsph.edu/ckid/admin/. Then, follow packaging instructions.

When pickup has been scheduled, complete "Online Shipping Form" on CKiD website to notify the NIDDK BR and KIDMAC that sample(s) have been shipped to NIDDK BR.

Reasons Code List*: 1= Not 2 = Difficult Urine 3 = Participant 4 = Collection 5 = Inadvertently 6 = Oversight 7 = Insufficient required Collection Refused Contamination Destroyed volume

Sample Type (Required Volume in Top Color Tube Type):	(a) Sample Obtaine Yes N	(c) Additional Requirements:
D1. Urine for NIDDK Biorepository (15.0 - 60.0 mL of urine in specimen container and transferred into collection cup with protease inhibitors)	1 2 (skip to c→)	i. Was supernate decanted into urine transport cryovials? Yes1 No2 ii. Date Frozen: / /

OPTIONAL LOCAL LAB TEST (IF CLINICALLY INDICATED)

Check with the PI at your clinical site to determine whether or not it is **CLINICALLY INDICATED** to obtain urine for local lab. These are instances when the PI needs results immediately and/or the participant needs additional local labs performed (i.e., local Urine Creatinine and Urine Protein).

D2.	Was a urine protein to creatinine ratio as	say performed at the clinical site's local laboratory?
	Yes 1	→ Complete Local Urine Assay Results Form L06, ONLY if local labs are
	No 2	CLINICALLY INDICATED
	SECTION E	: WHOLE BLOOD FOR NIDDK BIOREPOSITORY

BLOOD FOR GENETIC TESTING AT THE NIDDK BIOREPOSITORY SHOULD BE SHIPPED ONLY IF THE SAMPLE <u>WAS NOT</u> COLLECTED AT V1B OR IF THE SAMPLE OBTAINED AT V1B WAS INADEQUATE (i.e, cell lines were not immortalized).

If participant has consented to have whole blood stored at NIDDK Biorepository but it is not necessary to collect the whole blood, Code question E2b as "01."

E1.	Did the pa	rticipant consent to h	ave whole blood stored a 1	t NIDDK Biorepository?	
				10.	
		Reasons Code List*:	1= Not required	3 = Participant Refused	5 = Inadvertently Destroyed
			2 = Difficult Blood Draw	4 = Red Blood Cell Contamination	6 = Oversight

	Sample Type (Required Volume in Top Color Tube Type):		a) Obtained:	(b) If No, specify reason	(c) Additional Requirements:
		<u>Yes</u>	<u>No</u>	*SEE CODE LIST ABOVE	
E2.	Whole Blood for NIDDK Biorepository	1	2		i. Date of Blood Draw:
	(6 mL of blood in 1 (6 mL) ACD tube)	(skip to c→)			
	80			(END FORM)	/
					M M D D Y Y Y Y
					ii. Blood Drawn By : (initials)
					iii. Gender of participant :
					Male1
					Female2
					iv. Age of participant : years

CKiD Chronic Kidney Disease in Children Cohort Study SECTION A: GENERAL INFORMATION

A1. PARTICIPANT ID: AFFIX ID LABEL OR ENTER NUMBER IF ID LABEL IS NOT AVAILA					
			- -		
A2.	CKID VISIT #:				
A3.	FORM VERSI	ON:	0 3 / 0 1 / 1 8		
A4.	SPECIMEN C	OLLECTION DATE:	$\frac{1}{M} \frac{1}{M} \frac{1}{D} \frac{1}{D} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y}$		
A5.	FORM COMP	LETED BY (INITIALS):	1180		
The	e following san	nples should be collecte	ed.		
Sar	nples:	Shipped to	Shipped:		
Ser	um	CBL	IMMEDIATELY		
Ser	um	CBL	Batched		
			(Ship in Jan, Apr, Jul or Oct)		
Uri	ne	CBL	IMMEDIATELY		
loh	Iohexol Blood* CBL		IMMEDIATELY		
			lly if Cohort 3 participants who consent		

If consent is obtained for biological samples, collect the following:

Samples: Shipped to: Shipped: Serum (Biological) NIDDK Biorepository Batched

(Ship in Jan, Apr, Jul or Oct)

Plasma (Biological) NIDDK Biorepository Batched

(Ship in Jan, Apr, Jul or Oct)

Urine (Biological) **NIDDK Biorepository** Batched

(Ship in Jan, Apr, Jul or Oct)

Toenail Clippings NIDDK Biorepository IMMEDIATELY

(Biological)

BATCHED SAMPLES SHOULD BE SHIPPED QUARTERLY (Jan, Apr, July or Oct) OR MORE OFTEN IF DESIRED BY THE SITE COORDINATOR!

> Samples should NOT be stored for more than one year. For specific questions, contact your CCC prior to shipment.



		SECTION B: PREGNANCY TEST AND FIRST MORNING URINE COLLECTION				
B1.	ls p	participant a female of child-bearing potential?				
		s				
PROMPT: QUESTION B2 IS FOR FEMALE PARTICIPANTS OF CHILD-BEARING POTENTIAL ONLY. URINE PREGNANCY TEST DATE MUST FALL WITHIN 72 HOURS BEFORE STUDY VISIT DATE.						
If per INITI		ning iohexol protocol, B2 MUST BE COMPLETED BEFORE IOHEXOL TESTING IS D.				
B2.	a.	Urine pregnancy test date://				
	b.	Urine pregnancy results:				
		Positive				
		Negative 2				

FIRST MORNING URINE COLLECTION

Obtain urine collected at home in the specimen container that was shipped to the family before the visit. IF URINE WAS NOT collected at home, collect FRESH urine sample during CKiD visit.

(Refer to MOP Section 11 and/or CBL flowchart for additional information and directions)

Pour at least1mL of urine into the CBL transport tube.

1

Check that all information is correct on the urine collection tube and follow packaging instructions and ship to CBL.

Reasons Code List*: 1= Not required 3 = Participant Refused 5 = Inadvertently Destroyed 7=Insufficient Volume 2 = Difficult Urine Collection 4 = Collection Contamination 6 = Oversight

	Sample Type (Required Volume):	(a) Sample Ob	otained:	(b) If No, specify reason *SEE CODE LIST ABOVE	(c) Additional Requirements:
		<u>Yes</u>	<u>No</u>		
B3.	Urine Creatinine, Urine Protein, Urine Albumin (CBL)	1 (skip to c→)	2	O	i. Is this a first morning urine sample? Yes1 No2
	(1 mL-10 mL)	(5/11)		(skip to C1)	ii. Time of Collection: : 1 = am, 2 = pm

SECTION C: Visit 4 BLOOD DRAW

For Initial Blood Draw with <u>Syringe</u>, <u>Vacutainer</u> OR <u>Butterfly</u> Method: Select the Type of Consent Obtained (options 1 through 3) That Pertains to the CKiD Participant:

If participant consented to BIOLOGICAL samples:

Collect 14-15 mL if participant is < 30 kg OR 20-21 mL if participant is $\ge 30 \text{ kg}$.

If < 30 kg, immediately transfer (using 18 gauge needle) or draw:

- 8.5 mL into (2) Tiger-Top SSTs for CBL & NIDDK Biorepository
- 3 mL into (1) PST for NIDDK Biorepository
- 1 mL in lavender-top tube for local CBC (tube not provided in CBL kit)
- 1.5 mL in appropriate tube (not provided) for local Renal Panel
- 1 mL of additional blood in SST for CBL (if initial sample is GROSSLY HEMOLYZED)

If ≥ 30 kg, immediately transfer (using 18 gauge needle) or draw:

- 12.5 mL into (2) Tiger-Top SSTs for CBL & NIDDK Biorepository
- 5 mL into (2) PST for NIDDK Biorepository
- 1 mL in lavender-top tube for local CBC (tube not provided in CBL kit)
- 1.5 mL in appropriate tube (not provided) for local Renal Panel
- 1 mL of additional blood in SST for CBL (if initial sample is GROSSLY HEMOLYZED)

2 If participant did NOT consent to BIOLOGICAL samples:

Collect 5-6 mL from all participants (regardless of weight) as specified below.

Immediately transfer (using 18 gauge needle) or draw:

- 2.5 mL into (1) Tiger-Top SSTs for CBL
- 1 mL in lavender-top tube for local CBC (tube not provided in CBL kit)
- 1.5 mL in appropriate tube (not provided) for local Renal Panel
- 1 mL of additional blood in SST for CBL (if initial sample is GROSSLY HEMOLYZED)

For Participant Completing Iohexol Study Visit

Only Cohort 3 participants who consent to iohexol protocol or Cohorts 1 & 2 participants with previous iGFR>90

For IOHEXOL study visits:

• 1mL of additional blood into Tiger Top SST for CBL Iohexol Blank (B0) blood sample

Iohexol is infused at the time of initial blood draw.

Refer to page 10 for **Instructions for Iohexol Infusion and GFR Blood Draws.**

PROCESSING OF BLOOD FOR CBL & NIDDK BR

Invert the SST 5 times & PST 8-10 times gently to mix.

Stand SST upright to allow clotting at room temperature for 30 mins and not more than 1 hour (60 mins).

Centrifuge SST & PST at MAX SPEED between 1100-1300 g (3000rpm with 10cm radius rotor) for 10 minutes in swinghead units **OR** 15 minutes in fixed angle units (balance tube in centrifuge).*If incomplete separation, centrifuge again for 10-15 minutes.

If sample is GROSSLY HEMOLYZED.

If sample is moderately, slightly or NOT HEMOLYZED, proceed with CBL and NIDDK BR preparation.

You must send hemolyzed sample to CBL. If participant has eaten, aliquot hemolyzed sample for fasting lipid profile and send to CBL. Also, if the sample is GROSSLY HEMOLYZED (Dark Red), collect 1 mL of additional blood in a SST. Centrifuge and then

transfer serum into the

Transport Tube provided.

extra Orange Top

For IOHEXOL STUDY VISITS ONLY:

B0 sample

Using the disposable pipette,
pipette 0.5 mL of serum into
Round-bottom Orange Top
Transport Tube labeled "B0"
for Iohexol Blank (B0) sample.
Follow packaging instructions
and ship to CBL with
accompanying forms, iohexol
blood draws and urine. No
FRIDAY shipments.
Refrigerate specimen and ship

on next business day.

CBL Studies

Using the disposable pipette, pipette 0.75 mL of serum into Orange Top Transport Tube labeled "Serum CBL" for CBL renal/uric acid and lipid. Follow packaging instructions and ship to CBL with accompanying forms, iohexol blood draws, and urine. **No**

FRIDAY shipments.

Refrigerate specimen and ship on next business day.

Cystatin C

Using the disposable pipette, pipette 0.5 mL of serum into Blue Screw-Top Cryovial for Cystatin C.
Store sample in freezer at -70°C or

Store sample in freezer at -70°C or lower, batch up to 20 samples and ship on dry ice every four months to the CBL. When shipper is needed, complete "CBL Dry Ice Shipper Request Form" on the CKiD website:

http://www.statepi.jhsph.edu/ckid/admin/
Then, follow packaging instructions and ship to CBL with accompanying forms. No FRIDAY shipments.
Ship on next business day.

NIDDK BR (Serum & Plasma)

Pipette 3 mL (<30kg) or 5 mL (≥ 30 kg) of serum into clear top cryovial & 1.5 (<30kg) or 2.5 mL(≥ 30 kg) of plasma into cryovial into green cap insert (use different pipettes for serum and plasma).

*If there is any extra serum and/or plasma, then pipette the extra serum into the clear top cryovial marked "NIDDK BR SERUM" and the extra plasma in green cap insert cryovial marked "PLASMA (Extra)."

Store samples in freezer at -70°C or lower, & batch up to 40 samples and ship on dry ice in January, April, July or October to the NIDDK BR. When shipper is needed, complete "NIDDK BR Shipper Request Form" on the CKiD website:

http://www.statepi.jhsph.edu/ckid/admin/. Then, follow packaging instructions.

When pickup has been scheduled, complete "On-line Shipping Form" on CKiD website: http://www.statepi.jhsph.edu/ckid/admin/ to notify the appropriate personnel from the CBL and the NIDDK BR.

C1.	ACTUAL TIME OF BLOOD DRAW	::	1 = AM	2 = PM

PROMPT: IF SUSPECTED BLOOD DRAW ADVERSE EVENT (i.e., infection), complete ADVERSE EVENT (ADVR) Form

Reasons Code List*: 1= Not required 4 = Red Blood Cell Contamination 7 = Exceed maximum allowable volume

2 = Difficult Blood Draw 5 = Inadvertently Destroyed

3 = Participant Refused 6 = Oversight

(Requ	Sample Type ired Volume in Top Color Tube Type):	(a) Sample Obta	ined:	(b) If No, specify reason *SEE CODE LIST ABOVE	(c) Additional Requirements:
		<u>Yes</u>	<u>No</u>) *
C2.	Renal/Uric Acid Chemistries (2.0 mL in Tiger Top SST)	1 (skip to c→)	2	(skip to C3)	Indicate the appearance of the serum after centrifuging. Grossly (Dark Red)
C3.	Cystatin C (1.0 mL in Tiger Top SST)	1 (skip to c→)	2	(skip to C4a)	Date Frozen:/
C4a.	Local CBC (1.0 mL in Lavender Top tube)	1 (skip to C4b)	2	(skip to C4b)	N/A
C4b.	Local Renal Panel (1.5 mL in Local SST)	1 (skip to C5)	2	(skip to C5)	N/A
C5.	Serum for Fasting Lipid Panel (0.5 mL in Tiger Top SST)	1 (skip to c→)	2	(skip to C6)	Pid the participant fast after midnight? Yes1 No2*

^{*}If the participant did not fast, the Nephron Lipid Report will indicate that the participant did not fast.

Sites can obtain results for lab values that have been identified as "KEY VARIABLES". To obtain results, go the CKiD Nephron Website: https://statepiaps8.jhsph.edu/nephron/groups/aspproc/, click on "Report Menu" and choose the appropriate lab report (i.e., Selected Renal Panel Lab Variables Report.)

C6.	Did the participant consent to have biological samp	oles (i.e., serum, plasma and urine sar	nples) stored at the NIDDK Biorepository?
	Yes	1	::O'
	No	2 (Skip to E2)	

Reasons Code List*:	1= Not required	4 = Red Blood Cell Contamination	7 = Exceed maximum allowable volume
	2 = Difficult Blood Draw	5 = Inadvertently Destroyed	
	3 = Participant Refused	6 = Oversight	

	Sample Type (Required Volume in Top Color Tube Type):	(a) Sample Obtai <u>Yes</u>	ned:	(b) If No, specify reason *SEE CODE LIST ABOVE	(c) Additional Requirements:
C7.	Serum for NIDDK Biorepository (**6.0 mL or **10.0 mL of blood in Tiger Top SST)	1 (skip to c→)	2	(skip to C8)	Date Frozen: ///
C8.	Plasma for NIDDK Biorepository (***3.0 mL of blood in one Green Top or ***5.0 mL in two Green Top PSTs)	1 (skip to c→)	2	 (skip to D1)	Date Frozen: //

^{**} Collect 6.0 mL of whole blood for participants < 30 kg and 10.0 mL for participants \ge 30 kg

^{***} Collect 3.0 mL of whole blood for participants < 30 kg and 5.0 mL for participants \ge 30 kg

SECTION D: URINE COLLECTION AND PROCESSING FOR REPOSITORY

Collect FRESH urine into an initial urine collection cup or hat (provided by the site).

Pour 15-60 mL (preferably 60 mL) of FRESH urine into 90 mL urine collection cup with 4 protease inhibitor tablets. Do not fill the urine past the 60 mL mark on the collection cup. One protease inhibitor tablet should be used for 10-15 mL of urine (see **Table A**). For example if 30 mL of urine is collected, ONLY 2 PI tablets are needed. (Like all unused supplies, unused protease inhibitor tablets should be returned to the CBL.)

Invert the urine cup gently 5 - 10 times.

TABLE A:

of Protease
Inhibitor Tablets

10 - 15 mL
16 - 30 mL
31 - 45 mL
46 - 60 mL

4

The PROTEASE INHIBITOR TABLET(s) MUST BE COMPLETELY DISSOLVED in the urine.

Once the protease inhibitor tablet(s) are completely dissolved, pour urine into up to six (6) 10 mL urine centrifuge tubes. (For each tube: remove yellow top cap, pour urine into tube and SCREW cap back onto tube.) Place no more than 10 mL in each tube.

-- OR –

Sites may also substitute with tubes normally used to centrifuge urine at site.

Centrifuge urine tube(s) at MAX SPEED between 1100-1300g (3000rpm with 10cm radius rotor) for 10 mins (swinghead units) – **OR** – 15 mins (fixed angle units).

Decant (pour off) the supernates (liquid reaction) into up to seven (7) 10 mL urine cryovials. Pour no more than 9 mL of urine into each 10 mL cryovial to allow for expansion.

Check that all information is correct on the urine cryovials, promptly freeze and store sample(s) at -70°C or lower. Batch samples and ship at least quarterly (include maximum of 36 cryovials per shipper). When shipper(s) is needed, complete "NIDDK Shipper Request Form" on CKiD website: http://www.statepi.jhsph.edu/ckid/admin/. Then, follow packaging instructions.

When pickup has been scheduled, complete "Online Shipping Form" on CKiD website to notify the NIDDK BR and KIDMAC that sample(s) have been shipped to NIDDK BR.

Reasons Code List*: 1= Not required 2 = Difficult Urine 3 = Participant 4 = Collection 5 = Inadvertently 6 = Oversight 7 = Insufficient Volume

Sample Type (Required Volume in Top Color Tube Type):	(a) Sample Obt	ained:	(b) If No, specify reason *SEE CODE LIST ABOVE	(c) Additional Requirements:
D1. Urine for NIDDK Biorepository (15.0 - 60.0 mL of urine in specimen container and transferred into collection cup with protease inhibitors)	1 (skip to c→)	2	 (skip to E2)	i. Was supernate decanted into urine transport cryovials? Yes1 No2 ii. Date Frozen: / /

SECTION E: OPTIONAL TESTS LOCAL LAB TEST (IF CLINICALLY INDICATED)

Check with the PI at your clinical site to determine whether or not it is **CLINICALLY INDICATED** to obtain urine for local lab. These are instances when the PI needs results immediately and/or the participant needs additional local labs performed (i.e., local Urine Creatinine and Urine Protein)

and .					
E2.	Was	a urine protein to creatinine ratio assay perf	ormed at the clinical site	e's local laboratory?	
		Yes 1 → No	Complete Local Urine CLINICALLY INDICAT	e Assay Results Form L06, ONLY if local labs are TED)
			IOHEXOL PROTOCO	OL	
E3.	Is the	e participant completing iohexol study visit?		ned 1	
			No	$2 \rightarrow$ (Skip to Section H)	
<u>O</u>	NLY	COMPLETE SECTIONS F & G IF	PARTICIPANT IS	S COMPLETING IOHEXOL STUDY VISI	<u>T</u> .
	,	should complete iohexol prot	ocol. If you have add	ohorts 1 & 2 participants with previous iGFR: ditional questions, contact CCC. ood for the lohexol "B0" Blank sample) I-Based GFR.	
		SECTION	F: INFUSION SYRING	GE WEIGHT	
F1.		LE MUST FIRST BE ZEROED BEFORE W SAME SCALE MUST BE USED TO WEIG		LUMINUM FOIL PRIOR TO WEIGHING THE SYRII AND POST IOHEXOL INFUSION.	NGE
	a.	Syringe Weight Pre-Iohexol Infusion:	(g)		
	b.	Syringe Weight Post-Iohexol Infusion : _	(g)	(Post-Infusion Weight should be at least 6.0g than Pre-Infusion Weight. If Post-Infusion Weight i at least 6g less, please confirm.)	
PRE	AND	POST SYRINGE WEIGHT MUST B	E OBTAINED IN O	RDER TO CALCULATE PARTICIPANT'S (3FR

SECTION G: IOHEXOL - Refer to Instructions for Iohexol Infusion and GFR Blood Draws Flow Chart on Page 10

- BEFORE INFUSING 5 mL OF IOHEXOL, SET TIMER = 0. SIMULTANEOUSLY START TIMER AND BEGIN IOHEXOL INFUSION
- **COMPLETE INFUSION BETWEEN 1 TO 2 MINS**
- LEAVE TIMER RUNNING THROUGHOUT IOHEXOL INFUSION AND SUBSEQUENT BLOOD DRAWS

Instructions for Iohexol Infusion and GFR Blood Draws for Make-up GFRs

Place two IV lines (18-22 gauge polyethylene catheters) using two separate vascular access sites ---OR---

Place one butterfly and one IV line (18-22 gauge polyethylene catheter) using two separate vascular access sites; use tape to stabilize butterfly for iohexol infusion

--OR---

Use butterfly for pre-iohexol and individual blood draw sticks; use tape to stabilize butterfly for Iohexol infusion

Complete pre-iohexol infusion blood draw according to instructions

Start timer and infuse iohexol over 1-2 minutes

If infusion site for iohexol IV or butterfly infiltrates, study MUST BE DISCONTINUED

Must wait at least 48 hours to repeat study, and repeat visit should occur within 3 months of initial

Flush with 10 mL normal saline to ensure infusion of all of the iohexol; IOHEXOL IV OR BUTTERFLY MAY NOW BE REMOVED

10 minutes post-infusion CHECK POST-INFUSION VITALS DO NOT DRAW BLOOD AT 10 MINUTES

Obtain post-infusion weight of syringe on the same scale as prior to infusion. Record weight on the Specimen Collection Form prior to shipment to the CCC

Draw 1 ml of blood into SST at 120 mins (B1), and 300 mins (B2).

*For IV ONLY: Discard initial 1 mL blood waste at each blood draw (or per device guidelines)

*For IV ONLY: Flush after each blood draw with at least 3 mL normal saline

*Record the time each blood draw is completed

If rash develops, consider it a reaction to iohexol and **notify PI immediately**. Consider administering 1mg/kg Benadryl IV (maximum dose 50mg).

If systolic BP decreases > 25 mm Hg, diastolic BP decreases > 20 mm Hg or pulse increases > 20 beats per min, consider this an anaphylactic reaction to iohexol and **notify PI immediately**; consider administering 1 mg/kg Benadryl IV (maximum dose 50 mg) and draw up to 0.1 mL 1:1000 Epinephrine for SQ injection and 2 mg/kg Solumedrol IV if necessary.

COMPLETE ADVERSE EVENT FORM and send to CCC for data entry

If blood draw is difficult with poor volume delivery, repeat draw 5 minutes later; record time on Specimen Collection Form and tube. If blood draw is impossible, repeat with new venipuncture.

Following each blood draw: gently invert tube 5-10 times

Stand SST upright at room temp for 30 minutes, but no longer than 1 hour

Centrifuge at MAX SPEED between 1100-1300 g for 10 minutes in swinghead or 15 minutes in fixed angle*

Transfer serum into the cryovial labeled "Iohexol Serum."

Following packaging and shipping instructions; send urine, blood and copies of completed shipping form(s) & confirmation of written consent to CBL

Physician should be immediately available (in person or by phone) during Iohexol Infusion Encourage fluids throughout the visit.

*1100-1300 g = 3000 rpm with 10 cm radius rotor



G1.	IOI	HEXOL INFUSION		
	a.	INFUSION START TIME:	:	1 = AM 2 = PM

- > DO NOT DRAW BLOOD FROM THE IV SITE WHERE IOHEXOL WAS INFUSED. ANOTHER IV SITE MUST BE USED.
- > WASTE 1 mL OF BLOOD IF DRAWING FROM A SALINE/HEPARIN LOCK (OR PER DEVICE GUIDELINES).
- COLLECT 1 mL OF BLOOD FOR EACH IOHEXOL BLOOD DRAW IN THE PROVIDED SST.
- > RECORDING THE EXACT NUMBER OF MINUTES ON THE TIMER IS MORE IMPORTANT THAN DRAWING THE BLOOD EXACTLY AT 120 & 300 MINUTES AFTER IOHEXOL INFUSION. FOR EXAMPLE, IF BLOOD IS DRAWN AT 133 MINS INSTEAD OF 120 MINS, DOCUMENT BLOOD DRAWN @ 133 MINS.
- > TIME SHOULD BE RECORDED IMMEDIATELY <u>AFTER</u> EACH BLOOD SAMPLE IS OBTAINED (i.e., B1, B2).

POST VITALS SHOULD BE TAKEN 10 MINUTES AFTER INFUSION USING LOCAL BLOOD PRESSURE MEASUREMENT (i.e. DINAMAP)

- If rash develops after lohexol Infusion, consider it a reaction to lohexol and notify PI immediately. Consider administration of 1 mg/kg Benadryl IV (maximum dose: 50 mg Benadryl IV).
- In the rare event that systolic BP decreases more than 25 mm Hg, diastolic BP decreases more than 20 mmHg, or pulse increases more than 20 beats per min, notify PI immediately to evaluate reaction and complete the Adverse Event (ADVR) Form. Consider the possibility of an anaphylactic reaction to lohexol. Consider administration of 1 mg/kg Benadryl IV (maximum dose: 50 mg Benadryl IV). Draw up to 0.1 mL 1:1000 Epinephrine for SQ injection and 2 mg/kg Solumedrol IV for administration as ordered by physician.

	(i) Post Vitals:					
G2a.	Post- infusion blood pressure:	/				
b.	Post-infusion temperature:					
	70,	1 = °C Typical range: 36.1 – 38.3 2 = °F Typical range: 94.5 – 100.6				
C.	Post-infusion number of heart beats per minute:					
d.	Post-infusion respirations per minute:					

INVERT TUBE 5-10 TIMES AFTER EACH BLOOD DRAW LET SST TUBE STAND 30 MINUTES (BUT NO LONGER THAN 1 HOUR) CENTRIFUGE AT MAX SPEED BETWEEN 1100-1300g (3000rpm with 10cm radius rotor) for 10 MINUTES IN SWING HEAD OR 15 MINUTES IN FIXED ANGLE (BALANCE TUBES IN CENTRIFUGE)

	ALL TIMES should be documented from the initial infusion time	HOURS/	i) TUAL MINUTES IMER	(ii) ONLY if Timer malfunctions, record Clock Time using the same clock used for G1a	(iii) Difficult Blood Draw Yes	v: No	Blood D	v) rawn via uncture No	(v) Blood Volume Collected (1 mL):	(\ Centri at Clinio Yes	fuged
G3a.	B1 2 hrs (120 min):	hr	mins	: 1 = AM 2 = PM	1 (Skip to b)	2	1	2	mL	1 (Skip to G4a)	2 (Skip to G4a)
b.	B1 2 nd attempt:	hr	mins	: 1 = AM 2 = PM	. 1	2	1	2	mL	1	2
G4a.	B2 5 hrs (300 min):	hr	mins	: 1 = AM 2 = PM	1 (Skip to b)	2	1	2	mL	1 (Skip to H1a)	2 (Skip to H1a)
b.	B2 2 nd attempt:	hr	mins	: 1 = AM 2 = PM	1	2	1	2	mL	1	2

TOENAIL CLIPPINGS FOR THE REPOSITORY SHOULD BE SHIPPED ONLY IF THE SAMPLE WAS NOT COLLECTED AT V4

SECTION H:

			0_0
H1	a.	Is this a study Visit 4?	Yes 1 (skip to H1c)
			No 2
	b.	Were toenail clippings collected at Visit 4?	Yes 1 (END; if toenail clippings collected at V4 do not collect at V6)
			No 2
	C.	Did the participant consent to have biological	samples (i.e., nail clippings) stored at NIDDK Biorepository?
		Yes	1
		No	2 (END)



TOENAIL CLIPPING COLLECTION

- The collection of TOENAILS is preferred. DO NOT collect fingernail clippings. Also DO NOT collect toenails if participant has nail fungus, or discoloration causing pain or discomfort.
- STAINLESS STEEL NAIL CLIPPERS MUST BE USED TO COLLECT NAIL CLIPPINGS. Use small (pediatric size) stainless steel nail clippers (see Figure A) for younger participants and large stainless steel nail clippers (see Figure B) for older children. Both sizes are included in the CKiD starter package.
- > Clean the blades of the nail clippers with SaniZide Plus prior to use (provided by the CBL).
- Whenever possible, the Study Coordinator should clip all (10) toenails, removing approximately 1 millimeter from each nail (See Figure C). Be prepared to collect flyaway nails.
- ➤ (To use nail clippers, see Figures A D). Refer to CKiD MOP Section 12 for further details.
- Carefully place the nail clippings into the cryovial (see Figure D). After using the nail clipper,
- > spray the clipper with **SaniZide Plus** and wipe with clean cloth.

ALTHOUGH PICTURES DEPICT THE CLIPPING OF FINGERNAILS, AT VISIT 4 TOENAIL CLIPPINGS ARE PREFERRED.

Figure A











Provide 10 nail clippings that are at least 1 mm tall

Figure D

H2.	Were	e 10 toenail clippings collected?	
		Yes	1 (END)
		No	2
	a.	How many toenail clippings were collected?	C. C
	b.	Specify reason "10" toenail clippings were not collected: (e.g.	, Nail fungus or discoloration causing pain or discomfort)
		Nail fungus or discoloration	1 (END)
		Nails not long enough	2 (END)
		Participant Refused	-7 (END)
		Other	3
		i. Specify:	

LOCAL LABORATORY – RENAL PANEL RESULTS FORM L03

Chronic Kidney Disease in Children (CKiD) SECTION A: GENERAL INFORMATION

A1.	PARTICIPANT ID: AFFIX ID LABEL OF	R ENTER NUMBER IF ID LABEL IS NOT AVAILABLE		
		_ - _ -		
A2.	Protocol type:	Regular Study Visit 0 Post-Dialysis Visit 1 Post-Transplant Visit 2		
A3.	CKiD VISIT #:			
A4.	FORM VERSION:	0 4 / 0 1 / 1 8		
A5.	DATE FORM COMPLETED:	$\frac{1}{M} \frac{1}{M} \frac{1}{D} \frac{1}{D} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y}$		
A6.	FORM COMPLETED BY (INITIALS):			
A7.	Is this study visit an irregular (accelerate	ed) visit? Yes 1 No 2		
10.3				
NY M	ISSING OR INCOMPLETE TEST RE	SULTS MUST BE EXPLAINED ON THIS FORM.		

SECTION B

B1.	ARE TEST RESULTS AVAILABLE?	
	Yes	1 (B2)
	No, Sample Inadequate	2 (END
	No, Other Reason	3
	(SPECIFY)	



LOCAL LABORATORY – RENAL PANEL RESULTS FORM L03

B2.	. DATE SAMPLE DRAWN:				
	////////	Y Y Y			
B3.	Renal Panel Blood Res	ults:			
a.	Sodium		(MEQ/L) or (mmol/L)		
b.	Potassium	·	(MEQ/L) or (mmol/L)		
c.	Chloride	_	(MEQ/L) or (mmol/L)		
d.	Carbon Dioxide	<u> </u>	(MEQ/L) or (mmol/L)		
e.	Urea Nitrogen (BUN)		(mg/dL)		
f.	Serum Creatinine	LI.L4	(mg/dL)		
g.	Glucose (GLU)		(mg/dL)		
h.	Calcium (CA)		(mg/dL)		
i.	Phosphate	·	(mg/dL)		
j.	Albumin	·	(g/dL)		



LOCAL LABORATORY - CBC RESULTS FORM L04

A1.	PARTICIPANT ID: AFFIX ID LABEL OR	ENTER NUMBER IF ID LABEL IS NOT AVAILABLE
A2.	Protocol type:	- -
A3.	CKiD VISIT #:	Post-Transplant Visit 2
A4. A5.	FORM VERSION: DATE FORM COMPLETED:	0 4 / 0 1 1 8
-	FORM COMPLETED BY (INITIALS):	M M D D Y Y Y Y
A7.	Is this study visit an irregular (accelerate	ed) visit? Yes
NY MIS	SSING OR INCOMPLETE TEST RESUL	TS MUST BE EXPLAINED ON THIS FORM.
B1.	60)	CTION B
DI.	Yes	` ,
	No, Sample Inadequate No, Other Reason	
B2.	No, Other Reason	



LOCAL LABORATORY - CBC RESULTS FORM L04

B3. CBC Blood Results:

a.	Leukocyte Count (white blood cells	s)	.				* ((cu mm))
----	-------------------	-------------------	----	---	--	--	--	-----	---------	---

*Use the table below if results are						
reported in units of 10 ³ uL.						
$4.5 \times 10^3 \text{ uL} = 4500 \text{ cu mm}$	$9.0 \times 10^3 \text{ uL} = 9000 \text{ cu mm}$					
$5.0 \times 10^3 \text{ uL} = 5000 \text{ cu mm}$	$9.5 \times 10^3 \text{ uL} = 9500 \text{ cu mm}$					
$5.5 \times 10^3 \text{ uL} = 5500 \text{ cu mm}$	$10.0 \times 10^3 \text{ uL} = 10000 \text{ cu mm}$					
$6.0 \times 10^3 \text{ uL} = 6000 \text{ cu mm}$	$10.5 \times 10^3 \text{ uL} = 10500 \text{ cu mm}$					
$6.5 \times 10^3 \text{ uL} = 6500 \text{ cu mm}$	$11.0 \times 10^3 \text{ uL} = 11000 \text{ cu mm}$					
$7.0 \times 10^3 \text{ uL} = 7000 \text{ cu mm}$	$11.5 \times 10^3 \text{ uL} = 11500 \text{ cu mm}$					
$7.5 \times 10^3 \text{ uL} = 7500 \text{ cu mm}$	$12.0 \times 10^3 \text{ uL} = 12000 \text{ cu mm}$					
$8.0 \times 10^3 \text{ uL} = 8000 \text{ cu mm}$	$12.5 \times 10^3 \text{ uL} = 12500 \text{ cu mm}$					
$8.5 \times 10^3 \text{ uL} = 8500 \text{ cu mm}$	$13.0 \times 10^3 \text{ uL} = 13000 \text{ cu mm}$					

b.	Erythrocyte Count (red blood cells)		(M/cu mm) or (x10 ⁶ uL)
c.	Platelet Count (PLTs)		(K/cu mm) or (x10 ³ uL)
d.	Hemoglobin	.	(g/dL)
e.	Packed Cell Volume (Hematocrit)		(%)
f.	Mean Corpuscular Hemoglobin (MCH)		(pg/cell)
g.	Mean Corpuscular Hemoglobin Concentration (MCHC)		(g/dL)
h.	Mean Corpuscular Volume (MCV)	_ . .	(fL)
i.	Red Blood Cell Distribution Width (RDW)	_ ·	(%)



LOCAL LABORATORY - URINE ASSAY RESULTS Form L06 (ONLY COMPLETE IF LOCAL URINE ASSAY WAS PERFORMED)

A1.	PARTICIPANT ID: AFFIX ID LABEL OR	ENTER NUMBER IF ID LABEL IS NOT AVAILABLE	
		- -	
A2.	Protocol type:	Regular Study Visit 0 Post-Transplant Visit 2	
A3.	CKID VISIT #:		
A4.	FORM VERSION:	0 4 / 0 1 / 1 8	
A5.	DATE FORM COMPLETED:	$\frac{1}{M} \frac{1}{M} \frac{1}{D} \frac{1}{D} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y} \frac{1}{Y}$	
A6.	FORM COMPLETED BY (INITIALS):		
A7.	Is this study visit an irregular (accelerate	d) visit? Yes 1 No 2	
NY MISSING OR INCOMPLETE TEST RESULTS MUST BE EXPLAINED ON THIS FORM.			
	SEC	CTION B	
B1.	ARE TEST RESULTS AVAILABLE?		
B1.	ARE TEST RESULTS AVAILABLE? Yes		
B1.	Yes		
B1.	X U'		
B1.	Yes No, Sample Inadequate No, Other Reason		
B1.	Yes No, Sample Inadequate		
	Yes No, Sample Inadequate No, Other Reason		
	Yes No, Sample Inadequate No, Other Reason (SPECIFY) DATE SAMPLE DRAWN:		
	Yes No, Sample Inadequate No, Other Reason (SPECIFY) DATE SAMPLE DRAWN:	2 (END) 3 D D Y Y Y Y	
B2.	Yes No, Sample Inadequate No, Other Reason (SPECIFY) DATE SAMPLE DRAWN: M M I	2 (END)	



CENTRAL LABORATORY – RENAL PANEL TESTS FORM L05

	A1.	PARTICIPANT ID: ENTER N	JMBER ONLY IF LAB	EL IS NOT AVAILABLE
			- - _	
	A2.	Protocol type:	Regular Study V Post-Dialysis Vis Post-Transplant	sit 1
	A3.	CKiD VISIT #:		
		FORM VERSION:	0 4 / 0	
ANY	MISSIN	IG OR INCOMPLETE TEST	RESULTS MUST B	E EXPLAINED ON THIS FORM.
			SECTION B	
B1.	ARE T	EST RESULTS AVAILABLE?		
		Yes No, Sample Inadequate No, Other Reason	2	(B2) (END)
				(END)
		(SPECIFY)		
B2.	DATE	SAMPLE DRAWN:		
	/_			
M	M D	DYYYY		

CENTRAL LABORATORY – RENAL PANEL TESTS

FORM L05

B3.	Renal Panel Blood Results		
a.	Sodium (NA)	_	(mmol/L)
b.	Potassium (K)	.	(mmol/L)
C.	Chloride (CL)	_	(mmol/L)
d.	Carbon Dioxide (CO ₂)		(mmol/L)
e.	Urea Nitrogen (BUN)		(mg/dL)
f.	Serum Creatinine – Enzmatic	.	(mg/dL)
g.	Glucose (GLU)		(mg/dL)
h.	Calcium (CA)		(mg/dL)
i.	Phosphate (PO ₄)		(mg/dL)
j.	Uric Acid (Urate)		(mg/dL)
k.	Albumin (ALB)		(g/dL)
B4.	a. Indicate the appearance of the serum Gross hemolysis		
De	Yes		
B6.	Urine Results		, , , , , ,
a.	Creatinine, Urine		(mg/dL)
b.	Protein, Urine		(mg/dL)
	Enter "-1" for post-transplant visit participants		
c.	Microalbumin		(mg/dL)

CENTRAL LABORATORY – IOHEXOL CONCENTRATIONS RESULTS FORM L07

	A1.	PARTICIPANT ID: ENTER NUMBI	ER ONLY IF LABEL IS NOT AVAILABLE
	A2.	Protocol type:	Regular Study Visit 0 Post-Transplant Visit 2
	A3.	CKID VISIT #:	
	A4.	FORM VERSION:	0 4 / 0 1 / 1 8
4 5 137	MOOIL	IO OD INGOMBI ETE TEGT DEG	NIII TO MUCT DE EVEL AINED ON THIS FORM
ANY	MISSIN	IG OR INCOMPLETE TEST RES	SULTS MUST BE EXPLAINED ON THIS FORM.
		SEC	CTION B
B1.	ARE T	EST RESULTS AVAILABLE?	XX O
		Yes	1 (B2)
		No, Sample Inadequate No, Other Reason	2 (END)
		No, Other Reason	
		(SPECIFY)	(END)
B2.	DATE	SAMPLE DRAWN:	
	1		
M	/	D Y Y Y	
B2a	. WHIC	CH LABORATORY ANALYZED THE	SAMPLE?
	СВ		
	Min	nesota	
	>		
B3.	IS T	HIS A 2-POINT CONCENTRATION	?
	Yes	S	1
	No.		2

CENTRAL LABORATORY – IOHEXOL CONCENTRATIONS RESULTS FORM L07

B4.	IS THIS	A CALIBRATED CO	NCENTRATION?	
	Yes		1	
	No		2	
		SECTION C:	IOHEXOL CO (mg/dL)	NCENTRATION
	C3.	B 120 min:	·	
	СЗа	B 240 min:	·	£(0) Y
	C4	B 300 min:		Y

CENTRAL LABORATORY Intact Parathyroid Hormone (iPTH) and High Sensitivity C-Reactive Protein (hsCRP) FORM L08

	A1	. PARTICIPANT ID: ENTER NUMB	ER ONLY IF LABEL IS NOT AVAILABLE
	A2	. Protocol type:	Regular Study Visit
	АЗ	. CKiD VISIT #:	
	A4	. FORM VERSION:	0 4 / 0 1 / 1 8
ANY	MISS	NG OR INCOMPLETE TEST RE	SULTS MUST BE EXPLAINED ON THIS FORM.
		SE	CTION B
B1.	ARE	TEST RESULTS AVAILABLE?	1 (B2)
		No, Sample Inadequate No, Other Reason	3
		(SPECIFY)	(END)
B2.	DATE	SAMPLE DRAWN: M	$-\frac{1}{M}$ $\frac{1}{D}$ $\frac{1}{D}$ $\frac{1}{Y}$ $\frac{1}{Y}$ $\frac{1}{Y}$ $\frac{1}{Y}$
	B3. il	PTH & hsCRP Results:	
	a. (i	intact) Parathyroid (iPTH)	. (pg/mL)
	b. F	ligh Sensitivity C-Reactive Protein (h	s CRP) . (mg/L)
	te	Vas serum sample shipped at room emperature?	<u> </u>
		/es1 lo0	

CENTRAL LABORATORY – LIPID PROFILE FORM L09

	AI.	- _ - _		
	A2.	Protocol type:	Regular Study Visit Post-Dialysis Visit Post-Transplant Visit	1
	A3.	CKiD VISIT #:		
	A4.	FORM VERSION:	0 4 / 0 1	/ 1 8
ANY	MISSIN	IG OR INCOMPLETE TEST	RESULTS MUST BE EXPLA	AINED ON THIS FORM.
B1.	ARE T	EST RESULTS AVAILABLE?	SECTION B	
		Yes No, Sample Inadequate No, Other Reason	1 (B2) 2 (END)	
		(SPECIFY)	(END)	
B2.	DATE	(SPECIFY) SAMPLE DRAWN:	(END) M M D D Y Y Y	<u></u>
B2. B3.		Silvi	/	/
	Lipid	SAMPLE DRAWN:	/	 Y (mg/dL)
B3.	Lipid Choles	SAMPLE DRAWN: Profile Results:	/	/ Y (mg/dL) (mg/dL)
B3. a.	Lipid Choles Total 7	SAMPLE DRAWN: Profile Results: sterol (CHOL)	/	
B3. a. b.	Lipid Choles Total 1 High D	SAMPLE DRAWN: Profile Results: sterol (CHOL) Triglycerides (TRG)	/	(mg/dL)

CENTRAL LABORATORY - CYSTATIN C RESULTS FORM L11

Chronic Kidney Disease in Children (CKiD) SECTION A: GENERAL INFORMATION

A1. PARTICIPANT ID: ENTER NUMBER ONLY IF LABEL IS NOT AVAILABLE

	A2.	Protocol type:	Regular Study Visit 0 Post-Transplant Visit 2
	A3.	CKID VISIT #:	
	A4.	FORM VERSION:	0 4 / 0 1 / 1 8
ANY	MISSIN	IG OR INCOMPLETE TEST RE	SULTS MUST BE EXPLAINED ON THIS FORM.
		SE	CTION B
B1.	ARE T	Yes	
B2.	DATE	SAMPLE DRAWN: M	$\frac{1}{M}$ $\frac{1}{D}$ $\frac{1}{D}$ $\frac{1}{Y}$ $\frac{1}{Y}$ $\frac{1}{Y}$ $\frac{1}{Y}$
B3.		laboratory analyzed the sample? BL1	
B4.	Was IF	FCC standard used?	
		Yes, IFCC standard used No, IFCC standard was not used.	
B5.	Serun	n Cystatin C – CBL .	

CENTRAL LABORATORY - IRON TESTS

FORM L12

Chronic Kidney Disease in Children (CKiD) SECTION A: GENERAL INFORMATION

A1. PARTICIPANT ID: ENTER NUMBER ONLY IF LABEL IS NOT AVAILABLE

			_ - _ -		
	A2.	CKiD VISIT #:			
	A3.	FORM VERSION:	0 7 /	0 1 /	0 8
ΔΝΥ	MISSIM	IG OR INCOMPLETE TEST RE	SIII TS MIIST	RE EXPLAINED	ON THIS FORM
AITI	WIIOOII			DE EXI LAINED	OR THIS FORM.
		SE	CTION B	XO(3)	
B1.	ARE T	EST RESULTS AVAILABLE?		00	
		Yes No, Sample Inadequate No, Other Reason		.1 (B2) .2 (END) .3	
			O	_ (END)	
		(SPECIFY)			
B2.	DATE	SAMPLE DRAWN:			
	/				
M	M D	D Y Y Y Y			

CENTRAL LABORATORY – IRON TESTS

FORM L12

B3.	Iron Results		
a.	Serum Iron		(ug/dL)
b.	Total Iron-Binding Capacity (TIBC)		(ug/dL)
c.	Tranferrin Saturation (TSAT)		(%)
d.	Ferritin		(ng/dL)
e.	Transferrin		(mg/dL)

CENTRAL LABORATORY – VITAMIN D

FORM L13

	A1.	PARTICIPANT ID: ENTER NUI	MBER ONLY IF LAB	EL IS NOT AVAILABLE
	A2.	CKID VISIT #:		
	A3.	FORM VERSION:	_10_/_	1 5 / 0 9
4 5 15 7				
ANY	MISSIN	IG OR INCOMPLETE TEST R	ESULTS MUST B	E EXPLAINED ON THIS FORM.
		S	SECTION B	
B1.	ARE T	EST RESULTS AVAILABLE?		3
		Yes No, Sample Inadequate No, Other Reason	2	(B2) (END)
		(SPECIFY)		(END)
B2.	DATE	SAMPLE DRAWN:	>	
M	/_ M D	$-\frac{1}{D}$		

CENTRAL LABORATORY - VITAMIN D

FORM L13

B3.	Vitamin D 25 Hydroxy Res	ults	
a.	25-OH Vitamin D2		(ng/mL)
b.	25-OH Vitamin D3		(ng/mL)
C.	25-OH Vitamin Total	_	(ng/mL)
			A.3
			404
			*//0//
			ACK >
		M. (A • • • • • • • • • • • • • • • • • • •
		X'O	
		4.62	
		70	
		(0)	
	A 53		
	$\langle VOV \rangle$		
	*()()		
	ACC.		
	× *		